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Abstract 
 
The importance of zinc in immune system is complex and recognised mostly by the effects of 
zinc deficiency which affects both innate and adaptive immunity. The results presented here 
provided insight into the complex role of zinc in immunity through examination of the roles of 
zinc in dendritic cell activation and regulation of complement protein interactions. Little is 
known about the mechanism by which zinc affects immune cell function. Here we show that 
Toll-like receptor 4 signalling upon lipopolysaccharide (LPS) binding, alters the expression of zinc 
transporters, to maintain the stable intracellular free zinc. This indicates the importance of zinc 
on every level of dendritic cells (DCs) maturation, beginning with antigen recognition, through 
antigen processing and cell migration to the lymphatic organs, to finally antigen presentation to 
T-cells. Hydroxyapatite along with LPS can trigger DCs maturation. Following this finding we 
presented a global picture of proteomic changes that occur in maturing DCs, which was 
characterised by reduced expression of proteins that drive cellular processes including 
metabolism and protein translation. Proteomic results may also change the current 
understanding of antigen presentation by DCs, implicating major histocompatibility complex 
(MHC) class I in “delayed” antigen presentation. Zinc is also crucial in innate immunity as it 
inhibits the interaction of complement proteins C1q, Factor H and C3 with histidine rich 
glycoprotein (HRG). The results suggest for the first time, that binding of complement proteins 
to HRG is not solely dependent on the N-terminus. Also the role of zinc in the early onset of 
diseases related to tissue calcification was examined, showing its enhancing effect on HRG 
binding to hydroxyapatite. 
 
 
 
 
 
 
 
vi 
 
Acknowledgements 
 
Firstly, I would like to express my sincere gratitude to my advisors Dr Alan Stewart and Dr Simon 
Powis for their continuous support of my Ph.D study and related research, for their patience, 
motivation, and immense knowledge. Their guidance helped me in all the time of research and 
writing of this thesis. I could not have imagined having a better advisors for my Ph.D study. 
Besides my advisor, I would like to thank the rest of my thesis committee: Prof. David Harrison 
and Dr. Paul Reynolds, for their insightful comments and encouragement, but also for the hard 
questions which persuaded me to widen my research from various perspectives. 
I thank my fellow labmates in for the stimulating discussions, for the sleepless nights we were 
working together, and for all the fun we have had in the last four years.  
I would like to thank my family: my parents and to my sister and brother for supporting me 
spiritually throughout writing this thesis and my life in general. Thank you for encouraging me 
in all of my pursuits and inspiring me to follow my dreams. I always knew that you believed in 
me and wanted the best for me.  
Last but not the least, I owe thanks to a very special person, my fiancé Nikos for his continued 
and unfailing love, patience and support during my pursuit of Ph.D degree that made the 
completion of thesis possible. You were always around at times I thought that it is impossible to 
continue, you helped me to keep things in perspective.  
 
 
 
 
 
 
 
 
 
 
vii 
 
Podziękowania 
 
Pragnę podziękować wszystkim bez których niniejsza praca nie mogłaby powstać.  
 
Po pierwsze, chciałabym wyrazić wdzięczność moim promotorom, dr. Alanowi Stewart i  
dr. Simonowi Powis za ich ciągłe wsparcie, cierpliwość, motywację i ogromną wiedzę. Ich cenne 
uwagi merytoryczne niezmiernie mi pomogły podczas moich badań. Nie mogłabym sobie 
wyobrazić lepszych mentorów na studiach doktoranckich. 
 
Poza moimi promotorami, chciałabym podziękować członkom komisji: Prof. Davidowi Harrison i 
dr. Paulowi Reynolds, za ich wnikliwe komentarze, zachęty, ale także za trudne pytania, które 
przekonały mnie, aby rozszerzyć moje badania o kolejne perspektywy. 
 
Pragnę podziękować również koleżankom i kolegom z pracy za stworzenie wspaniałej atmosfery 
naukowej (i nie tylko), inspirujące dyskusje oraz za bezsenne noce spędzone wspólnie w 
laboratorium. 
 
Chciałabym podziękować mojej rodzinie: rodzicom, siostrze, bratu, za duchowe wsparcie i 
zachętę podczas pisania tej pracy. Zawsze wiedziałam, że wierzyliście we mnie i chcieliście dla 
mnie jak najlepiej. 
 
Na koniec dziękuję wyjątkowej osobie: mojemu przyszłemu mężowi Nikosowi, za jego miłość, 
cierpliwość i wsparcie. 
 
 
 
 
 
 
 
viii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
Contents 
Chapter 1. Introduction ................................................................................................................. 1 
1.1. Innate immune system .................................................................................................. 1 
1.1.1. Complement system ............................................................................................. 2 
1.2. Dendritic cells – a link between innate and adaptive immune system......................... 7 
1.2.1. Dendritic cell maturation ...................................................................................... 8 
1.2.2. Toll-like receptors signalling .................................................................................. 8 
1.2.3. Antigen presentation .......................................................................................... 12 
1.3. Zinc in immune system ................................................................................................ 15 
1.3.1. Zinc in innate immunity ....................................................................................... 17 
1.3.2. Zinc in adaptive immunity ................................................................................... 18 
1.3.3. Zinc and inflammation ......................................................................................... 19 
1.4. Zinc homeostasis ......................................................................................................... 19 
1.5. Zinc transporters as the main mechanism of zinc homeostasis ................................. 20 
1.5.1. Subcellular localisation .............................................................................................. 21 
1.5.2. The role of zinc transporters in the immune system ................................................ 23 
1.6. Histidine-rich glycoprotein (HRG) .................................................................................... 24 
1.7. Age-related macular degeneration (AMD) ....................................................................... 29 
1.7.1. Retinal immune defence ........................................................................................... 29 
1.7.2. Complement activation and regulation in the retina in relevance to AMD .............. 31 
1.7.3. Sub-retinal pigment epithelial deposit formation..................................................... 32 
1.8. Hypothesis and aims ........................................................................................................ 34 
Chapter 2. Zinc homeostasis and the role of zinc in dendritic cell function ............................... 35 
2.1. Introduction ..................................................................................................................... 35 
2.1.1. Zinc in immune cell signalling .................................................................................... 35 
2.1.2. Zinc homeostasis in dendritic cells ............................................................................ 36 
2.2. Materials and methods .................................................................................................... 38 
2.2.1. Cell culture methods ................................................................................................. 38 
2.2.2. Western blotting ....................................................................................................... 39 
x 
 
2.2.3. Immunofluorescence ................................................................................................ 41 
2.2.4. Zinc imaging............................................................................................................... 42 
2.2.5. Flow cytometry.......................................................................................................... 43 
2.2.6. The Human Tumor Necrosis Factor-alpha (TNF-α) assay .......................................... 44 
2.2.7. Polymerase chain reaction to semi-quantify gene expression ................................. 44 
2.3. Results .............................................................................................................................. 50 
2.3.1. Morphological characteristic of DCs ......................................................................... 50 
2.3.2. Characteristic of zinc transporters in moDC ............................................................. 50 
2.3.3. Toll-like receptor 4-mediated alteration in intracellular zinc level in DCs ................ 62 
2.3.4. The effect of LPS and hydroxyapatite on TNF-α secretion by moDC ........................ 65 
2.4 Discussion .......................................................................................................................... 67 
2.4.1. Morphological characteristic of moDC ...................................................................... 67 
2.4.2. Zinc homeostasis in moDC upon LPS stimulation ..................................................... 67 
2.4.3. HAP and LPS induced TNF-α secretion ...................................................................... 71 
Chapter 3. Proteomic alterations in maturing dendritic cells ..................................................... 72 
3.1. Introduction ..................................................................................................................... 72 
3.1.1. Proteomic studies on maturing human dendritic cells ............................................. 72 
3.1.2. SWATH ....................................................................................................................... 76 
3.2. Methods ........................................................................................................................... 79 
3.2.1. Sample preparation ................................................................................................... 79 
3.2.2. LC-ESI-MSMS analysis ................................................................................................ 80 
3.3. Results .............................................................................................................................. 82 
3.3.1. Cytokine Production. ................................................................................................. 82 
3.3.2. Identification of proteins upregulated upon moDC maturation ............................... 83 
3.3.3. Identification of proteins down-regulated upon moDC maturation......................... 86 
3.4. Discussion ....................................................................................................................... 112 
Chapter 4. The role of zinc in complement protein interactions .............................................. 117 
4.1 Introduction..................................................................................................................... 117 
4.1.1. Complement proteins ............................................................................................. 117 
xi 
 
4.1.2. The role of zinc, complement proteins and histidine-rich glycoprotein (HRG) in AMD 
development ..................................................................................................................... 117 
4.1.3. The role of HRG in the immune system .................................................................. 118 
4.2. Materials and methods .................................................................................................. 121 
4.2.1. Purification of human and rabbit HRG .............................................................. 121 
4.2.2. Purification of human factor H (FH) .................................................................. 121 
4.2.3. SDS-PAGE and Western blotting ....................................................................... 122 
4.2.4. TEV protease preparation ................................................................................. 122 
4.2.5. Production of recombinant HRG N1/N2 domain fragment .................................... 123 
4.2.6. Enzyme-linked immunosorbent binding assay (ELISA) ..................................... 130 
4.2.7. Hydroxyapatite-coated magnetic bead binding assay ...................................... 133 
4.2.8. X-ray crystallography of native HRG and recombinant N1/N2 domains of HRG
 133 
4.3. Results ............................................................................................................................ 135 
4.3.1. Protein purification ................................................................................................. 135 
4.3.2. The role of zinc in the regulation of HRG–complement protein interactions ........ 149 
4.3.3. The role of zinc and pH in the regulation of HAP-protein interactions................... 154 
4.3.4. Crystallography........................................................................................................ 159 
4.4. Discussion ....................................................................................................................... 161 
4.4.1. The role of zinc in the regulation of HRG–complement protein interactions ........ 161 
4.4.2. The role of zinc and pH in the regulation of HAP-protein interactions................... 163 
4.4.3. Attempts to structurally characterise HRG ............................................................. 166 
Chapter 5. Conclusion ............................................................................................................... 167 
References ................................................................................................................................. 173 
Appendices ................................................................................................................................ 193 
Appendix 1 ............................................................................................................................ 193 
1 
 
Chapter 1. Introduction 
1.1. Innate immune system 
The innate immune system is the first line of defence against pathogens, providing immediate 
immune response. After pathogens are recognised through their molecular pattern, 
granulocytes are attracted to the infected tissue where they migrate via chemotaxis (Amulic et 
al., 2012). Granulocytes internalise pathogens through phagocytosis and kill them by an 
oxidative burst with reactive oxygen species (ROS) (Mayer et al., 2014), which was reported to 
be a zinc dependent process (Maares and Haase, 2016). Additionally, granulocytes secrete 
chemokines and cytokines, including IL-8 and IL-1 receptor antagonist (IL-1ra), after the contact 
with bacterial lipopolysaccharides (LPS) (Hasan et al., 2016). Zinc is crucial for granulocyte 
functioning as zinc deficiency was shown to decrease cytokine production, phagocytosis and 
chemotaxis. Furthermore, zinc is involved in the formation and release of neutrophil 
extracellular traps (NETs), used to capture extracellular pathogens (Hasan et al., 2012).  
Shortly after granulocyte activation, monocytes migrate to the site of infection. They 
differentiate into macrophages, and together with granulocytes kill pathogens via phagocytosis 
and oxidative burst. Additionally, macrophages and dendritic cells (DC) present antigen to T-cells 
and secrete pro-inflammatory cytokines (Mayer, 2014; Prasad, 2009). Zinc regulates monocyte 
and macrophage functioning in multiple ways. Zinc deficiency increases phagocytosis and the 
oxidative burst of monocytes, and increases monocyte maturation into macrophages (Dubben 
et al., 2010). It also inhibits secretion of IL-12 and the activation of macrophages by the adaptive 
immune system (TH1 and TH2) and therefore inhibits ROS generation (Bao et al., 2011). 
Zinc influences the secretion of pro-inflammatory cytokines in monocytes in a dose dependent, 
and cell-dependent manner. In monocytes, cytokines are released at low extracellular zinc 
concentrations, and inhibited at high zinc doses. On the other hand, in peripheral blood 
mononuclear cells (PBMCs), IL-6-, IL-1b- and TNF-release is induced by high (ca. 100 mM) zinc 
concentrations (Wellinghausen et al., 1996; Wellinghausen et al., 1997). Correspondingly, 
cytokine production has been shown to be decreased in PBMCs by zinc deficiency (Mayer et al., 
2014). However, zinc deficiency does not affect phagocytosis and oxidative burst of PBMCs. 
Natural killer (NK) cells are crucial for immune response against viral infections and tumours. 
Haematopoiesis of NK cells from CD34+ common hematopoietic progenitor is enhanced by 10-
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20 µM of zinc (Muziolli et al., 2007). Also the number of NK cells is influenced by alterations in 
extracellular zinc, but are unaffected by intracellular zinc changes, as shown by increased NK cell 
numbers after zinc supplementation (Metz et al., 2006), but no change in the amount of NK cells 
after zinc chelation with TPEN (membrane permeable zinc chelator) (Mariani et al., 2008). On 
the functional level, zinc regulates proper interaction of NK cells with MHC I receptors on target 
cells (Vales-Gomez et al., 2000) and the addition of zinc increases cytokine production, including 
IFN-γ (Metz et al., 2006). 
Recently the new group of immune cells has been identified. Innate lymphoid cells (ILCs) 
differentiate from haematopoietic stem cells, via an ID2+ precursor. They belong to lymphocytes 
but due to the lack of B or T receptors, are unable to respond to an antigen presented via MHC 
molecules (Walker et al., 2013). Based on the transcription factors that regulate their 
development and on cytokines secreted, ILCs are divided in to three subgroups: type 1 
comprising ILC1s and NK cells (produce IFNγ, perforin and granzymes), type 2 ILCs (ILC2s; 
produce IL-5, IL-9, IL-13 and amphiregulin) and type 3 comprising ILC3s and lymphoid tissue-
inducer (LTi) cells (produce IL-17, IL-22, lymphotoxin and IFNγ) (Spits et al., 2013). ILCs are a 
multifunctional group. ILC1s play a role in the inflammation, NK-cells are responsible for the 
immunity against viruses and intracellular pathogens but also tumour surveillance. ILC2s protect 
against helminthic infection by activating T-cells recruiting and activating mast cells and 
eosinophils, and stimulate B cell proliferation (Palm et al., 2012). ILC3s are crucial in the 
intestinal immune system maintaining intestinal homeostasis and protecting against 
extracellular bacteria (Walker et al., 2013). So far, except well characterised NK cells, it is not 
known how zinc influences the function of ILCs.  
 
1.1.1. Complement system 
The human complement system is a key part of the innate immune system and acts as a first 
line of defence, performing its function in blood plasma, tissues and within cells (Kolev et al., 
2014). It comprises more than 35 plasma and cell membrane bound proteins, produced mainly 
by the liver (Nan et al., 2013). In plasma, complement proteins are typically present at 0.3-7 µM 
concentrations (Law and Reid, 1995). There are three complement pathways, which lead to the 
elimination of pathogens and cytotoxic complexes: classical pathway (CP; antigen-antibody 
complex interactions), alternative pathway (AP; binding to pathogen surface receptors) and the 
lectin pathway (LP; initiated by recognition of exposed carbohydrates/ligands by mannose-
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binding lectin (MBL) and/or ficolins; (Fig. 1.1; Collard et al., 2001). All three routes lead to a 
central complement protein C3. C3 is relatively abundant in plasma (ca. 5-8.5 µM) compared to 
other complement proteins (Law and Reid, 1995; Nilsson and Ekdahl, 1998) and additionally, as 
a modest acute phase protein, shows 50% increase in concentration following complement 
pathway activation.  
To enable detection of pathogens, the AP is constantly active at low grade, and is not influenced 
by viable host cells. However, the complement system is activated by apoptotic cells, which aids 
immunological complex clearance and helps cells to maintain normal homeostasis (Lu et al., 
2008). Full activation of the complement system occurs only after pathogen recognition, and 
results in inflammation, as well as opsonisation and phagocytosis of bacteria, viruses and other 
pathogens. The C5 complement protein is cleaved by C5 convertase to C5b, which then interacts 
with C6. Subsequent binding of C7, C8 and C9, results in the formation of membrane attack 
complex (MAC), a large (10 nm-wide) pore in the pathogen or apoptotic cell membrane, leading 
to the activation of adaptive immune response (Bubeck, 2014).  
 
 
Figure 1.1. A simplified schematic representation of three pathways of complement activation. 
Abbreviations: mannose binding lectin (MBL); mannose-binding protein-associated serine 
protease 2 (MASP-2); decay-accelerating factor (DAF); complement regulatory protein, cluster 
of differentiation 46 (CD46); MAC-inhibitory protein, cluster of differentiation 59 (CD59); 
complement factor B (B); complement factor D (D) (Asgari et al., 2010). 
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Classical complement pathway 
The first protein component of the classical complement pathway, C1 begins the cascade in 
which each component activates the next, like domino blocks (Fig. 1.1). The C1 complex, consist 
of C1q, two molecules of C1r, and two molecules of C1s (C1qr2s2; Ricklin et al. 2010). Because 
of its extra-hepatic origin, C1q is quite an exceptional complement protein. It is mostly produced 
by immature dendritic cells, monocytes, and macrophages (Ghai et al., 2007). It has a complex 
structure, formed by 18 chains of three types, forming six globular target domains attached to 
a collagen-like region (Fig. 1.2). C1q binds to target molecules based on the charge of their 
surface. It has over 100 ligands, including IgG and IgM, non-immune complex proteins like C-
reactive protein (Kishore et al., 2004) and histidine rich glycoprotein (Manderson et al., 2009). 
It also binds pathogen-associated molecules such as lipopolysaccharide as well as others 
(Roumenina et al., 2008). Binding of C1q to its ligands occurs via electrostatic interactions 
between a Ca2+ ion located on the globular head of C1q and negatively charged binding sites on 
the target. 
After binding to the target surface, C1q is initially activated by the proteases (Roumenina et al., 
2005). Then, through conformational changes in the complex, binding at the globular head of 
C1q is detected at C1r (Gaboriaud et al., 2014). Consecutively, conformational changes in C1 
complex lead to C1s being cleaved by C1r, which leads to its activation (Gaboriaud et al., 2004) 
and the formation of a C1r2C1s2 active tetramer. The C1r2C1s2 complex then cleaves C4 into 
C4a and C4b, and leads to covalent binding of C4b at the cell/pathogen surface. C2 splits into 
C2aa and C2ba and then C4b binds C2ba, forming C3 convertase (C4b2ba. The convertase 
cleaves C3 into biologically active C3a and C3b (Gaboriaud et al., 2004; Wallis et al., 2010). 
 
 
Figure 1.2. Schematic representation of components of the initiating complexes of lectin and 
classical complement pathways. Abbreviations: mannose binding lectin (MBL); mannose-binding 
protein-associated serine protease (MASP); CUB1, EGF, CUB2, CCP2 and SP are MASP 
subdomains (Wallis et al., 2010). 
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Alternative complement pathway 
Under normal physiological conditions, the AP is the only complement pathway active in human 
plasma. The low-grade activation is crucial to monitor for foreign antigens. This process is known 
as AP tick-over, which is the hydrolysis of a labile thioester bond, which converts C3 to its 
hydrolysed, bioactive form, C3(H2O) (Harboe and Mollnes, 2008). The hydrolysis is spontaneous 
and can be increased when C3 interacts with some biological or artificial surfaces, including 
biomaterial and lipid surfaces. During C3 hydrolysis, another complement protein, Factor B (FB) 
binds to the newly exposed binding site, and forms a complex C3(H2O)-FB, which is later cleaved 
by factor D (FD), which acts as a serine protease. Newly formed convertase complex C3(H2O) Bb 
cleaves native C3 to C3a and C3b (Nilsson and Nilsson Ekdahl, 2012). During physiological 
conditions this process creates a loop, where small amount of C3b binds to hydroxyl groups on 
C3(H2O). When binding to the surface of host cells, C3b is immediately inactivated, by a 
sequence of complement regulators. The only exceptions are apoptotic cells, where the number 
of surface complement regulators is decreased (Verbovetski et al., 2002). To eliminate 
pathogens, C3(H2O)Bb convertase is formed on their surface and cleaves C5 into the 
anaphylatoxin C5a and fragment C5b. The complex enters into cell membranes and interacts 
with C8 when C5b associates with C6 and C7. That also triggers the binding of several units of 
C9 that form a membrane attack complex (Ricklin et al., 2010). 
Complement pathways are highly regulated. One of the most important regulators is 
complement factor H (FH), which with its 2–5 µM concentration is a rather abundant plasma 
protein (Saunders et al. 2006). FH and its shorter splice variant, CFHL1, regulate C3 convertase 
by competing with factor B to C3b, and by dissociation of C3bBb complex (Zipfel and Skerka, 
1999). FH consists of 20 CCP domains, and has at least two binding sites for C3b, at the N-
terminus (CCP 1-4) and the C-terminus (CCP19-20) of the protein. Additionally, the N-terminus 
(CCP1-2) competes with FB for binding to C3b (Fig. 1.3). The interaction between FH and C3b on 
the surface is quite weak with Kd values in the µM range (Perkins et al., 2012). Additionally, FH 
binds glycosaminoglycans (GAG) through CCP7 and CCP20. Binding of GAG helps FH recognize 
heparan sulphate on the cell surface and therefore aids its functional activity (Merle et al., 2015). 
Another known ligand of FH is C-reactive protein (CRP), which binds to CCP7 and CCP19-20 and 
through this interaction, boosts complement inhibition (Perkins et al., 2012). 
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Figure 1.3. Schematic view of Factor H with the position of binding to its ligands. Factor H 
consists of 20 SCR domains. The positions of two C3b binding sites SCR-1/4, two heparin-binding 
sites on SCR-7 and SCR-20, two C3d binding sites on SCR-19 and SCR-20, two C-reactive protein 
(CRP) binding sites at SCR-6/8 and SCR-16/20, and zinc binding sites at SCR-6/8 are shown. The 
location of eight N-linked glycosylation sites is shown by symbols; a ninth site at SCR-4 is not 
occupied (Perkins et al., 2012).  
 
FH has an additional control mechanism, involving five FH-related proteins (CFHR1-5) that 
belong to FH family. They are splice variants of the gene, coding for FH and therefore show high 
sequence homology with FH. However, their sequences are shorter than FH, with only 5 to 9 
CCP domains (Skerka et al., 2013). CFHRs increase complement activation by binding of CFHR3 
and CFHR4 to C3b, C3d and GAG on the cell surface, which as a result prevents FH from binding. 
A high degree of sequence similarity exists between the C-termini of CFHR3 and CFHR4, and FH 
(Heinen et al., 2009).  
Lectin complement pathway 
The lectin pathway is initiated by the binding of mannose-binding lectin (MBL), protein that 
possesses a collagen-like domain and a CRD to carbohydrates of microorganisms (Turner, 1996). 
The overall structure of MBL is a bit similar to C1q, however MBL forms multiple oligomers 
(trimers, tetramers and higher ordered oligomeric forms) (Fig. 1.2) (Matsushita and Fujita, 
2001). MBL is linked to MBL-associated serum protease-1 (MASP-1), MASP-2, and MASP-3 (Jack 
et al., 2001). The interaction is calcium dependent and in the absence of Ca2+ ions, lectin 
complement pathway cannot be activated (Teillet, 2005). When MBL is bound to its target, 
MASPs become active and cleave C4 and C2, which results in the formation of C3 convertase 
(C4b2ba), which is then followed by the rest of the complement cascade (Takahashi et al., 2007). 
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Complement related diseases 
Complement proteins and associated pathways are involved in many diseases. For example, C5 
plays pathophysiological role in myocardial ischemia and reperfusion injury (Busche and Stahl, 
2010). Some polymorphisms in FH, particularly in GAG-binding sites, can create imbalance in 
complement regulation and cause or contribute to various diseases (Brandstatter et al., 2012). 
One of them is the life-threatening kidney disease, haemolytic uraemic syndrome (HUS), where 
the majority of patients demonstrate dysfunctional FH due to mutations or FH autoantibodies 
(Brandstatter et al., 2012). This was found to be associated with a homozygous deletion in CFHR1 
(Hofer et al., 2013). Additionally, mutations in C-terminus of FH (CCP19–20) were identified in 
numerous HUS patients. Those mutations prevent the interaction between FH and C3b, or FH 
and GAG, or both, which leads to lack of surface protection against a complement attack 
(Ferreira et al., 2009; Merle et al., 2015). In addition, autoimmunity is strongly associated with 
complement proteins, mainly with deficiency of the early components of the classical pathway: 
C1q and C4 (Sturfelt and Truedsson, 2005). Addition of zinc to FH causes it to form oligomers 
containing 4-10 monomers, which inhibit its activity. FH-zinc oligomer formation is thought to 
be relevant in age-related macular degeneration (AMD) and occurs when zinc levels increase to 
above 60 μM (Perkins et al., 2010).  
1.2. Dendritic cells – a link between innate and adaptive immune system 
Dendritic cells (DCs) serve as a link between innate and adaptive immunity and are considered 
as professional antigen presenting cells (APCs). T-lymphocytes cannot recognize antigen by 
themselves. To initiate an immune response DCs are needed. Immature DCs are present in non-
lymphoid tissue where they meet the antigen and recognise it through specialized pattern 
recognition receptors (PRRs). DCs retain the memory of captured antigen and when they 
maturate and migrate to lymph nodes the uptake of further antigen is being reduced. In the 
lymph node the antigen is then being processed and presented through MHCII molecules to 
both lymphocytes T and B.  
Primary DCs are very rare with the frequency of only 0.02–0.06 x 106 cells/ml of blood (Stemcell 
Technologies; 2nd Sep 2016). Recent research showed that based on molecular markers and cell 
function, DCs can be divided into a few subsets. The two main groups are plasmacytoid DCs that 
express CD123 and BDCA-2, myeloid DCs that express BDCA-1 and BDCA-3 and Langerin DCs that 
express CD1a and CD14 markers. Due to DCs being present in the blood, lymphoid tissues, skin 
8 
 
and lungs, additional variability in surface markers expression is introduced by environmental 
differences. Therefore, to standardize the identification of DCs, multiple research is now being 
carried to compare DC subsets at the transcriptional level (Patel and Metcalf, 2016).  
1.2.1. Dendritic cell maturation 
Maturation increases the abilities of DCs to present antigen, this includes phenotypic and 
functional maturation. During a process called phenotypic maturation, the morphology of DCs 
changes, more specifically their size increases and characteristic cytoplasmic projections 
develop. Mature DCs lack several surface antigens including CD19, CD20 molecules to interact 
with B-cells, CD3 for T-cells, CD56 for NK cells, CD14 for monocytes and CD34 for haemopoietic 
stem cells (Tan et al., 2010). Instead, other surface molecules appear, which are crucial for their 
antigen presenting function. Those maturation markers are peptide–MHC class I and II 
molecules, and T cell costimulatory molecules like CD80 and CD86 (Turley et al., 2000; Trombetta 
et al., 2003), and are being highly expressed on the surface of mature DCs. Functional maturation 
progresses nearly in parallel to phenotypic maturation. However, in contrast to phenotypic 
maturation, which can be induced by many environmental stimuli, for functional maturation DCs 
need to sense microbial compounds through its PPRs. Functional changes include altered 
endocytosis, and later, migration to the nearest lymph node to meet T-cells. In addition, cytokine 
expression significantly increases upon DC maturation (Hammer and Ma 2013).  
1.2.2. Toll-like receptors signalling  
Innate immune response relies on the pattern-recognition receptors (PRRs), which recognize 
microbial structures, known as pathogen-associated molecular patterns (PAMPs). Dendritic cells 
express various PRRs, including nucleotide-binding oligomerization domain (NOD)-like receptors 
(NLRs), retinoic acid-inducible gene I (RIG-I) -like receptors (RLRs), Toll-like receptors (TLRs) and 
C-type lectins including -glucan receptor - Dectin-1 which is involved in response against fungal 
pathogens. (Brown, 2006). It was thought that in healthy hosts, protection against fungal 
infection relies on Th1-cell immune response (Romani, 2004). Nonetheless, recently discovered 
subset of T helper cells – Th17, are now considered substantial for immune response against 
microbial pathogens including fungi (Vautier et al., 2010). 
TLRs are a type of membrane bound PRR. In humans, there are ten TLRs classified so far (TLR1-
TLR10). Mice have additionally TLR11-13, but lack TLR10 (Gay and Gangloff, 2007). Based on the 
similarities among cytoplasmic domains, TLRs, together with the interleukin-1 receptors (IL-1Rs) 
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form the toll/interleukin-1 (TIR) superfamily. Extracellular domains of TLR are formed by tandem 
repeats of leucine-rich regions. This so-called leucine-rich repeats differ between TLRs, which 
allows the binding of specific ligands. Additionally to ligand specificity, TLRs are discriminated 
based on cellular localization and signal transduction (Dowling and Dellacasagrande, 2016). 
Localization depends on ligands being recognised. Receptors detecting mainly bacterial 
membrane components (TLR1, TLR2, TLR4, TLR5, TLR6) are located on the plasma membrane, 
whilst other TLRs are present on organelles and other intracellular compartments (TLR3, TLR7, 
TLR8 and TLR9) when detecting foreign nucleic acids. However, small amounts of the so-called 
“intracellular TLRs” can be also found on the cell surface, probably to detect low amounts of 
circulating nucleic acids (Guerrier et al., 2014).  
The main function of TLRs is to initiate an innate immune response. They induce the phenotypic 
and functional maturation of antigen presenting cells and the production of cytokines (Kawai 
and Akira, 2010). TLR3, TLR4, TLR7, TLR8, and TLR9 signalling activates Th1-type immune 
responses characterized by secretion of proinflammatory cytokines, while TLR2 and TLR5 initiate 
Th2-type immune responses which are associated with secretion of anti-inflammatory cytokines 
(Duthie et al., 2011). Furthermore, TLR3, TLR7, and TLR9 stimulate proliferation, maturation, and 
survival of B cells (Crampton et al., 2010; Green et al., 2012). It is also suggested that intracellular 
TLRs play a role in autoimmunity, because their prolonged activation leads to overstimulation 
of B cells (Green and Marshak-Rothstein, 2011).  
After interaction with specific ligands, two TLR receptor chains dimerize and undergo 
conformational changes that results in recruitment of the intracellular adaptor protein, MyD88 
(myeloid differentiation primary response gene 88), which initiates signalling. Additionally, after 
ligand binding TLR4 can be rapidly internalised by a clathrin- and dynamin-mediated process 
(Chaturvedi and Pierce, 2009). The only exception is TLR3, which signals via TRIF. TLR2, TLR4, 
TLR5 and TLR9 can also, in addition to MyD88 pathway, activate the TRIF cascade (Nilsen et al., 
2015; Robinet et al., 2016). Regardless of adaptor protein, activation leads to the activation of 
NF-kB, p38, JNK, and/or IFN-regulatory factor (IRF) signalling. As a result, inflammatory cytokines 
are produced (Fig. 1.4; Perkins and Vogel, 2015). TLR signalling bears the information about the 
type of immunogen; therefore, the expression of TLRs differs between DC subsets to customize 
the response. 
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Figure 1.4. Signalling pathways of toll-like receptors (TLRs). After interaction with specific 
ligands, TLRs activate MyD88 or TRIF signalling pathway. Regardless of adaptor protein, 
activation leads to the activation of the NF-kB, p38, JNK, and/or IFN-regulatory factor (IRF) 
signalling. As a result, inflammatory cytokines are being produced (Dowling and Mansel, 2016). 
 
Some events in TLR1, TLR2 and TLR4 signalling may be zinc-dependent. It was shown in 
numerous studies, that signalling cascade induced by recognition of bacterial components is 
influenced by zinc on many levels, including MAPKs activation, which is enhanced by the addition 
of zinc, or blocked when zinc is chelated. Additionally, the expression of pro-inflammatory 
cytokines like TNF-α, IL-1β and IL-6 by macrophages and primary monocytes, is limited by the 
chelation of intracellular zinc (Haase et al., 2008) and enhanced by the addition of physiological 
zinc concentrations (Yamasaki et al., 2007; Haase et al., 2008). A lack of zinc was also reported 
to selectively affect post-LPS phosphorylation of several kinases (inhibitor of nuclear factor 
kappa-IKK, mitogen-activated protein kinases-MAPKs and mitogen-activated protein kinase 
kinase-MKK) but not influence interleukin-1 receptor-associated kinase 1 (IRAK1; Dowling and 
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Mansel, 2016). To summarise, zinc is required to prevent dephosphorylation of several kinases, 
and for NF-kB activation, and thereby for transcription and release of a number of cytokines. 
1.2.2.1. TLR4 signalling after activation with LPS and hydroxyapatite (HAP) 
TLR4 was the first TLR identified in mammals and recognizes the active, lipid A component of 
lipopolysaccharide (LPS) from Gram-negative bacteria (Dowling and Mansel, 2016). The 
interaction starts with LPS-binding protein (LBP) in the serum binding LPS on the bacterial 
membranes and LPS aggregates in aqueous solutions. LBP facilitates extraction of LPS monomers 
by CD14 protein by changing the arrangement of LPS aggregates. LPS is transferred by albumin 
and then bound by N-terminal highly hydrophobic pocket of CD14. Subsequently, with the 
assistance of albumin, CD14 transfers LPS to MD-2 in the TLR4/MD-2 complex and later “M” 
shaped dimers of TLR4/MD-2 complexes are being formed. Then through the phosphate groups 
of lipid A, LPS interacts with positively charged amino acids of TLR4 (Plociennikowska et al., 
2014).  
LPS is not the only known ligand for TLR4. There are numerous endogenous activators including: 
CD138, endoplasmin, fibrinogen, fibronectin, heparan sulphate, HSP22, HSP60, HSP70, HSP72 
(Yu et al., 2010), but also divalent metal cations nickel and cobalt have been shown to trigger 
activation of human TLR4.  The interaction of those metals occurs with non-conserved histidine 
residues, and may mediate TLR4 dimerization even in the absence of MD2 (Daringer et al., 2015). 
It is not known whether other metal cations, including zinc can trigger TLR4 activation. In 
addition, hydroxyapatite (HAP), a calcium phosphate mineral, can induce inflammatory reaction 
via TLR4 signalling as shown in macrophages exposed to HAP particles (Grandjean-Laquerrière 
et al., 2007). Both LPS and HAP ligands induce the same sequence of TLR4 signals, starting with 
TLR binding TIRAP and MyD88, which results in phosphorylation of MAPKs and early activation 
of NF-kB (Fig. 1.5) (Haase et al., 2008). Additionally, after activation of MyD88, binding of TRAM 
and TRIF adaptors to TLR4 receptor causes delayed activation of NF-kB (Kagan et al., 2008). Late 
activation of NF-kB also triggers the activation IFN regulatory factor 3 (IRF3) (Fitzgerald et al., 
2003), which then, together with TRIF induce IFN-β production (Monroe et al., 2010). IFN-β is 
crucial for induction of expression of surface molecules required for antigen presentation such 
as CD40, CD80, and CD86 (Hoebe et al., 2003).  
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Figure 1.5. The role of zinc in TLR4 
signalling. After binding LPS or HAP, TLR4 
initiates a signalling cascade involving 
the adaptor proteins MyD88 or TRIF, 
which result in the production of 
proinflammatory cytokines (Brieger et 
al., 2013).  
 
 
 
1.2.3. Antigen presentation 
Antigen presentation is the capacity of some immune cells, called antigen presenting cells (APC), 
to capture antigens and then allow their recognition by T-cells. It is important because during 
their development in the thymus, only T-cells that show dual specificity (recognize self-carrier 
molecules, but only non-self-antigens) are picked during positive selection for further 
development. Therefore, antigens are processed and presented via major histocompatibility 
complex (MHC; also called called human leukocyte antigen, HLA) or cluster of differentiation 1 
protein (CD1) molecules. There are two subgroups of MHCs: class I and class II which present 
peptides at the cell surface to CD8+ and CD4+ T-cells, respectively (Vyas et al., 2008). CD1 on the 
other hand are involved in the presentation of lipid antigens to T cells (Porcelli, et al., 1989). 
MHC I molecules are present on all nucleated cells (Kulski et al., 2003) and their function is to 
present endogenous proteins including pathogen peptides, degraded by cytosolic and nuclear 
proteasomes. Degraded peptides are transported via transporter associated with antigen 
presentation (TAP) into the endoplasmic reticulum (ER), where MHC class I molecules are 
waiting, stabilized by chaperones, including calreticulin, ERp57 and tapasin. After peptide 
binding, peptide–MHC class I complexes leave the ER and via Golgi migrate to the cell surface 
for antigen presentation to CD8+ T-cells via T-cell receptor (TCR; Fig. 1.6 A) (Huges et al., 1997).  
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Figure 1.6. Antigen presentation by MHC class I (A) and MHC class II (B) presentation pathways. 
(A) For the presentation of intracellular antigenic peptides by MHC class I molecules peptides 
are first degraded by the proteasome. Then, translocated via transporter associated with 
antigen presentation (TAP) into the endoplasmic reticulum (ER) lumen where MHC class I 
molecules are being loaded. Released peptide–MHC class I complexes migrate to the cell surface 
where the antigen is being presented to CD8+ T cells. (B) MHC class II molecule complexed with 
invariant chain (Ii) are transported to late endosomes, where li is being digested and only class 
II-associated Ii peptide (CLIP) fragment remains complexed with MHC class II. CLIP is then 
exchanged for antigenic peptide and MHC class II molecules are transported to the plasma 
membrane to present antigenic peptides to CD4+ T cells. APC, antigen-presenting cell; β2m, β2-
microglobulin; ERAD, ER-associated protein degradation; MHC class II compartment (MIIC); TCR, 
T cell receptor (Neffies et al., 2011). 
 
Additionally, in the process known as cross-presentation, exogenous antigens are being 
presented by MHC class I to CD8+ T cells via one of the two main intracellular pathways: 
'cytosolic' and 'vacuolar' pathways (Fig. 1.7). In the cytosolic pathways, antigens are degraded 
by the proteasome and then trimmed by amino-terminal peptidases prior to being loaded on 
MHC class I. Cut peptides are transported by transporter associated with antigen processing 1 
(TAP1) and TAP2 into the ER. There MHC class I molecules are loaded with peptides the same 
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way as in the classical MHC class I-mediated antigen presentation pathway. Alternatively, after 
degradation by proteasomes, antigens can be transported back into phagosomes and loaded 
there. In vacuolar pathway of antigen cross-presentation, antigen is being degraded and loaded 
on MHC class I molecules in endocytic compartments. Vacuolar pathway is therefore 
independent of TAP and proteasome (Fig. 1.7; Joffre et al., 2012).  
 
 
Figure 1.7. Intracellular pathways for cross-presentation in dendritic cells. After phagocytosis, 
exogenous antigens can be processed in two ways, either by cytosolic pathway, which involves 
degradation in the proteasome and on MHC class I in endoplasmic reticulum (ER) or vacuolar 
pathway where antigens are degraded into peptides in the phagosome, where they are then 
loaded on MHC class I molecules (Joffre et al., 2012).  
 
MHC II molecules are present only on the surface of APCs (macrophages, certain B-cells and 
dendritic cells). Each MHC II protein complex is composed of two proteins, α and β. Those two 
membrane spanning proteins, together with li chain, form trimeric αβIi complexes (Roche et al., 
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1991). MHC II αβIi complexes are transported to early endosomes, which then together develop 
into the late endosomes (Fig. 1.6 B). In late endosomes, Ii is degraded, leaving a residual class II-
associated Ii peptide (CLIP) in the peptide-binding groove of the MHC class II heterodimer. CLIP 
fragment is then exchanged for an antigenic peptide degraded in the endosomal pathway. This 
exchange is facilitated by HLA-DM molecule. Loaded MHC class II then migrate to the cell surface 
to present antigens to CD4+ T-cells (Neefjes et al., 2011).  
Antigens are loaded mostly in late endosomes, but some MHC II-protein complexes can be 
formed in early endosomes or lysosomes, or even at the plasma membrane (Griffin et al., 1997; 
Pinet and Long, 1998). Expression of MHC II changes during DC maturation. In immature cells, 
complexes are formed and stored for a very short time on their surface, and then endocytosed 
and degraded. As maturation progresses, both the generation of new complexes and their 
turnover on the cell surface gradually increases. In fully mature DCs cell surface expression of 
MHC II is more than 10 times higher than in immature DCs (van Niel et al., 2008).  
Bacterial lippopolisacharide (LPS) and other TLR ligand are crucial in the presentation of 
previously internalised antigens. It was shown by Turley et al., (2000) that complex formation 
between previously internalized antigens and MHC class II molecules and also trafficking of 
those complexes to the cell surface was effective only following treatment of DCs with LPS. LPS 
also stimulated antigen cross-presentation via MHC class I (Delamarre et al., 2003). 
Proinflammatory TLR signaling in macrophages or DCs also stimulates phagosome maturation, 
antigen processing and favours presentation phagosomal cargo being TLR ligand via MHC class 
II (Mantegazza et al., 2013).  
 
1.3. Zinc in immune system 
Zinc is one of the most abundant metallic chemical elements on earth, and it is known for its 
exceptional biological importance (Hambidge and Krebs, 2007). Zinc is referred to as a trace 
element because of its low concentration in plasma; nonetheless, it is one of the essential trace 
elements in the human body. Most of the total 3 g of zinc in the body is bound to proteins (Scott 
and Bradwell, 1983; Rink and Gabriel, 2000). The importance of zinc in humans was only 
recognised in the 1960s. Now deficiency of zinc is considered one of the main reasons of 
malnutrition and is estimated to affect over 25% of the world’s population, and considered the 
eleventh most important health risk factor in the world (Maret and Sandstead, 2006). 
Copenhagen Consensus 2008 stated that zinc deficiency (along with vitamin A deficiency) is the 
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number one global health issue that can be addressed in a cost effective manner, to reduce child 
morbidity and mortality (Copenhagen Consensus 2008 Challenge Paper, Hunger and 
Malnutrition; www.copenhagenconsensus.com).  
In mammals, zinc is absorbed from the diet by enterocytes that line the gut through the action 
of the Zip4 transporter protein; it is then released into the portal circulation by the ZnT1 
transporter protein for systemic distribution (Cousins, 2010). The physiological plasma zinc 
concentration is in the range of 15-20 μM (Gorgani et al., 1999b), with zinc mostly (75%) bound 
to serum albumin. This accounts for as much as 98% of exchangeable/deliverable zinc. The rest 
is bound to other plasma proteins such as alpha-2 macroglobulin (Lu et al., 2012) and histidine 
rich glycoprotein (HRG). Of great importance is the fact that the affinity of zinc for those proteins 
drops in low pH.  Conditions of local acidosis (e.g. ischemia or hypoxia) generally can be caused 
by problems with blood vessels, with resultant damage to or dysfunction of tissue (Borza and 
Morgan, 1998, Jones et al., 2005b). The concentration of unbound Zn2+ ions in plasma is in the 
range of 0.5-1 μM (Vallee and Falchuk, 1993, Tubek et al., 2008) and in the cells in extremely 
low nanomolar and even picomolar concentrations (Maret, 2015). In some pathological states, 
the zinc level can be highly elevated (intracellular zinc level of up to 60 μM in age-related macular 
degeneration (AMD)) (Perkins et al., 2010). Localised zinc concentrations can be also increased, 
such as at the cell surface following its release from activated platelets (Leung et al., 1983). Zinc 
concentration in platelets is 30-60 times higher than in plasma. It is accumulated in cell 
cytoplasm and in α-granules (Marx et al., 1993). Other cells able to release zinc are erythrocytes, 
lymphocytes and neutrophils (Whitehouse et al., 1982). In addition, as a result of 
lipopolysaccharide (LPS) administration, nitric oxide can cause release of zinc from thiol groups 
of zinc fingers, which increases free zinc levels (Andonova et al., 2001, Kolb and Kolb-Bachofen, 
1998).  
Zinc is required for the activities of over 300 enzymes, including deoxythymidine kinase, which 
is essential for DNA synthesis and cell division, and is important for the structural integrity of 
nearly 2000 transcription factors (Prasad, 2012). It also plays a huge role in cell integrity and 
cellular metabolism, protein synthesis (Maret, 2009) and wound healing (Heyneman, 1996). 
There is a group of calcium-dependent zinc-containing endopeptidases called matrix 
metalloproteinases (MMPs). MMPs are members of the metzincin group of proteases which 
share the conserved zinc-binding motif in their catalytic active site. They mainly act as regulators 
of extracellular tissue signalling networks and also degrade the various components of the 
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extracellular matrix (ECM) (LÖffek et al., 2011). MMPs contribute to the homeostasis of many 
tissues and participate in several physiological processes, including bone remodelling, 
angiogenesis, cell migration and proliferation. Dysregulated MMPs activity leads to pathological 
conditions such as arthritis, inflammation and cancer (LÖffek et al., 2011). It was also shown that 
several MMPs are directly involved in the immune response and innate immunity. Those include 
MMP-7 in the lung which by cytokine release recruit neutrophils (Chen et al., 2009) and 
recruitment of immune cells by macrophage derived MMP-2 and MMP-9 in a monocyte-driven 
model of autoimmune kidney inflammation (Triantafyllopoulou et al., 2010). 
Because of this, zinc deficiency has many dangerous effects, particularly immunological 
disorders (Ibs and Rink, 2003). The effect of zinc deficiency on the immune system is complex 
and influences both innate and adaptive immunity, contributing to several chronic inflammatory 
diseases including acrodermatitis enteropathica, rheumatoid arthritis (RA), chronic asthma, 
systemic lupus erythematosus and Alzheimer disease (Bonaventura et al., 2015). 
1.3.1. Zinc in innate immunity 
The exact mechanisms by which zinc influences the innate immune system are not yet fully 
understood. It is known that zinc supplementation increases chemotaxis of granulocytes 
(Hujanen, 1995) and that a lack of zinc increases phagocytosis and cytotoxicity of monocytes 
(Mayer et al., 2014). Additionally, both zinc deficiency and surplus have a role in the 
neutralization of pathogens, through the regulation of superoxide anion production whose role 
is the destruction of pathogens after phagocytosis (Hasegawa et al., 2000). Another role of zinc 
is to promote adhesion of monocytes to endothelial cells (Chavakis et al., 1999). Also the 
importance of zinc for the production of cytokines such as interleukins IL-1β, IL-6 and TNF-α (Fig. 
1.8) was observed for many cell types, including monocytes where zinc deficiency inhibited the 
production of IL-6 and TNF-α (Mayer et al., 2014). Zinc deficiency also causes reduction of NK 
cell activity (Allen et al., 1983), decreased cell production, reduction in cell mediated immunity 
and phagocytosis, lymphocyte proliferation, and affects the maturation of dendritic cells 
(Kitamura et al., 2006). According to Kitamura et al (2006), LPS induced maturation of DCs 
triggers decrease in intracellular free zinc, which is crucial for the increased expression of MHC-
II and co-stimulatory molecules on the DCs surface. These results imply zinc is a crucial element 
in antigen presentation and therefore activation of the adaptive immune response.  
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Figure 1.8. The effect of zinc deficiency on the innate and adaptive immune cells and their 
interactions. The number of most of immune cells decreases as a result of zinc deficiency, 
however immune defence against pathogens is maintained. Mainly cytokines production is 
affected (Maares and Haase, 2016).  
 
1.3.2. Zinc in adaptive immunity 
Changes in zinc homeostasis have been shown to affect adaptive immunity in multiple ways. For 
example, zinc influences lymphocyte formation and the production of cytokines, which in fact 
leads to changes in activity and function (Maares and Haase, 2016). Also T-cells are very sensitive 
to zinc; zinc deficiency is known to cause thymus atrophy, reduction in Th1 cell numbers (T-cell 
lymphopenia) and decreased activity of thymulin, a zinc dependent hormone produced by 
thymic epithelial cells  (Dardenne et al., 1982, Mitchell et al., 2006). The role of thymulin is to 
induce the differentiation of T-cells and enhances several functions of the various T-cell subsets 
(Bach and Dardenne, 1989). In addition, studies on mice showed that a lack of zinc during T-cell 
maturation leads to significant apoptosis of T-cell precursors (King et al., 2005). Another role of 
zinc is to maintain the balance between the Th1 and Th2 subsets as its deficiency significantly 
affects the production of Th1 cytokines and (although less significantly) the Th2 response 
(Prasad, 2000). Other effects of zinc deficiency on T-cells includes inhibition of the development 
of pro-inflammatory Th17 cells (Kitabayashi et al., 2010) and increases the number of cytotoxic 
and memory T-cells (Prasad, 2000), which could lead to autoimmune reactions.  
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B-cells are in general less affected by zinc than T-cells. Yet, zinc has an influence on their 
development as its deficiency causes a reduction of immature and pre-mature B-cells. 
Additionally, antibody production by those cells is affected by zinc deficiency (Stefanidou et al., 
2006).  
1.3.3. Zinc and inflammation 
Zinc is indirectly associated with inflammation. Zinc deficiency triggers increased cytokine 
production, including IL-1-β release (Summersgill, 2014), which is involved in the pathogenesis 
of rheumatoid arthritis. That suggests that a lack of zinc contributes to the disease and zinc 
supplementation could be used as a treatment (Dore-Duffy, 1990). Other cytokines whose levels 
are elevated when zinc is reduced are IL-6, IL-8 and TNF-α (Mariani et al., 2006). Furthermore, 
zinc deficiency potentiates proliferative response of T and B lymphocytes as a result of IL-6 and 
IL-2 signalling but in contrary lessens IL-4 signalling, leading to an impairment of the immune 
system (Gruber et al., 2013).  
1.4. Zinc homeostasis  
Surprisingly, despite its many functions, our body has only a limited ability to store zinc and such 
stores are inadequate for long periods of zinc deficiency (Liuzzi et al., 2005). For this reason, zinc 
homeostasis is strictly controlled. Transport through the plasma/cellular membrane occurs via 
ZIP and ZnT transporters: ZIP (encoded by the Slc39 genes) transports Zn to the cell cytosol and 
ZnT (encoded by the Slc30 genes) transports Zn from the cell cytosol (Cousins et al., 2006), 
(Palmiter and Huang, 2004; Eide, 2004). Another mechanism involves the storage and release 
from “zincosomes” controlled by the same zinc transporters (Wellenreuther et al., 2009). The 
last mechanism is binding zinc by metalothioneins (MTs) (Maret, 2009). 
Metallothioneins, small cysteine rich proteins, have a great zinc binding capacity and chelate 
zinc in the cytoplasm. Each of this protein can bind up to seven Zn2+ ions, depending on the 
oxidation of metallothioneins thiol residues (Krezel and Maret, 2007; Maret 2006). They can also 
act as an exchangeable zinc pool, releasing zinc when needed (Blewett and Taylor, 2012). MTs 
react with zinc in two ways; they are either buffering or muffling of zinc. Under normal 
physiological conditions their function is to buffer zinc with different affinities at the nano- to 
picomolar range (Krezel and Maret, 2007). However, in case of elevated cytosolic zinc, the role 
of zinc-binding proteins is to move it out of the cell or store it within subcellular compartments. 
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The difference between those two processes is that muffing is much slower than buffering 
(Gunzel et al., 2007). MTs can also bind heavy metals, with the capacity very often higher than 
for zinc. For example, Cd2±MT complexes are 100 to 1000-fold more stable than Zn2+–MT 
complexes (Carpene et al., 2007; Bell and Vallee, 2009).   
Another mechanism of zinc homeostasis is the reversible storage of zinc in “zincosomes”. These 
intracellular vesicles can store milimolar amounts of zinc, and then release it back to the 
cytoplasm when needed (Haase and Maret, 2005). For a long time, zinc stored in those vesicles 
was considered as free or just loosely bound. In fact, it is not free but present as complexes, 
mainly bound to light, redox-inactive ligands (sulphur, histidine and oxygen; Wellenreuther et 
al., 2009).  
1.5. Zinc transporters as the main mechanism of zinc homeostasis 
Zinc enters the body as a divalent, hydrophilic cation with a single oxidative state, which means 
it cannot be oxidized or reduced. Zn2+ ions cannot cross the membrane by passive diffusion and 
thus specialized transporters are required to facilitate transport of zinc in and out of the cytosol. 
Zip (Zrt-Irt-Protein) and ZnT (Zn-transporter) transporters are important components of a 
network that builds zinc homeostasis. Mammalian zinc transporters are grouped based on their 
predicted membrane topology, into two major families, encoded by solute-linked-carrier (SLC) 
genes, the SLC30 (ZnT) and SLC39 (Zip) families. There are 10 isoforms of ZnTs and 14 of Zips 
encoded in the human genome (Kambe, 2013). Zip proteins are grouped into four subfamilies, 
I, II, Gufa and LIV-1. Most of them (9 in total) belong to the LIV-1 subfamily (Zip 4, 5, 6, 7, 8, 10, 
12, 13, 14; Jeong and Eide, 2013). 
X-ray crystal structures of zinc transporters are not yet available, thus both structure and 
mechanisms of transport are yet to be discovered. It is however postulated that ZIP proteins 
transport zinc independently of ATP, by symporters, or secondary active transport (Hojyo and 
Fukada, 2016). Additionally, Zip2-mediated zinc transport was shown to be very likely a co-
transport with HCO3- (Gaither and Eide, 2000). In contrast, ZnT transport seems to require ATP 
as it was shown by Ohana et al (2009) that the proton gradient generated by V-type ATPases 
powers zinc transport into the Golgi apparatus. Nonetheless, the exact molecular mechanisms 
remain unclear. 
Most ZIP members have eight predicted transmembrane (TM) domains with their N- and C- 
termini facing the extracytoplasmic space and a histidine-rich region between TM3 and TM4. 
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This histidine rich loop was postulated to be a zinc binding site but its specific function is still not 
known. The greatest homology amongst Zip transporters exists within a signature 12 amino 
acids sequence (HSVFEGLAVGLQ), localised to TM4 (Eng et al., 1998). Transporters from LIV-1 
subfamily are different from other Zips by having a highly conserved putative metalloprotease 
motif (HEXPHEXGD) in TM5. Additional histidine residues on the N-terminal ectodomain and 
extracellular loop between TM2 and 3 are also found in LIV-1 subfamily members (Taylor et al., 
2004). These histidine residues located on N-terminal domain are thought to bind zinc, making 
more zinc accessible for transport. Additionally, there are three glycosylation sites located near 
to the N-terminus (Taylor et al., 2005; Wang et al., 2004).  
ZnT family members have six conserved TMs with both N- and C-termini facing the cytoplasm. 
In contrast to ZIP proteins, the C-terminal tails of ZnTs are long and consist of 82 to 203 amino 
acids (longest in ZnT6). Between TM2 and TM3 is a conserved serine flanked by two histidines. 
Zinc transporter activity depends on the histidine-rich zinc binding region located between TMs 
IV and V. ZnTs can form hetero- (SLC30A5/SLC30A6) or homodimers (SLC30A7), which is 
especially important for ZnT6 as it cannot transport zinc itself but only modulate the activity of 
other transporters (Ohana et al., 2009; Suzuki et al., 2005). 
1.5.1. Subcellular localisation  
Both families of zinc transporters (except ZnT10) have been well characterised in many cell 
types. In humans, Zip1 and ZnT1 are ubiquitously expressed, whereas other Zips and ZnTs show 
more tissue/cell-specific expression.  
The majority of the Zip transporters can be found at the plasma membrane. Zip1 is mostly 
present on the plasma membrane, when cells are cultured in a media with low zinc 
concentration, it serves as the main zinc importer. However, when sufficient amounts of zinc is 
present, Zip1 can translocate to intracellular organelles (Milon et al., 2001). Zips 2-6 and Zip8, 
Zip10 and Zip14 are also located on at the plasma membrane (Table 1.1; Jeong and Eide, 2013). 
Zip4 is responsible for zinc uptake in the small intestines, where it is located on enterocytes at 
the plasma membrane (Cousins, 2010). Zip3 and Zip8 are additionally located on lysosomes. 
Zip7, Zip9 and Zip13 are present on intracellular organelles and therefore can only transport zinc 
from the cytoplasm into intracellular stores (Table 1.1).  
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Table 1.1. Known subcellular localizations of ZIP zinc transporters (Jeong and Eide, 2013). 
 
ZnT1 is localized on the plasma membrane as it is the main exporter of zinc from the cell cytosol 
to the extracellular space. Other exporters found on plasma membrane but also on organelles 
are ZnT2, ZnT4 and ZnT5. ZnT3, ZnT6, ZnT7, ZnT8 and Znt9 are located on intracellular 
membranes and transport zinc to stores or organelles (Table 1.2). The subcellular localization of 
ZnT10 is not known (Schweigel-Röntgen, 2014). 
 
 
Table 1.2. Known subcellular localizations of ZnT zinc transporters (Huang and Teppamorndech, 
2013).  
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1.5.2. The role of zinc transporters in the immune system 
As described above, zinc deficiency is known to cause defects in the immune system. These 
effects are manifested through deficits in macrophage and neutrophil chemotaxis and 
phagocytosis, reduced secretion of pro-inflammatory cytokines by macrophages and reduced 
NK activity. The acute phase response to stress, trauma, and infection includes a transient and 
rapid decline in the plasma zinc concentration. Such observations also suggest that zinc affects 
the immune system in a dose dependent manner, with low concentrations of zinc being pro-
inflammatory and high, anti-inflammatory (Foster and Samman, 2012).  
Many Zip and ZnT transporters are expressed in immune cells and there are a few links found 
between their functioning and effective immune responses (Overbeck et al., 2008). The 
expression of most zinc transporters are influenced by LPS treatment. For example, it was shown 
that stimulation of macrophages with LPS and TNF-α caused uptake of zinc from extracellular 
space by upregulation of Zip8. This in fact weakened the pro-inflammatory response as zinc 
bound NF-κB and inhibited IκB kinase β (Liu et al., 2013). In addition, expression of ZIP14 in 
macrophages is upregulated as a result of LPS (or LPS plus IFN-γ) stimulation. Similar to ZIP8, this 
inhibited the pro-inflammatory response by impairing IL-6 and TNF-α release (Sayadi et al., 
2013). A study on human T-cells, showed that immune activation causes upregulation of several 
zinc transporters, with the highest effect seen for Zip8. Additionally, ZIP8 regulates efflux of zinc 
from the lysosomes and consequently controls IFN-γ expression (Aydemir et al., 2009). Also, 
ZnT5 is required for the mast cell activation in mast cell-mediated allergic reactions (Nishida et 
al., 2009). 
Despite zinc transporters being deeply involved in the immune functioning, their presence in 
dendritic cells (DCs) is still not fully characterised. Current studies have shown that LPS 
stimulation caused downregulation of ZIP6 and ZIP10 transporters in DCs, but increased 
expression of ZnT1, ZnT4 and ZnT6. The effect was associated with a decrease in intracellular 
zinc concentration, which was suggested to be necessary for LPS-induced DC maturation 
(Kitamura et al., 2006). Defective or dysregulated zinc transporters are involved in the 
development and/or progression of many diseases; therefore, it is crucial to understand their 
expression pattern in cells essential for the proper immune response.    
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1.6. Histidine-rich glycoprotein (HRG) 
Histidine-rich glycoprotein (HRG) is a 75 kDa glycoprotein, present at relatively high 
concentrations in human plasma (ca. 100-150 µg/ml). Human HRG plasma levels increase with 
age (Drasin and Sahud, 1996). The protein is synthesised by the parenchymal cells of the liver 
(Koide et al., 1986; Hulett and Parish, 2000). 
HRG has a multidomain structure, composed of 507 amino acids, with six predicted N-linked 
glycosylation sites (Poon et al., 2010a). It consists of two cystatin like N-terminal domains (N1 
and N2), a central histidine rich region (HRR) flanked by two proline rich regions (bigger PRRI 
and smaller PRR2) and a C-terminal domain (C; Fig. 1.9; Jones et al., 2005a). The HRR region 
bears an extraordinary repeating amino acid sequence (GHHPH) between residues 330 and 389 
and is implicated in metal binding (Morgan, 1981; Koide et al., 1986). The domains are held 
together by six disulfide bonds (Sorensen et al., 1993), however only five disulfide bonds might 
be essential for the native conformation of the protein (Ronca and Raggi, 2015), as the Cys185-
Cys399 bond is amenable to redox activity (Kassaar et al., 2014).  
HRG has a high binding capacity for Zn2+ and other divalent cations. The binding occurs via 
histidine residues, with a stoichiometry for Zn2+ of approximately 1:1-1:10 (Morgan, 1978). 
Nonetheless, when other plasma proteins that compete for zinc are present, HRG chelates only 
1% of the metal (Fu and Horn, 2002). The binding of other divalent metal cations was examined 
for rabbit HRG and showed that Hg2+, Cu2+, Zn2+, Ni2+, Cd2+, and Co2+ bind in descending order of 
binding affinity (Mangani et al., 2003). The affinity of HRG for zinc is pH dependent. HRG with 
isoelectric point of 7.09 (calculated by ExPasy based on protein sequence), at pH 7.4 is negatively 
charged and can bind Zn2+ to neutral histidine residues. Whereas at low pH, positively charged 
protein binds Zn2+ by protonation of histidines and possibly causes a conformational change of 
HRG (Borza et al., 1996). Also binding of HRG to its ligands, heparin and heparan sulfate was 
shown to be pH dependent (Fu and Horn, 2002; Borza and Morgan, 1998). 
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Figure 1.9. Schematic representation of protein domains, post-translational modifications of 
human HRG (Poon et al., 2010a). 
 
HRG is not found only in humans but also in many other vertebrates (Jones et al., 2005b). Rabbit 
plasma HRG is very similar to human protein, with two homologous N-terminal domains, 
histidine rich region flanked by two proline-rich regions and a C-terminal domain. The sequence 
alignment of human HRG (GenBank under the accession number AAI50592.1) and rabbit HRG 
(XP_008264798.1), show that the two proteins share 292 identical amino acids (60% identity), 
385 semi-conserved and conserved amino acids (68% positives) and 53 gapped amino acids (9% 
gap) over 545 residues, as calculated by the NCBI BLAST software. The highest similarity 
homology occurs at the N1 and N2 terminal domains, with the proteins sharing 84% overall 
identity (Fig. 1.10; Ronca and Raggi, 2015). 
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Figure 1.10. (A) Alignment of human HRG (GenBank under the accession number AAI50592.1) 
and rabbit HRG (XP_008264798.1). (B) Domain structure of human and rabbit HRG proteins 
(Ronca and Raggi, 2015). 
 
Through its ability to interact with numerous ligands, HRG serves as a regulator of numerous 
physiological processes including angiogenesis by both stimulatory (Simantov et al., 2001; 
Klenotic et al., 2010) and inhibitory (Dixelius et al., 2006) mechanisms. It has been also shown 
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that HRG acts in the coagulation system (Tsuchida-Straeten et al., 2005) by interaction with 
many molecules including: heme, plasminogen (Lijnen et al., 1980), heparanase (Poon et al., 
2010b), fibrinogen (Leung et al., 1983) and heparin (Kassaar et al, 2015). HRG also plays an 
important role in the immune system. It is involved in immune complex clearance by binding to 
various components of the immune system including the complement proteins within both the 
classical and alternative pathways, antibodies, Fab region on immunoglobulin G and membrane 
attack complex components. HRG also modulates formation and function of immune complexes. 
Despite of its huge importance, immune complexes can become toxic by building deposits in 
small blood vessels and lead to pathologies such as rheumatoid arthritis, vasculitis or 
glomerulonephritis. To streamline transport of the immune complex to the liver and spleen, 
where the phagocytosis occurs, complement proteins need to be involved. HRG modulates 
complement (by augmentation or inhibition) through interactions with C8, C9, factor D and S-
protein. It also binds strongly to C1q, FH, C4b-binding protein, C3, C4 and IgG (Manderson et al., 
2009, Chang et al., 1992). As the whole process of pathogen recognition, complex formation and 
clearance is very complicated, a vast array of proteins is needed to control, including HRG. The 
most abundant serum immunoglobulin that forms complexes is IgG. It is already known that 
HRG bind to all IgG subclasses and also to IgM, but the affinity is dependent on L-chain isotype. 
The average Kd value for this interaction is 85 nM but higher for those with Lλ chain than Lκ and 
is decreased in the presence of zinc (Gorgani et al., 1997a, Gorgani et al., 1999b). Interestingly, 
HRG in physiological concentrations can inhibit insoluble IgG immune complexes formation but 
also promote the phagocytosis of soluble complexes by macrophages (Gorgani et al., 1999a). 
It is of great importance to eliminate necrotic cells (Jones et al., 2005b, Jones et al., 2005c) and 
apoptotic cells (Gorgani et al., 2002) from the immune system. HRG regulates activation of 
complement on necrotic cells, via interactions with C1q. This interaction occurs in the late stage 
of cell death when the cell membrane becomes permeable (Manderson et al., 2009). Zinc is 
thought to inhibit the interaction of HRG with C1q (Gorgani et al., 1997b). However, the effect 
of zinc on other complements remains to be determined. HRG also regulates other immune 
processes including antitumor (Huang et al., 2011), antibacterial (Rydengard et al., 2006, 
Rydengard et al., 2007, Kacprzyk et al., 2007) and antifungal (Rydengard et al., 2008) activities. 
As mentioned above it also modulates complement proteins by augmentation or inhibition 
(Easterbrooksmith et al., 1988, Gorgani et al., 1997a, Chang et al., 1992) and controls 
phagocytosis (Poon et al., 2010a). 
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Activated platelets can release zinc into plasma. Incidentally, activated platelets simultaneously 
can also release HRG in localised areas (Leung et al., 1983). Zinc concentrations in the cytoplasm 
and alpha-granules of human platelets is 30–60-fold higher than in plasma (Morgan, 1981). It 
has been proposed by Kluszynski et al. that platelets release Zn2+ ions from α-granules 
(Kluszynski et al., 1997; Gorodetsky et al., 1993), which serves as a cofactor for the binding HRG 
molecules to heparin (for heparin neutralization; Kassaar et al, 2015) and also to tropomyosin 
on endothelial cells (to exert an antangiogenic effect; Jones et al., 2005b). It is important that 
zinc is released locally because it provides better control for fibrinogenesis and angiogenesis. 
It has been postulated by Lu et al. (2012), that HRG activation by zinc may occur 
pathophysiologically through fatty acid-mediated inhibition of zinc binding by albumin. Albumin 
is the most abundant plasma protein (600 μM) and contains 588 amino acids in three domains. 
It has many functions, but its main functions are the transport and delivery of molecules such as 
fatty acids, metal ions and drugs. Fatty acid transport is achieved through five major and up to 
five additional low-affinity binding sites (Leung et al., 1983). There is also evidence that zinc 
dependent activation of HRG may be important for development of thrombotic disorders. As 
thrombotic disorders often co-exist with disorders connected with high levels of plasma fatty 
acids (diabetes, obesity), there is a potential relation between fatty acids binding to albumin, 
the subsequent release of zinc and the increased complexation of zinc with HRG (Fig. 1.11; 
Stewart et al., 2009). 
 
 
Figure 1.11. With high levels of HRG associated with thrombotic disorders, there must be a 
relation between fatty acids binding to albumin, subsequent release of zinc and the increase of 
zinc-HRG complex formation. Increasing fatty acid level shifts the equilibrium towards the right 
(Stewart et al., 2009).  
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1.7. Age-related macular degeneration (AMD) 
Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss 
in elderly people. It affects nearly 8.7 % of the population over the age of 55, which is estimated 
to 196 million people by the year 2020 (Wong et al., 2014). It is associated with the development 
of drusen between retinal pigment epithelium (RPE) and Bruch's membrane. Drusen are 
pathological extracellular deposits primarily containing glycolipids, proteins, and cellular debris 
(Liu et al., 2012). Besides age, certain risk factors contribute to the development of the disease, 
including smoking and family history (Klein et al., 2004; Thornton, 2005). It is now known that 
genetic factors can be responsible for as much as 50 to 70% of the total variability in disease 
risk. Further familial studies also showed that genetic factors play a significant role in the 
variability in the severity of AMD (Seddon et al., 2005). 
AMD is connected with the development of drusen between retinal pigment epithelium (RPE) 
and Bruch's membrane, which block exchange of nutrients from the vasculature leading to cell 
death and sensory loss within the central visual field. The late stage of the disease can be 
characterised as either wet-AMD (neovascular) or dry-AMD (non-neovascular), also called 
geographic atrophy caused by degeneration of photoreceptors. In neovascular disease, newly 
formed, abnormal vessels, grow in the sub-retinal space causing RPE detachment. Both forms 
result in vision damage through cell death (Tan, 2016).  
1.7.1. Retinal immune defence 
The retina is crucial for vision. It is constituted by four major layers of cells. Phototransduction 
occurs in the rods and cones of the neurosensory retina. The next layer, the retinal pigment 
epithelium (RPE) serves as a blood/eye barrier, regulates nutritional transport and phagocytes 
outer segments of photoreceptors (Strauss, 2005). The third retinal layer, Bruch’s membrane 
(BM) is actually a multilayer extracellular matrix and serves as a carriage of wastes and nutrients 
between choroid and RPE. The outermost layer of retina, the choriocapillaris is highly 
vascularized and connects the retina with the choroid, which provides nutrients and oxygen (Fig. 
1.12) (Lutty et al., 2010).  
The macula is the central part of the retina. It has not only many more rods and cones, but also 
RPE cells. The central macula (fovea) is especially rich in photoreceptors, with 30 cones per each 
RPE cell, and the central part of fovea, is built only by red and green cones. That assures high 
visual acuity. The number of rods may vary and during aging decrease by 30%, however the 
30 
 
number of cones is not affected by age. Additionally, during AMD development, rod 
degeneration is much higher than cones; nonetheless, rod loss triggers also cone damage. The 
macula has exceptionally high choroidal circulation, to maintain oxygen needs of photoreceptor 
cells (Algvere et al., 2016).  
. 
 
Figure 1.12. The neuronal structure of the retina. The diagram of a human eye, showing the path 
of a light beam (A) passing through the pupil, lens and reaching the macula. The retina is built 
by four main layers (B): choriocapillaris that connects the retina with choroid, Bruch’s membrane 
(BM), retinal pigment epithelium (RPE), and neurosensory retina with photoreceptors (Xu and 
Chen, 2016).  
 
The retina is sometimes called an immune privileged tissue as it has unique mechanisms that 
reduce the risk of infection and reduce inappropriate immune response (Forrester et al., 2008). 
Those mechanisms include a blood/retina barrier, to prevent circulating pathogens from 
entering the retina and also preventing the activation of T-cells in blood (Forrester and Xu, 2012). 
Additionally, due to the lack of a lymphatic system, APC present in choroid cannot respond to 
the pathogens in retina when the blood/retina barrier is intact. Finally, the retina has its own, 
internal immunoregulatory mechanism maintained by retinal cells (Streilein, 1999; Wenkel and 
Streilein, 2000).  
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The innate immune system of the retina is formed by three types of immune cells and a 
complement system. Innate immune cells in the retina are: CD11b+ microglia, 
CD11b+CD14+CD45+ macrophages and DCs (Forrester et al., 2010; Xu et al., 2009). In mice, 
CD11c+ DEC205+ DCs (Gregerson and Yang, 2003) and MHC II+33D1+ DCs (Xu et al., 2007) have 
been identified. These were shown to be activated in the early inflammation of the retina and 
phagocytose dead ganglion cells (Lehmann et al., 2010). During the late inflammation and in 
diseases such as AMD, microglia are activated (Karlstetter et al., 2015). 
1.7.2. Complement activation and regulation in the retina in relevance to 
AMD 
The complement system is a second line of innate immune defence in the retina as 
demonstrated in the RPE and choroid of both human (Anderson et al., 2010) and mouse eyes 
(Luo et al., 2011). It has been proposed for a long time (first reports date back to late 1800s), 
that dysregulated immune response can be a cause of AMD (Tan et al., 2016). Several proteins 
pertained to alternative complement pathway (AP) were linked to the disease. As the retina is 
separated from the blood circulation, complement proteins together with complement 
regulatory proteins are produced by retinal microglia and RPE cells (Luo et al., 2011). These 
include FH, which is being expressed by RPE cells (Chen et al., 2007) and the choriocapillaris (Fett 
et al., 2012). In fact, retina expresses only selected complement proteins, which suggests that 
for full activation of the complement system, the blood/retinal barrier needs to be broken. The 
complement system of the retina can be upregulated because of obsolescence (Chen et al., 
2010), but is also regulated by inflammatory cytokines, such as TNF-α and IFN-γ (Chen et al., 
2008; Lau et al., 2011). 
Multiple evidence suggest that the complement system is involved in the pathogenesis of AMD. 
Individuals suffering from AMD were reported to have increased plasma levels of C3a, C3d, Bb, 
and C5a (Lechner et al., 2016). Various complement components, including C3, C5b-9, FB, and 
FH were also identified in drusen and in AMD lesions (Anderson et al., 2010). Additionally, 
polymorphisms in a number of complement genes, FH, FB, C2, SERPING1, and C3 increase the 
risk of AMD (Cipriani et al., 2012; Edwards, 2008). In relation to AMD, a polymorphism in FH has 
the biggest significance with about 40% of affected individuals carrying an “at-risk” SNP (T1277C) 
in one or both copies of their complement factor H (CFH) gene (Haines, 2005). This 
polymorphism in the FH gene leads to a change in the protein at amino acid 402 from a tyrosine 
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to histidine (Y402H). Because of this mutation, FH is thought to more readily forms oligomers, 
which inhibit its activity.  
AMD is also associated with complement factor H related proteins (CFHR).  CFHR comprise a 
group of five plasma proteins: CFHR1, CFHR2, CFHR3, CFHR4 and CFHR5, which can each bind to 
the central complement component C3b. Mutations, genetic deletions and duplications in the 
individual CFHR genes are associated with a numerous diseases including AMD where the 
homozygous deletion of CFHR1 and CFHR3 is associated with a lower risk for AMD (Hughes et 
al., 2006). It is probably caused by the competition between CFHR1 and CFHR3 with factor H for 
binding to C3b. On the other hand, it was shown that a particular CFHR1 variant, CFHR1A, is 
strongly associated with AMD and genetically linked to risk variant Y402H (Martinez-Barricarte 
et al., 2012).  
1.7.3. Sub-retinal pigment epithelial deposit formation 
During obsolescence, the retina experiences multiple changes, including shifts in the number 
and distribution of photoreceptors (Curcio et al., 2000), thickening of BM (Feeney-Burns and 
Ellersieck, 1985), accumulation of sub-RPE deposits (Strauss, 2005) and upregulation of the 
retinal complement system (Chen et al., 2010). The formation of small, “hard” drusen deposits 
in sub-RPE is also a normal age related change and do not indicate disease. However, the second 
type of drusen, “soft” with no distinct borders accumulating between BM and RPE or in RPE 
itself, concur with the development of the AMD (Jager et al., 2008). Drusen are pathological 
extracellular deposits primarily containing over 40% of lipids, proteins (including complement 
proteins), and cellular debris (Liu et al., 2012). It is also believed that the place of drusen 
formation is also the main site of immune complex formation in AMD (Tan et al., 2016). 
Recently Thompson et al., (2015) proposed a novel mechanism of drusen formation (Fig. 1.13). 
According to the authors, drusen originate as cholesterol rich lipids, secreted by RPE and then 
enrolled in the BM. These micrometre sized lipid droplets are then coated by insoluble HAP, the 
mineral that is known for high protein binding capacity. Once sub-RPE HAP coated spherules are 
formed, they bind various, RPE secreted proteins, including FH, amyloid beta and vitronectin. It 
is also very likely that during AMD pathogenesis, the blood/retina barrier has been broken, as 
plasma protein HRG was also identified on HAP coated spherules. It suggests that serum proteins 
might be retained by binding to the HAP surface and therefore build up the deposits to clinically 
relevant size.   
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Figure 1.13. Proposed mechanism for growth and/or initiation of sub-RPE deposit formation. 
Formation is initiated by the HAP deposition (magenta) onto cholesterol-containing droplets 
(black). Consequently, proteins (blue) bind to the HAP surface facilitating further deposition in 
a self-driven oligomerisation process ultimately to form the visible deposit (yellow; Thompson 
et al., 2015). 
 
Zinc also appears to play a role in AMD development. In the healthy eye, the BM contains 47 
ppm of zinc. However, in AMD the amount increases to 137 ppm in the membrane and 
approximately 232 ppm in deposits (Dr Imre Lengyel, personal communication). It is feasible that 
together FH-zinc oligomer formation (Perkins et al. 2010), FH-HRG binding and the interaction 
between HRG, complement proteins and HAP are essential for drusen formation and occurs 
when zinc levels are elevated (Perkins et al., 2010). 
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1.8. Hypothesis and aims  
The major hypothesis underlying this thesis is that zinc is an important regulator of multiple 
aspects of immunity including antigen presentation and immune complex clearance. The 
primary aims of this work are directed towards gaining better insight into the complex role of 
zinc in dendritic cell activation and regulation of complement protein interactions. 
The specific aims of this thesis are therefore to: 
1. Get an insight into the mechanism of zinc homeostasis during DC maturation, by 
characterising alterations in the expression of chosen zinc transporters. 
2. Quantitatively describe global proteomic changes in DCs upon LPS and hydroxyapatite 
(HAP) induced maturation. 
3. Define the role of zinc in immune complex clearance, by characterizing its influence on 
HRG–complement interactions and determine whether these interactions occur via N 
terminus of HRG and to investigate whether zinc and pH alterations may contribute to 
AMD development by promoting HRG-hydroxyapatite interactions.  
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Chapter 2. Zinc homeostasis and the role of zinc in dendritic cell 
function 
2.1. Introduction 
2.1.1. Zinc in immune cell signalling 
Zinc is one of the crucial trace elements in human body. The physiological zinc plasma 
concentration is in the range of 15-20 μM (Gorgani et al., 1999b), with zinc mostly (75%) bound 
to albumin and other plasma proteins. This accounts for as much as 98% of deliverable zinc. The 
concentration of non-protein bound Zn2+ ions in plasma is in the range of 0.5 to 1 μM (Tubek et 
al., 2008). 
Zinc functions as a cofactor for nearly 3,000 proteins, which represent 10 % of human genome 
(Passerini et al., 2009). Its importance highlighted by the effects of zinc deficiency (Prasad, 2009), 
which leads to many pathological states including inflammation (Haase and Rink, 2009), 
neurodegeneration (Sensi et al., 2009) and cancer (Taylor at al., 2008).  
In immune cells, zinc has several functions, one of them being signal transduction. It serves as a 
second messenger, with the signalling pathways including T-cell activation, signalling after 
antibody recognition by Fcε, and after activating of pattern recognition receptors (PRRs; Kabu 
et al., 2006; Nishida et al., 2008). PPRs are a “primitive” part of the immune system as they 
evolved before adaptive immunity and other components of immune system. PPRs enable 
immune cells to recognise damaged host cells through damage-associated molecular patterns 
(DAMPs) or pathogen through pathogen associated molecular patterns (PAMPs). PRRs can be 
either membrane bound or cytoplasmic. Toll like receptor 4 (TLR4) is an example of a membrane-
bound PAMPs. It is activated mainly by bacterial lipopolysaccharide (LPS; West et al., 2006), but 
also by hydroxyapatite (HAP) (Velard et al., 2013). There is a growing evidence that zinc acts as 
a second messenger to trigger the activation of dendritic cells through Myeloid Differentiation 
Primary Response 88 (MyD88) or TIR-domain-containing adapter-inducing interferon-β (TRIF) 
signalling pathways (Kitamura et al., 2006; Brieger et al., 2013; Haase et al., 2008) in response 
to TLR4 activation. MyD88 is the early signalling pathway, where zinc acts as phosphatase 
inhibitor resulting in the production of inflammatory cytokines. Later, TRIF-dependent signalling 
leads secretion of interferon β (IFN-β) and expression of surface molecules required for T-cell 
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activation during antigen presentation (Brieger et al., 2013). The level of free zinc in the 
cytoplasm transiently increases via zinc release from zinc binding proteins or by transport from 
intracellular stores through zinc channels (Maret, 2008). 
2.1.2. Zinc homeostasis in dendritic cells 
Dendritic cells (DCs) primarily function as antigen presenting cells (APCs). They are crucial to 
initiate immune response. Immature DCs are present in non-lymphoid tissue where they 
become activated by antigens through PRRs, including TLRs. After activation, they maturate and 
migrate to lymph nodes where the antigen is processed and presented. Zinc deficiency causes 
defects in immune response and includes: hypoplasia of lymphoid tissues, reduction of T-helper 
cell numbers (Prasad, 2000), reduction of NK cell activity (Allen et al., 1983), decreased cell 
production, reduction in cell mediated immunity and phagocytosis, as lymphocyte proliferation, 
IL-2 production, DTH response, Ab response . Zinc deficiency is also known to cause thymus 
atrophy, reduction in Th1 cells number and decrease thymulin activity (Dardenne et al., 1982, 
Mitchell et al., 2006). This, together with the knowledge that zinc acts as a second messenger in 
immune cell signalling, suggests that zinc homeostasis influences dendritic cells function. Mainly 
zinc transporters control cellular zinc homeostasis. There are 24 such transporters in humans; 
14 Zrt-, Irt-like proteins (Zips encoded by the Slc39A genes), which transport Zn2+ to the cell 
cytosol and 10 Zn transporters (ZnTs encoded by the Slc30A genes), which transport Zn2+ from 
the cell cytosol (Cousins et al., 2006; Palmiter and Huang, 2004; Eide, 2004). Both families of zinc 
transporters (except ZnT10) have been characterised in many groups of cells. Zip1 is ubiquitous 
in human cells, whereas other Zips and ZnTs exhibit more tissue-specific expression. Several zinc 
transporter isoforms have been implicated in the function of immune cells; examples include 
ZnT5 in allergic response, and Zip8 and Zip14 in cytokine release (Nishida et al., 2009; Aydemir 
et al., 2009; Sayadi et al., 2013). Although zinc transport is strongly linked to immune 
functioning, the expression of zinc transporters and their specific roles in dendritic cells are still 
not well characterised. A study by Kitamura et al. in 2006, demonstrated that stimulation of the 
TLR system in DCs by LPS induces significant alterations in the expression of several zinc 
transporters (Kitamura et al., 2006). However, in this study the relative expression levels were 
only measured until 6 hours post-LPS stimulation. The life span of dendritic cells differs between 
cell populations and ranges between 7 to 14 days (Merad and Manz, 2009).  
The aims of this chapter are to examine the importance of zinc for DC maturation and to get an 
insight into the mechanism of zinc homeostasis during this process, by characterising alterations 
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in the expression of chosen zinc transporters. Changes in levels of mRNA transcript encoding for 
those transporters will be assessed using qPCR. Alterations in the expression of zinc transporter 
proteins during LPS-induced maturation will also be determined using immunofluorescence 
microscopy as well as flow cytometry. Intracellular free zinc levels is examined using the zinc-
specific membrane permeable fluorophore, ZnAF-2F DA and flow cytometry. In addition, 
intracellular zinc will be visualised by fluorescent microscopy using the same fluorophore. 
Finally, by measuring cytokine release, it will be determined whether LPS and hydroxyapatite 
can trigger DCs maturation and therefore initiate immune response.   
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2.2. Materials and methods 
2.2.1. Cell culture methods 
2.2.1.1. Cell culture of human monocyte derived dendritic cells (moDCs) 
Monocyte-derived DCs used for all the studies were prepared according to a well-established 
protocol (Zhou and Tedder, 1996). Blood was obtained from a healthy donors and purified over 
density gradient (Histopaque, Sigma Aldrich, Haverhill, UK), at room temperature to isolate 
peripheral blood mononuclear cells (PBMC). Monocytes were then enriched by a two-hour 
adhesion step (adherence to culture dishes), with non-adherent cells being washed away. As a 
result, on average, 0.7 x 106 monocytes were isolated per 1 ml of blood used. MoDCs were then 
obtained from these human monocytes by culturing in RPMI 1640 medium (Gibco, Thermo 
Fisher Scientific) supplemented with 10% foetal calf serum (FCS), 50 ng/ml interleukin-4 (IL-4; 
eBioscience, Haltfield, UK) and 50 ng/ml granulocyte-macrophage colony-stimulating factor 
(GM-CSF; Abcam, Cambridge, UK) for 5 days. The resultant, immature, moDCs were then treated 
with 100 ng/ml of bacterial LPS (Sigma Aldrich) for up to 72 h. All tissue culture procedures were 
performed in a class 2 containment cabinet. Cells were grown in 6, 12, or 24-well culture dishes, 
in an incubator at 37oC in a humidified atmosphere of 5% CO2.  
Ethical approval for the use of moDCs was granted by the University of St Andrews School of 
Medicine Ethics Committee. 
2.2.1.2. Cell counting 
For cell counting, 10 µl of cell suspension was mixed 1:1 with trypan blue dye and incubated at 
room temperature for 2 min. The number of viable and dead cells (viable cells do not take up 
the dye) was then measured either by haemocytometer or by an automated cell counter (TC20, 
BioRad). 
2.2.1.3. Cell isolation 
During cell culture, moDCs attach to the culture dish. Therefore, to harvest mature moDC, cells 
were firstly washed with sterile phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4, 1.8 mM KH2PO4 pH 7.4). Followed by a quick rinse with a few drops of trypsin 
solution (Trypsin-EDTA, 0.05%; Gibco), cells were incubated with 100 µl of fresh trypsin for 5 min 
at 37oC. 
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2.2.2. Western blotting 
2.2.2.1. The comparison of chemiluminescent and near infrared (NIR) western blot techniques 
Western blot is a technique commonly used for protein detection and analysis. 
Chemiluminescent protein detection is made possible due to the use of enzyme-conjugated 
antibodies, which allow detection with X-ray films or CCD camera. With all its advantages, this 
traditional Western blot technique has also some limitations. It does not allow the use of a 
mixture of primary antibodies, which means that only one protein can be analysed at a time. 
Therefore, the target protein and control have to be detected separately, with the membrane 
stripped in between or samples re-run. Stripping is useful and a very common practice as it 
allows investigating more than one protein at the same blot, however it is not advisable to make 
quantitative comparison of targets probed after stripping. Even very careful stripping removes 
some sample protein from the membrane. To overcome these issues fluorescently-labelled 
antibodies (with emission in near-infrared (NIR) spectrum) are now commonly used in western 
blotting. The reason behind using the NIR part of the spectrum is to limit auto-fluorescence of 
membranes and biological molecules as seen at longer wavelengths. There is a big choice of 
secondary antibodies directly labelled with NIR fluorophores, which can be distinguished based 
on emitted colour. For increased accuracy, a mixture of antibodies can be used with one of them 
directed against housekeeping protein that serves as an internal, normalization control. 
Fluorescent detection also shows much higher sensitivity than chemiluminescent detection and 
exceeds visible fluorescence detection. Overall, it is fast, accurate and quantitative method of 
protein analysis.  
2.2.2.2. Protein extraction 
MoDCs were grown on 6 or 12-well plates and stimulated with LPS as described above (2.2.1.1.). 
When cells were mature, culture plates was placed on ice and cells were washed twice with cold 
phosphate buffered saline (PBS), followed by the addition of 200 μl of 10x RIPA buffer (Cell 
Signalling Technology, Danvers, MA, U.S.A.) diluted to a 1x solution using ddH2O. Cells were 
incubated for 10 min, then scrapped with cell scrapper, transferred to Eppendorf tubes and lysed 
for an additional 10 min, at 4oC. Cell lysates were centrifuged at 14,000 rpm at 4oC for 10 min, 
to pellet cell debris. The resultant supernatants were then transferred to fresh tubes. 
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2.2.2.3. Protein quantification 
To determine the protein concentrations in the cell lysates, the BCA protein assay kit (optimised 
for 96-well plates) was used (Pierce, Thermo Fisher Scientific). The BCA Protein Assay is a 
formulation based on bicinchoninic acid (BCA) for the colorimetric detection and quantitation 
of total protein (Smith et al., 1985). The absorbance at 570 nm was measured using a Dynex 
MRX microplate reader (Dynex Technologies, Worthing, UK). Protein concentrations were 
calculated using a standard curve created using solutions of bovine serum albumin at known 
concentrations.  
2.2.2.4. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
The quantified protein samples were resuspended in NuPAGE LDS Sample Buffer (Invitrogen, 
Thermo Fisher Scientific) with an addition of 10% β-mercaptoethanol for reducing conditions. 
Then denatured by heating at 95oC for 5 min. Samples were loaded into precast  NuPAGE 4-12% 
Bis-Tris 1.0 mm protein gels (Invitrogen, Thermo Fisher Scientific), and run for approximately 1 
h at 160 V in running buffer (NuPAGE MES SDS Running Buffer, Thermo Fisher Scientific). After 
electrophoresis, gels were electroblotted to allow immuno-detection of proteins (Western blot). 
2.2.2.5. Western blotting 
To detect zinc transporters and TLR 4 in moDC cell lysates, NIR immunoblotting technique was 
used.  
To minimize the background, which is especially important when using the fluorescent 
secondary antibodies, Immobilon-FL PVDF membrane was used (Millipore, Billerica, U.S.A.). The 
membrane was pre-conditioned with 100% methanol for 5 min, and then soaked with transfer 
buffer (25 mM Tris, 190 mM glycine, 20% methanol) for 10 min. The SDS-PAGE protein gel, 
prepared as described above (2.2.3.4.), was equilibrated with transfer buffer for 10-15 min, and 
so were other elements of the "blotting sandwich". The sandwich was arranged in a semi-dry 
electrophoretic transfer cell system (Trans-Blot SD; Bio-Rad, Hemel Hempstead, UK), from the 
platinum anode with: extra thick filter paper/membrane/gel/extra thick filter paper. Air bubbles 
were removed between each layer. The transfer was carried out at 16 V for 30 min, and then 
the membrane was carefully removed, rinsed with water, and placed in blocking solution (1:1 
PBS and Odyssey Blocking solution, PBS based; Li-Cor, Cambridge, UK) for an hour, with 
agitation, at room temperature.  
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Membranes were incubated with primary antibodies at the following dilutions: β-actin at 1:1500 
(C4, Santa Cruz Biotechnology, Dallas, U.S.A.), Zip7 at 1: 1500 (Thermo Fisher Scientific), pZip7 
at 1:150 (a gift from Dr Kathryn Taylor, Cardiff University, UK), Zip6 at 1:100 (also a gift from Dr 
Kathryn Taylor), ZnT1 at 1:1500 (Abcam, Cambridge, U.S.A.), ZnT7 at 1:1500 (Sigma-Aldrich), 
TLR4 at 1:1000 (ProSci Inc., Poway, U.S.A.). All antibodies were diluted in PBS (or in the case of 
pZip7 TBS) supplemented with 0.01% Tween 20 and 0.01% SDS. The primary antibody was 
incubated with the blot overnight at 4oC with agitation. This was followed by four 5 min washes 
and a 20 min wash with TBS, PBS or TBS containing 0.05% Tween 20 (TBST) respectively.  
Membranes were then incubated with a mixture of either donkey anti-goat IRDye 680 (1:20,000 
dilution, Li-Cor) and donkey anti-mouse IRDye 800 (1:15,000 dilution, Li-Cor), or donkey anti-
goat IRDye 700 (1:20,000 dilution, Li-Cor) and donkey anti-rabbit IRDye 800 (1:15,000 dilution, 
Li-Cor) for 45 min at room temperature, agitating. Antibodies were diluted in PBS supplemented 
with 0.01% Tween 20 and 0.01% SDS, except of pZip7, which was prepared in TBS supplemented 
with 0.01% Tween 20 and 0.01% SDS. Excessive secondary antibody was washed away with four 
times 5 min washes with either TBS or PBS both containing 0.01% Tween 20, followed by 20 min 
wash with TBS or PBS. Membrane was then left to dry on a filter paper at 37oC for 1 h. 
Fluorescent protein bands were detected using an Odyssey imager (Li-Cor).  
The NIR blots allow quantification of proteins using an internal software Image Studio 4.0. The 
software measures density of each band end then compares it to the density of corresponding 
control band. Further calculations were performed using Microsoft Excel, with the assumption 
that the expression of β-actin control was not influenced by experimental conditions and 
remained stable between samples. 
2.2.3. Immunofluorescence  
To visualise alterations in zinc transporter expression upon TLR 4 signalling, 
immunofluorescence (IF) microscopy was used. This technique is a type of 
immunohistochemistry that uses fluorophores to visualise the target protein. There are two 
main types of IF; direct, when primary antibody is directly linked to fluorophore, or indirect, with 
two-step detection method where primary antibody binds to a target protein and a secondary 
antibody has a fluorophore conjugate. Indirect IF is more sensitive and was therefore used to 
immunostain zinc transporters and TLR4 receptor. 
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PBMC isolated from fresh blood as described above (2.2.1.1.), were cultured on sterilised, 13 
mm in diameter, round cover slips on 24-well cell culture dish. After two hours, non-adherent 
cells were washed away and only monocytes remained attached to the culture surface. 
Immature moDC were then obtained and treated with bacterial LPS as described above 
(2.2.1.1.). Cells were then washed once with PBS and fixed for 10-20 min, on ice with 4% p-
formaldehyde (prepared from in PBS from 16 % formaldehyde solution, Sigma-Aldrich), followed 
by permeabilization with ice-cold methanol, for 5 min at –20oC. Cells were then rinsed twice 
with PBS prior to blocking with 1% bovine serum albumin (BSA) dissolved in PBS, supplemented 
with 0.05% Tween 20, for 30 min at room temperature, followed by another wash with PBS. All 
subsequent incubations were performed in a humidified chamber to prevent cells from drying 
out. For IF the same antibodies as above (2.2.3.) were used. All antibodies were used at a 
concentration of 5 μg/ml, except for anti-pSLC39A7, which was used at 20 μg/ml. Antibodies 
were diluted in blocking solution. For each cover slip, 100 μl of diluted antibody was applied and 
incubated overnight at 4oC. Cells were then washed four times in 5 min intervals, in PBS 
supplemented with 0.05% Tween 20.  
Secondary antibodies, Donkey Anti-Rabbit AlexaFluor 568 (Thermo Fisher Scientific), or Donkey 
Anti-Mouse AlexaFluor 647 (Thermo Fisher Scientific), were diluted 1:200 in wash buffer, 100 μl 
was applied per cover slip and incubated for 1 h at room temperature. Cells were then washed 
again four times in 5 min intervals, in PBS supplemented with 0.05% Tween 20. For mounting 10 
μl of SlowFade Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific) was used. 
Mounted microscopy slides were were allowed to cure for 24 h at room temperature in the dark. 
After that time, excess mounting solution was drawn using a filter paper, and edges were sealed 
with nail varnish. Slides were stored in the dark and viewed the following day, under 20x 
magnification and 100x magnification oil immersion, using fluorescent microscope Leica CTR 
5500 (Leica Microsystems, Milton Keynes, UK).  
2.2.4. Zinc imaging 
To investigate the relationship between TLR 4 signalling and the abundance of intracellular zinc 
in moDCs, zinc was measured using the membrane permeable zinc-specific fluorescent probe, 
ZnAF-2F DA (AdipoGen, Liestal, Switzerland). MoDCs were grown on the coverslips as described 
above (2.2.4.) and treated with 100 ng/ml of bacterial LPS for up to 72 h. Cells were then washed 
twice with PBS, to remove serum that was added to media, and incubated with 10 µM ZnAF-2F 
DA in PBS at 37oC for 30 min in a humidified incubator. Cells were then washed once with PBS 
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and then once with PBS supplemented with 100 µM of ethylenediaminetetraacetic acid (EDTA; 
to remove excess extracellular zinc). EDTA chelates extracellular zinc, which would otherwise 
result in increased background on IF images. For mounting, SlowFade® Diamond Antifade 
Mountant with DAPI (Thermo Fisher Scientific) was used. Slides were allowed to cure for 24 h in 
the dark, as advised by the manufacturer and edges were sealed with nail varnish. To avoid 
photo bleaching, all the procedures were performed in the dark, and microscopy slides were 
stored in the dark at all times. As a control, unstained cells of 0 and 24 h post LPS stimulation 
time points were prepared. Due to the nature of the assay, which was a one-step, direct staining, 
no other controls were prepared. Slides were viewed under 20x magnification and 100x 
magnification with oil immersion on Leica CTR 5500 microscope (Leica Microsystems).  
2.2.5. Flow cytometry  
Based on the emitted fluorescence, flow cytometry allows three types of data are generated. 
Using forward scatter (FSC) approximate cell size is calculated. Side/orthogonal scatter (SSC) 
allows investigating cell complexity or granularity and finally labelling cell with fluorescent 
antibodies directed against specific molecules is used to investigate cell function. Cells analysed 
by flow cytometry can be either directly stained, using fluorophores or fluorophore conjugated 
primary antibodies; or indirectly stained, with fluorophore conjugated secondary antibodies. 
Flow cytometry allows analysing multiple biophysical properties of each cell, at rates of over 
1000 particles per second. This makes the approach semi-quantitative, as equal number of 
particles will be analysed in each sample, and therefore samples can be compared.  
Flow cytometry was used to measure the alterations in zinc transporter expression, TLR4 
receptor expression and the levels of intracellular zinc following LPS-triggered maturation of 
moDCs. MoDCs were treated with bacterial LPS for 24 h to 72 h as described above. Mature 
moDCs were dissociated using trypsin for 5 min at 37oC and washed twice with PBS. Cells were 
plated on 96-well, transparent, round bottom plate and either stained with 10 µM of cell 
permeable zinc fluorophore, ZnAF-2F DA at 37oC for 30 min to label intracellular zinc; or with 
primary and secondary antibodies for an indirect protein staining. Cells stained with zinc 
fluorophore were washed with PBS and then with 100 µM EDTA prior to fixation with 2% p-
formaldehyde for 15 min on ice (prepared from in PBS from 16 % formaldehyde solution, Sigma-
Aldrich). Prior to primary antibody staining, cells were fixed with 1% p-formaldehyde for 15 min 
on ice. Cells were washed twice with PBS and blocked with 3% BSA in PBS for 30 min at room 
temperature. Primary antibodies used for flow cytometry were the same as above (2.2.3.). All 
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antibodies were used at 1:1000 dilution, except of anti-pSLC39A7, which was used at 1:500 
dilution; dissolved in PBS supplemented with 3% BSA. Cells were incubated with primary 
antibodies for 1 h at room temperature and washed three times for 5 min with cold PBS. 
Secondary antibodies, donkey anti-rabbit AlexaFluor 568 (Thermo Fisher Scientific), or donkey 
anti-mouse AlexaFluor 488 (Thermo Fisher Scientific), were diluted 1:100 in 1% BSA in PBS, and 
incubated for 30 min, at room temperature, in the dark. Cells were then washed again three 
times in 5 min intervals, with cold PBS. Stained cells were kept at 4oC in the dark for 2 days. The 
instrument used was Guava easyCyte 8HT (Merck Millipore) and samples were analysed using 
Guava 2.7 software.  
2.2.6. The Human Tumor Necrosis Factor-alpha (TNF-α) assay 
Macrophages and mature dendritic cells are known to secrete TNF-α after TLR4 signalling upon 
LPS stimulation, which indicates that cells are active and functional. The response of dendritic 
cells for hydroxyapatite (HAP) stimulation is not known. To see whether generated moDC are 
functional and to verify that HAP can indeed activate moDCs, aliquots of cell culture media were 
analysed using an enzyme-linked immunosorbent assay (ELISA) for the quantitative 
determination of TNF- α. Cells were obtained as described before (2.2.1.1.). Differentiated 
moDCs were stimulated with 100 ng/ml of LPS over 72 h or cultured with up to 20 mg/ml of 
ethanol-sterilised HAP nanopowder (Sigma-Aldrich) for 24 h. Next, the culture media was 
collected and TNF-α concentration measured using the TNF alpha Human ELISA Kit (Invitrogen, 
Thermo Fisher Scientific). This kit is a sandwich ELISA assay, which comes with plates pre-coated 
with specific anti-TNF-α antibody. After addition of the sample to the wells, detection involved 
addition of biotinylated anti-TNF-α antibody followed by a streptavidin-HRP conjugate. The plate 
was then washed to remove unbound substances and substrate for HRP was applied. After the 
reaction was stopped using ELISA stop solution, the absorbance at 450 nm was measured using 
a Dynex MRX microplate reader (Dynex Technologies, Worthing, UK). The concentration of TNF-
α in the samples was determined based on standards supplied with the kit.  
2.2.7. Polymerase chain reaction to semi-quantify gene expression 
Polymerase chain reaction (PCR) is a common molecular biology technique used to amplify DNA. 
It is a versatile technique and during 30 years since its discovery, many variations have been 
developed. Those include reverse transcription PCR (RT-PCR) where RNA is converted to cDNA, 
which is then amplified and can be used inter alia to determine the relative expression of a gene, 
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and quantitative PCR (qPCR) which allows quantitative measurement of target gene in a sample. 
Quantitative PCR is very precise as it measures the amount of amplified product in real time 
using fluorescent DNA-binding dyes, such as SYBR Green.  
2.2.7.1. RNA extraction  
Prior to RT-PCR and qPCR procedures, RNA was purified using phenol-chloroform RNA extraction 
protocol. MoDCs were trypsinised for 10 min at 37oC. Following centrifugation (10,000 rpm for 
5 min), the media was removed and cells were washed with PBS. TRIzol Reagent (1 ml; 
Invitrogen, Thermo Fisher Scientific) was added to cells, mixed and incubated for 5 min at room 
temperature. Then 200 µl of chloroform was added, shaken vigorously for 15 s and incubated 
for 5 min at room temperature. Following incubation, samples were centrifuged for 15 min at 
13,000 rpm at 4oC. The colourless upper aqueous phase, containing RNA was transferred to a 
fresh tube. To precipitate the RNA, 0.5 ml of isopropanol for every 1 ml of TRIzol was added and 
then incubated at room temperature for 10 min, followed by centrifugation at 11,000 rpm at 
4oC. The pellet containing the RNA was visible on the side of the tube. After precipitation, the 
supernatant was removed and the pellet was washed with 1 ml of 75% ethanol for every 1 ml of 
TRIzol used. Samples were mixed by vortexing and centrifuged at 16,000 rpm for 5 min at 4oC. 
RNA was resuspended in 30 µl of RNAse-free water and incubated at 55oC, until the pellet 
completely dissolved. To check the concentration and quality of obtained RNA (based upon 
absorbance measurements) a NanoVue spectrophotometer (GE Healthcare, Little Chalfont, UK) 
was used. RNA was considered to be of sufficient purity when 260/280 nm absorbance ratio was 
between 1.95 and 2.1. To remove any DNA contaminations, 4 µg of RNA was mixed with 1 µl of 
DNAse (Ambion, Thermo Fisher Scientific) and compatible 10x reaction buffer, followed by 
incubation at 37oC for 25 min. Next 1 µl of inactivation reagent was added and samples were 
incubated at room temperature for 5 min and centrifuged at 10,000 × g for 15 min to remove 
pelleted DNA. RNA was quantified again and stored at -80oC until required.  
2.2.7.2. Synthesis of cDNA from RNA 
To synthesise cDNA for subsequent amplification, 2 μg of total RNA was used. The volume of the 
RNA in solution was increased to 12.5 μl with addition of UltraPure™ DNase/RNase-Free Water. 
The total reaction volume was 20 μl and included 12.5 μl of diluted RNA, 1 μl of dNTP (Sigma-
Aldrich), 1 μl of Oligo (dT) 15 Primer (Promega, UK), 200 units (1 μl) of reverse transcriptase 
(Revert Aid, Thermo Fisher Scientific) and 0.5 μl of RiboLock RNase Inhibitor (Thermo Fisher 
Scientific) in the appropriate reaction buffer. All steps were performed on ice in a PCR-grade 
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cabinet to avoid DNA contamination. Samples were incubated for 1 h at 42oC. The quality of 
obtained DNA was assessed using a NanoVue spectrophotometer (GE Healthcare, Little 
Chalfont, UK) as above. DNA was stored at -20oC until required. 
2.2.7.3. Reverse transcription-PCR  
RT-PCR was performed to determine the expression (semi-quantitatively) of zinc transporters 
(ZnT 1, 4, 5, 6, 7, 9 and Zip 1, 3, 6, 7, 8, 9, 10, 11 and 12) in moDC treated with LPS. The reaction 
volume of the RT-PCR reactions was 20 μl and included, 10 μl of BIO-X-ACT™ Short Mix (Bioline, 
London, UK), 7 μl of ultrapure water, 1 μl (250 nM) of each forward and reverse primers and 1 
μl (made from 100 ng RNA) of cDNA. As a negative control, samples without the addition of 
cDNA ware included. As a positive control and reference gene, primers for ribosomal protein 
RPLP0 were used. All primers were made by Eurofins MWG (Luxembourg). The thermal cycling 
steps were as follows: 1 cycle as initial denaturation at 95oC for 2 min, followed by 40 cycles of 
denaturation at 95oC for 30 s, annealing at 58oC for 30 s and extension at 68oC for 30 s. Final 
extension was done in 1 cycle at 68oC for 5 min. 
RPLP0 forward primer 
5’- GAGTGATGTGCAGCTGATCAAGACTGG-3'   
RPLP0 reverse primer 
5’- CAGAGTTTCCTCTGTGATATCAAGCACTTCAG-3'   
SLC30A1 (ZnT1) forward primer: 
5’- CATGCTGTCGGACGTGCTGG-3’ 
SLC30A1 (ZnT1) reverse primer 
5’- GCTGAAGCCGCTGTGATGGTG-3’ 
SLC30A4 (ZnT4) forward primer: 
5’- CGTTCTGTACTTGCTTTTCATGATTGGAG-3’ 
SLC30A4 (ZnT4) reverse primer 
5’- CCAACAGCTGCGGTGATGAGC-3’ 
SLC30A5 (ZnT5) forward primer: 
5’- GCTCTCTGTCGACGTTGGTGG-3’ 
SLC30A5 (ZnT5) reverse primer 
5’- CCTGGTGTGCTGCTTTGTTCATAGC-3’ 
SLC30A6 (ZnT6) forward primer: 
5’- CGAAGGTCCTGGAAGATACTGCTC-3’ 
SLC30A6 (ZnT6) reverse primer 
5’- CAGCCAGGACTTCTAATCTTTCAAACC-3’ 
SLC30A7 (ZnT7) forward primer 
5’- CCTGTCCATCAAAGACGATGAATACAAAC-3’ 
SLC30A7 (ZnT7) reverse primer  
5’- GCCAGAACTTCCGCTCTAACATACC-3’ 
SLC30A9 (ZnT9) forward primer 
5’- CCTGAGTCAAGTAAAGTTGTACTCCAC-3’ 
SLC30A9 (ZnT9) reverse primer  
5’- GCTTCCACATCTGATCTCAAGTATACAG-3’ 
SLC39A1 (Zip1) forward primer 
5’- CGAGGCGGTAGCTTCAGAGC-3’ 
SLC39A1 (Zip1) reverse primer 
5’- GCCAGGATGAACTCTTGCAGTGG-3’ 
SLC39A3 (Zip3) forward primer 
5’-CCTCTCTCTCTGCAACACCTTTGG -3’ 
SLC39A3 (Zip3) reverse primer 
5’-CCATGAAGGGGCTCTCATACTCC -3’ 
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SLC39A6 (Zip6) forward primer 
5’-CATGACTCAGATAGTTCAGGTAAAGATCC -3’ 
SLC39A6 (Zip6) reverse primer 
5’-CTTTGATGCATTGAAACACTCCTGAGG -3’ 
SLC39A7 (Zip7) forward primer 
5’-CTCACGAGAGCATCTGGCATGG -3’ 
SLC39A7 (Zip7) reverse primer 
5’-CTGAGCAAGATCTGAAGTAGAGAGC -3’ 
SLC39A8 (Zip8) forward primer 
5’-CCACTTTGGAAATGATAACTTTGGTCCTC -3’ 
SLC39A8 (Zip8) reverse primer 
5’-CTGAAGGAGAGACAAGGTGCAGG -3’ 
SLC39A9 (Zip9) forward primer 
5’-GGAACGACTGAAGCTGGTGACTG -3’ 
SLC39A9 (Zip9) reverse primer 
5’-CTTGCTGCTTCTGGATCGTCAGTAG -3’ 
SLC39A10 (Zip10) forward primer 
5’-GCTTCACAGACAGCATCGTGGAATG -3’ 
SLC39A10 (Zip10) reverse primer 
5’-GATTATGGGAATGCTGGTGGTTATGTG -3’ 
SLC39A11 (Zip11) forward primer 
5’-CGTGTTCGTATTCTCTAGTGGACAG -3’ 
SLC39A11 (Zip11) reverse primer 
5’-GGATCAGACTTCTTCTTCATCAACGTAG -3’ 
SLC39A12 (Zip12) forward primer 
5’-CAGATGCACTATTACTAATAGCTGGAGG -3’ 
SLC39A12 (Zip12) reverse primer 
5’-GCACCTTCACTGCTCACTATTCCAG -3’ 
Table 2.1. Sequences of gene-specific primers used in RT-PCR reactions.  
 
2.2.7.4. Agarose gel electrophoresis 
After the PCR amplification 3 μl of 6x DNA loading dye (Thermo Fisher Scientific) was added to 
tube and 15 μl of this mixture loaded onto a 1% agarose gel. Gels were prepared by melting 1% 
(w/v) agarose (Sigma-Aldrich) in Tris-acetate-EDTA buffer (TAE; 40 mM Tris pH 7.6, 20 mM acetic 
acid, 1 mM EDTA) with the addition of SYBR Safe DNA Gel Stain (Life Technologies) to enable 
detection of DNA bands. Sample wells were formed by inserting a comb into the gel before it 
set. Hyperladder IV (Bioline, 100-1,000 bp) was loaded into one well to allow identification of 
DNA sizes. DNA bands were separated at 150 V for approximately 40 min. DNA was visualised in 
a Gel Doc XR+ Imager and band intensities analysed using the Image Lab 2.0 software (Bio-Rad 
Laboratories, Inc.). 
2.2.7.5. Quantitative PCR 
For quantitative measurement of alterations in genes coding for zinc transporters in moDCs, 
qPCR was performed using the ViiA™ 7 Real-Time PCR System (Thermo Scientific) with PerfeCTa® 
SYBR® Green FastMix, ROX™ (Quanta Bioscience). Assays were performed on MicroAmp® 
Optical 384-Well Reaction Plate (Life technologies). The reaction volume was 10 μl and reaction 
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set up as follows: 5 μl of SYBR Green Mix, 0.3 μl (250 nM final concentration) of each forward 
and reverse primer, 1 μl (made from 100 ng of RNA) of cDNA and ultrapure water. To avoid 
pipetting errors and maximise assay precision, the plate was set up using a high-precision 
automated PCR setup, pipetting robot (QIAgility; QIAGEN). 
The following thermal cycling protocol was used: 1 cycle as initial denaturation at 95oC for 1 min, 
then 40 cycles of 95oC for 15 s and 60oC for 45 s. For Melt Curve (dissociation stage) the PCR 
cycling was 95oC for 15 s followed by 60oC for 1 min and again 95oC for 15 s.  
β-actin forward primer 5’-AGAGCTACGAGCTGCCTGAC-3’ 
β-actin reverse primer 5’-AGCACTGTGTTGGCGTACAG-3’ 
RPLP0 forward primer 5’-CATGTGAAGTCACTGTGCCAG-3’ 
RPLP0 reverse primer 5’-GATCAGCTGCACATCACTCAG-3’ 
SLC30A1 (ZnT1) forward primer: 5’-AACACCCTGGTGGCCAATAC-3’ 
SLC30A1 (ZnT1) reverse primer 5’-TCTGGGGTTTTCTGGGTCTGC-3’ 
SLC30A7 (ZnT7) forward primer 5’-CATGATCATGCTCATGGACATGG-3’ 
SLC30A7 (ZnT7) reverse primer  5’-CACCAATACTTCCAAGTGTATCTG-3’ 
SLC39A6 (Zip6) forward primer 5’-CAGCGATGGCCTAGCAATTG-3’ 
SLC39A6 (Zip6) reverse primer 5’-CATGCCAGCCTTTAGTAGAACAG-3’ 
SLC39A7 (Zip7) forward primer 5’-GGTTCTCAGTGGAATTGTTGCC-3’ 
SLC39A7 (Zip7) reverse primer 5’- CTCTTGTCTTCCATGTCCATGAC-3’ 
Table 2.2. Sequences of gene-specific primers used in qPCR reactions. 
 
To validate qPCR efficiency, an initial validation standard curve for each primer set was 
generated. Amplification efficiency is a rate at which the PCR amplicon is produced and shows 
the overall performance expressed as a percentage value. Each assay is defined as having 100% 
efficiency when the quantity of PCR product doubles during the geometric phase of 
amplification. Standard amplification curves were plotted for each primer pair using serial 
dilution of DNA. Reaction efficiencies and correlation coefficient (R2) (Table 2.3) were calculated 
automatically by ViiA™ 7 Real-Time PCR System Software based on standard curves plotted (see 
Appendix 1).  
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Target R2 Primer efficiency (%) Error 
SLC30A1 (ZnT1) 0.993 97.91 0.101 
SLC30A7 (ZnT7) 0.995 75.3 0.119 
SLC39A6 (Zip6) 0.994 96.65 0.109 
SLC39A7 (Zip7) 0.995 96.77 0.092 
β-actin 0.998 88.9 0.051 
RPLP0 0.996 91.96 0.075 
Table 2.3. To calculate amplification efficiency, reaction was set up for each primer pair, with a 
serial dilution of cDNA. That allowed to plot amplification standard curves expressed as a 
quantity of gene amplified per threshold cycle (CT). ViiA™ 7 Real-Time PCR System Software 
based on standard curves plotted calculated reaction efficiencies for all primer pairs 
automatically. R2 value indicates correlation coefficient.  
 
Normalisation was performed using two reference genes (β-actin and RPLP0). These were 
chosen as they were expected to maintain a constant level of the expression in all of the samples 
irrespectively of the treatment. To analyse relative quantification of genes, Comparative CT 
Method (ΔΔ𝐶𝑇) was used. ΔΔ𝐶𝑇 values when using the two reference genes were calculated 
using the following equation: 
ΔΔ𝐶𝑇=(𝐶𝑡 𝑡𝑎𝑟𝑔𝑒𝑡 𝑡𝑟𝑒𝑎𝑡𝑒𝑑− √𝐶𝑡 𝛽𝑎𝑐𝑡𝑖𝑛 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑥 𝐶𝑡 𝑅𝑃𝐿𝑃0 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 )− 
(𝐶𝑡 𝑡𝑎𝑟𝑔𝑒𝑡 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑− √𝐶𝑡 𝛽𝑎𝑐𝑡𝑖𝑛 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑥 𝐶𝑡 𝑅𝑃𝐿𝑃0 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒d) 
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2.3. Results  
2.3.1. Morphological characteristic of DCs 
MoDCs were differentiated from purified monocytes using interleukin-4/granulocyte–
macrophage   colony-stimulating   factor   treatment, a well-established method (Soo et al., 
2012). The cells obtained exhibited morphological characteristics typical of mature dendritic 
cells (Tan et al., 2010; Verdijk et al., 2004) with characteristic long cytoplasmic projections (Fig. 
2.1). 
 
Figure 2.1. Microscopy images (at 100× magnification) of immature and mature moDCs in (A) 
bright-field and (B) stained with AlexaFluor 568 recognising anti-Zip6 and DAPI. DCs displayed a 
typical morphology with long cytoplasmic projections (as indicated by the arrows). 
 
 
2.3.2. Characteristic of zinc transporters in moDC  
2.3.3.1. Alterations in mRNA expression 
Zinc transporters are the main regulators of zinc homeostasis. Therefore, to establish the link 
between TLR4 signalling and zinc homeostasis in moDCs, it is necessary to characterise the 
changes in expression of those transporters upon DC maturation. In order to do this moDCs were 
treated with LPS over a 10 h period with samples being taken after 2, 6, and 10 h (Fig. 2.2). LPS 
triggers dendritic cell maturation through TLR4 signalling. As a control, moDCs untreated with 
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LPS were used. RNA was isolated using trizol-chloroform extraction method and RT-PCR was 
performed. For this preliminary study, the RNA expression of six ZnT (1, 4, 5, 6, 7, 9), and nine 
Zip (1, 3, 6, 7, 8, 9, 10, 11, 12) transporters was verified. As a loading control, RPLP0 was used, a 
housekeeping gene encoding for ribosomal protein P0. Unfortunately, the control revealed that 
there was less template used for 10 h time point. 
Changes in expression differed between the transporters. For ZnT4, Zip3, Zip10 and Zip11 mRNA 
expression decreased gradually up to 10 h post-LPS treatment. Whilst ZnT1, ZnT7, ZnT9, Zip1, 
and Zip8 mRNA transcript expression increased up to 6 h post maturation, and then dropped 
significantly between 6 to 10 h (Fig. 2.2). Zip6 and Zip7 exhibited abrupt increases in expression 
with the peak at 2-6 h. Interestingly LPS treatment did not appear to affect the expression of 
ZnT5, ZnT6 and Zip12, with ZnT5 being the only plasma membrane associated zinc “exporter” 
expressed of those assessed. After 10 h post-LPS treatment Zip3 and Zip8 were the only zinc 
importers expressed of those assessed (Fig. 2.2).  
 
 
Figure 2.2. Bacterial LPS alteration of zinc transporters in moDCs is time dependent. Cells were 
cultured with LPS in the concentration of 100 ng/ml over 10 h with sampling done after 2, 6 and 
10 h and without the addition of LPS as a control (C). The expression of almost all of the zinc 
transporters (both Zips and ZnTs) is decreasing gradually over time with only two zinc importers 
and one exporter (circled in red) being expressed after 10 h of LPS treatment. 
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The significant changes in zinc transporter expression observed between 6-10 h suggest this 
period to be crucial for DC functioning and may represent the point at which DCs migrate in the 
lymphatic system (Alloatti et al., 2016). It is also very interesting to know if there are other 
significant alterations in mRNA transcript encoding for zinc transporters after 10 h post- LPS 
stimulation. Most of the zinc transporters assessed are present on both, cell membrane and 
membrane of cytoplasmic vesicles. It is therefore impossible to bring any conclusions about the 
compartmental movement of zinc during dendritic cell maturation, migration, and antigen 
presentation based solely on obtained results. To confirm previous findings and gain more 
insight into particular transporters, quantitative PCR (qPCR) was used. For this study, two zinc 
importers (Zip6 and Zip7) and two zinc exporters (ZnT1 and ZnT7) were chosen. Zip6 is present 
on the cell membrane and thus transports zinc from the extracellular space into the cytosol. 
ZnT1 is also present on the cell membrane but maintains the transport of zinc in the opposite 
direction. Zip7 and ZnT7 are both located on intracellular organelles and cytoplasmic vesicles, 
where ZnT7 transports zinc into the storage, and Zip7 releases zinc from endoplasmic reticulum 
(ER) into the cytoplasm. It was important that for more detailed studies, transporters located on 
either cell membrane or intracellular membranes were assessed. 
Mature monocyte-derived DCs were prepared and treated with 100 µg/ml of bacterial LPS, for 
up to 72 h. LPS-induced alterations in zinc transporter expression and the significant changes 
observed may indicate crucial period for DC function. Because of very high sensitivity of qPCR, 
careful design is crucial in this approach. All primers pairs used were designed to be located on 
separate exons, to prevent amplification of genomic DNA. Primers efficiency was calculated 
using standard amplification curve for 10-fold serial dilution of DNA. Efficiencies for all primer 
pairs were above 90%, except for ZnT7 with 75% and β-actin with 89% efficiency, with R2> 0.99 
(Table 2.3). 
The expression of mRNA transcripts encoding ZnT1 and ZnT7 were significantly upregulated 
after 12 h. For ZnT1, expression reached a 4-fold increase after 24 h and then a gradual decrease 
in expression was observed up to 72 h post-LPS stimulation (Fig. 2.3 A). For ZnT7, a 2 to 3-fold 
increase (relative to control) was prolonged with no significant changes between 24 h and 72 h 
(Fig. 2.3 B). In general, changes in mRNA expression of Zip transporters achieved 1.5-fold 
increases. Zip6 transporter after 6 h post LPS treatment, mRNA expression decrease and then 
steadily increase up to 48 h (Fig. 2.3 C). There was a slight increase in the expression of Zip7 24 
h post-LPS treatment and the effect is prolonged up to 72 h (Fig. 2.3 D).  
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Figure 2.3. LPS-induced alterations in zinc transporter expression. Real-time PCR of the relative 
amounts of mRNA transcripts encoding various zinc transporters (vertical axes) left untreated or 
treated for up to 72h with LPS. All results were normalised to the amount of two housekeeping 
genes, β-actin and RPLP0. Results are the average ± SD of six independent experiments. p>0.05 
(ns), p≤0.05 (*), p≤0.01 (**), p≤0.001 (***). 
 
Zip proteins transport zinc into the cytoplasm (Zip6 from the extracellular space and Zip7 from 
the intracellular vesicles) and ZnT proteins act as zinc exporters (ZnT1) or move zinc to storage 
vesicles (ZnT7). Given the observed differences in the expression of Zips and ZnTs, these results 
suggest that stimulation of TLR4 causes dramatic movement of zinc out of the cytoplasm (Fig. 
2.3). It also showed that in response to LPS stimulation, the message for ZnT7 production 
increases prior to ZnT1. This indicates that zinc is firstly transported into the storage vesicles and 
then the excess is removed to the extracellular space.  
2.3.2.2. Alterations in protein expression 
To determine whether alterations in mRNA levels are translated to protein production, Near 
Infrared (NIR) western blot with fluorophore-linked, secondary antibodies was performed on 
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cells lysates from moDC. This method allows detection of two different targets on the same blot, 
which allows normalisation against an internal control without stripping and re-probing of the 
blots. Cells were prepared exactly as described previously and treated for 72 h with bacterial LPS 
followed by cell lysis and protein quantification. To examine alterations in protein expression 
caused by LPS-mediated TLR4 activation, NIR western blot of four zinc transporters (ZnT1, ZnT7, 
Zip6 and Zip7) and the TLR4 receptor were performed. Additionally, a NIR western blot probing 
for Zip7 in its phosphorylated state was also carried out. This was particularly important as zinc 
transporters are activated through phosphorylation.  
Cell lysates from three independent biological repeats were prepared in the same way as 
previously described. Each membrane was incubated simultaneously with antibody against one 
of the zinc transporters (or antibody against TLR4) and anti-β-actin as a control (Fig. 2.4). Bi-
colour detection with near infrared fluorescence, IRDye® secondary antibodies were used. 
Generally, this approach gave very reliable results although some non-specific binding (as 
indicated by the presence of extra bands) was observed when probing with anti-Zip6 and anti-
phospho-Zip7 antibodies. The anti-phospho-Zip7 antibody revealed protein bands of distinct 
sizes (Fig. 2.4 F). The upper band is the phosphorylated Zip7 (Taylor et al. 2008). The lower band 
however is of very similar size to the band shown for total Zip7 protein as can be compared with 
Fig. 2.4 E. Two of the blots (for ZnT7 (Fig. 2.4 C, D) and Zip6 (Fig. 2.4 G, H)) are presented as two 
figures, control and target separately, as the band sizes for both target and control proteins are 
very similar and would overlap on one image.  
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Figure 2.4. NIR Western blot analysis of LPS-induced alterations in zinc transporter expression 
and TLR4 receptor. Dendritic cells were treated with LPS for up to 72 h. Each membrane was 
incubated subsequently with target antibody and antibody against β-actin control. Images C and 
D, and G and H represent the same membrane. Two secondary antibodies labelled with 
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spectrally distinct NIR fluorescent dyes were used. Here shown in greyscale. Results are the 
representative images for three independent experiments. 
 
The Odyssey imaging system has internal software, which allows quantitative analysis of NIR 
western blots. The expression of target protein was normalised to the expression of the β-actin 
control, for each probed western blot membrane. The results were then plotted using Microsoft 
Excel. Results are presented in arbitrary units and represent protein alterations of analysed zinc 
transporters (Fig. 2.5). The expression patterns differed between the transporters. Expression 
of ZnT1 increased slightly after 6 h and then gradually decreased up to 72 h, with the largest 
changes observed after 24 h post LPS stimulation (Fig. 2.5 A). The expression of ZnT7 transporter 
decreased after the first 6 h of the experiment then remained stable until 12 h, followed by slight 
decrease up to 24 h. Due to considerable variation between replicates, it is hard to say whether 
the expression of ZnT7 changed at 48 h of experiment. Nonetheless, when compared to the 24 
h time point, increased expression of ZnT7 at 72 h was observed (Fig. 2.5 B). The protein level of 
the Zip6 transporter appeared stable over the first 12 h post-LPS treatment. Then a decrease in 
the expression was observed at 24 h, followed by gradual increase at the 72 h time point (Fig. 
2.5 E).  
For Zip7, a gradual decrease in expression at the protein level was observed had almost halved 
(relative to the initial protein amount) at 24 h post-LPS treatment (Fig. 2.5 C). In addition, this 
transporter exhibited maximum phosphorylation at 6 h. A degree of dephosphorylation then 
occurs (observed at 12 h post-LPS treatment) and the level of phosphorylated protein stabilises 
until 72 h (Fig. 2.5 D). It is worth highlighting that Zip7 is located on the membrane of storage 
vesicles and transports zinc into the cytoplasm. Therefore, the Western blot results reveal that 
at 6 h post-LPS stimulation, the transport of zinc into storage vesicles was likely favoured as 
phosphorylation activates Zip7. Given that LPS is a ligand for TLR4 and the alterations in zinc 
transporters expression are a result of TLR4 signalling, it was important to check the expression 
of TLR4 itself over the course of the experiment (Fig. 2.5 F). Western blotting revealed that the 
expression of this receptor gradually increases up to 12 h and then fluctuates by increasing and 
decreasing every 24 h. Those fluctuations might mean that cells try to maintain the amount of 
receptor on stable level.  
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Figure 2.5. LPS-induced alterations in zinc transporter expression. NIR Western blot analysis of 
various zinc transporters and TLR4 receptor left untreated or treated for up to 72h with LPS. 
Results were normalised to the amount of β-actin. Results are the mean ± S.D. based upon three 
independent experiments.  
 
To help confirm the western blot findings and to gain more insight into TLR4-mediated 
regulation of zinc transporter expression (and additionally to look at the cellular localisation of 
chosen zinc transporters), immunofluorescence microscopy and flow cytometry were used. As 
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shown by immunoblotting (Fig. 2.5), the most significant changes in transporters expression 
occurred after 24 h post-LPS stimulation. Therefore, for further experiments only the 24 h time 
point versus untreated control were compared.  
For IF imaging moDCs were grown on microscopy cover slips for 24 h following addition of 
bacterial LPS. The transporters were detected using primary antibodies against zinc transporters 
combined by matching secondary Alexa Fluor antibodies and images taken under x20 
magnification. Images of treated and untreated sample for each transporter were taken with 
the same microscopy and camera settings. The general observation showed that the protein 
expression of all zinc transporters decreased after 24 h of LPS treatment (Fig. 2.6 A). It has 
previously been suggested that ZnT1 is localised exclusively on the cell membrane (Schweigel-
Röntgen, 2014). However, on the microscopy images it was visible in the cytosol and was 
particularly evident in this location after LPS treatment. Moreover, its localisation looked 
granular in appearance and therefore could represent its presence on vesicles. This may suggest 
that TLR4 signalling causes the main zinc exporter to internalize. Also the expression of ZnT1 
decreased after LPS-stimulation compared to the control. Cellular localisation of another zinc 
exporter, ZnT7 did not change upon treatment but the expression level decreased. Also 
expression of Zip6, which is thought to remove zinc from intracellular organelles to the 
cytoplasm, decreases but its subcellular localisation does not change. There were no changes in 
expression of TLR4 observed (Fig. 2.6 A). Collectively, these data are in agreement with western 
blot results. 
To support IF imaging data, and to assess the alterations in zinc transporters expression in a 
quantitative manner, flow cytometry was used. Cells were grown and prepared as described 
above, and treated with LPS for 24 h. After the incubation with primary and matching secondary 
antibodies, the fluorescence (representative of 5,000 cells per sample) was measured. The 
results are expressed as a percentage relative to the untreated control and revealed alterations 
in the protein expression of analysed zinc transporters. The findings were consistent with IF data 
and WB data (Fig. 2.6 B). The results from both fluorescent microscopy and flow cytometry 
showed decreases in protein expression of ZnT1, ZnT7 and Zip6 transporters after 24 h post-LPS 
treatment (Fig. 2.6). Those findings were consistent with previous western blotting results. 
Expression of TLR4 receptor did not change after 24 h relative to the untreated control (Fig. 2.6). 
However, when there were more time points (Fig. 2.5 F), fluctuations in expression were 
observed every 24 h after the initial 12 h of expression increase. 
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Figure 2.6. LPS-induced changes in the expression of zinc transporters in DCs. Fluorescent 
microscopy imaging of zinc transporters distribution inside moDC (A) and flow cytometry of zinc 
transporters, detected with Alexa Fluor® 594 dye (B), in DCs left untreated (as a control) or 
treated for 24 h with LPS. 
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2.3.2.3. Phosphorylation of Zip 7 transporter 
No commercial phospho-protein antibodies are available for zinc transporters. However, a 
phospho-Zip7 directed antibody was obtained as a gift from Dr Kathryn Taylor (Cardiff 
University). It allowed to perform not only western blot analysis of Zip7 transporter levels in the 
phosphorylated state compared to the total Zip7 (Fig. 2.4; 2.5), but also to examine the cellular 
localization of the phosphorylated form of the Zip7 transporter (Fig. 2.7) and to perform 
quantitative analysis of the phosphorylation level (Fig. 2.8).  
Reversible phosphorylation plays a significant regulatory role in many cellular processes, by 
altering the conformational state of a protein to activate or inhibit its function. The activation of 
Zip7 occurs via its phosphorylation by protein kinase CK2 (Taylor et al., 2012). As a result, 
activated Zip7 releases zinc from endoplasmic reticulum (ER) into the cytoplasm. 
Phosphorylation and therefore activation of the zinc transporter Zip7, can give an important 
insight into zinc homeostasis of dendritic cells. MoDCs were cultured on microscopy cover slips 
with the addition of bacterial LPS for 12 or 24 h. Transporters were detected using bi-color 
staining with Alexa Fluor antibodies of distinct absorbance. Images were obtained under 100x 
magnification with oil immersion.  
The IF images reveal co-localization of phosphorylated and total Zip7 transporters (Fig. 2.7), 
therefore for this particular transporter phosphorylation does not change the localization of the 
protein. The level of phosphorylation of Zip7 was low in the untreated control (Fig. 2.7; 0 h). 
After 12 h of LPS stimulation, phosphorylation increased and then at 24 h the level of 
phosphorylation decreased but did not reach the initial level (Fig. 2.7). For more quantitative 
measurement of the Zip7 transporter phosphorylation, flow cytometry was employed. Cells 
were grown and prepared as previously but treated with LPS for up to 72 h. After LPS treatment, 
cells were stained with either Zip7 or phospho-Zip7 antibody at a time. Results are presented as 
the expression of phosphorylated Zip7 and total Zip7 (Fig. 2.8) presented in arbitrary units (Fig. 
2.8). 
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Figure 2.7. Fluorescent microscopy imaging of total Zip7 (red) and Zip7 in the phosphorylated 
state (white) in MoDCs. Cells were treated with LPS for 24 h. Signal was detected with Alexa 
Fluor® 594 (red) and Alexa Fluor® 647 (white) conjugate.  
 
Flow cytometry data suggests that TLR4 signalling activates the Zip7 transporter. The highest 
phosphorylation is present after 12 h of LPS treatment with more than 50% of total protein 
phosphorylated. Zip7 remained phosphorylated until 48 h of the LPS treatment. After 72 h de-
phosphorylation occurred. 
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Figure 2.8. Phosphorylation of Zip7 transporter induced by LPS stimulation over 72 h. Expression 
of phosphorylated Zip7 and total Zip7 transporter, presented in arbitrary units. 
 
2.3.3. Toll-like receptor 4-mediated alteration in intracellular zinc level in 
DCs  
It has been postulated by Kitamura and colleagues (Kitamura et al., 2006), that alterations in 
zinc transporters expression caused by LPS-mediated stimulation of the TLR4 receptor result in 
a decrease in the free zinc concentrations in DCs. However, in that study expression was only 
examined for 6 h after LPS stimulation. In addition, the zinc probe used in this study was Newport 
green (also known as dichlorofluorescein, DCF). This fluorescent probe is zinc-specific but has 
only moderate zinc-binding affinity (Kd for Zn2+ is around 1 µM; DCF-N7991; Thermo Fisher 
Scientific). It is therefore not in a suitable range to detect intracellular free zinc concentrations, 
which are in the low nanomolar range (Maret, 2015). To gain a better insight into the alteration 
in zinc transporters expression pertaining to zinc homeostasis during moDCs maturation, current 
examination extends the Kitamura et al. study to 72 h post LPS-stimulation. To investigate the 
relationship between TLR4 signalling and the abundance of intracellular zinc fluorescent 
microscopy and flow cytometry with zinc probe ZnAF-2F DA were used.   
Cells were prepared and treated with LPS as described before and stained with ZnAF-2F DA. This 
fluorophore permeates the cell membranes of living cells and is then hydrolysed in the cytosol, 
such that it is then retained in the cell. ZnAF-2F DA was chosen because of its high affinity for 
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zinc. The levels of intracellular labile zinc (free or loosely bound zinc) in most of the cells are in 
the nanomolar range. Most of the available fluorescent zinc probes have dissociation constant 
(Kd) values for zinc in micromolar range, including Newport Green (Kd = 1 µM) and Fluozin (Kd = 
2 µM). In contrast, the Kd of ZnAF-2F DA for zinc is 5.5 nM, which affords sufficient sensitivity for 
biological applications. Additionally, ZnAF-2F DA is highly selective for zinc as it does not 
fluoresce in the presence of high concentrations of other biologically important cations including 
5 mM Ca2+, Mg2+, Na+ or K+ or 1 µM Cu2+ or Fe2+ (Hirano et al., 2002).   
Monocytes are adherent cells and attach to culture dish after approximately 1 h of culture. 
Nevertheless, when kept in culture for more than 24 h mature moDCs can detach from the 
surface. The process can be observed in the presented microscopy images (Fig. 2.9).  
The results showed that upon LPS treatment, the amount of zinc decreased (Fig. 2.9) at 2 h post 
LPS treatment and then remained stable until 72 h of LPS stimulation. Controls, cells not stained, 
showed no fluorescence at 488 nm wavelength (data not shown).  
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Figure 2.9. Fluorescent microscopy imaging of zinc distribution inside dendritic cell. MoDC were 
treated with LPS over 72h and incubated with ZnAF-2F DA (AdipoGen) - membrane permeable 
zinc fluorophore prior fixation. (A) Cells stained with ZnAF-2F DA (green) and DAPI (blue), (B) 
cells stained with ZnAF-2F DA only. Images were taken under x 20 magnification. Scale bar 
represent 68.7 µm. 
 
 To support IF results, showing LPS induced zinc alterations in moDC, flow cytometry was used. 
To make the results comparable to IF studies, the same zinc fluorophore, ZnAF-2F DA was used, 
as its λem = 515 nm made it suitable for both methods. Prior to staining, cells were trypsynised 
and transferred to round bottom 96-well plates, suitable for flow cytometry. To set up threshold, 
unstained, untreated cells were used. For each sample, fluorescent signal of 5000 cells was 
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measured. Results are present in a logarithmic scale of arbitrary units, showing changes in green 
fluorescence (Fig. 2.10). Minor fluctuations in the levels of zinc can be observed throughout the 
LPS treatment. These findings are consistent with IF data, which also showed no major 
alterations in intracellular, zinc in moDCs, caused by TLR4 signalling (Fig. 2.9). 
 
Figure 2.10. Flow cytometry of intracellular free zinc, detected with ZnAF- 2F DA, in DCs left 
untreated or treated for up to 72 h with LPS. 
 
2.3.4. The effect of LPS and hydroxyapatite on TNF-α secretion by moDC 
TLRs are localised on either the cell membrane or intracellular compartments. The isoforms 
known to be localised on the cell surface are TLR1, TLR2, TLR4, TLR5 and TLR6, which mainly 
recognise bacterial products such as LPS. Some non-bacterial particles can also be recognised by 
TLRs. These include the mineral, hydroxyapatite (HAP) which is a ligand for TLR4 and at least one 
more TLR (Velard et al., 2013). Following activation, TLRs activate signalling pathways that 
induce the production of chemokines, co-stimulatory molecules, and cytokines including TNF-α. 
Specifically, TLR4, after binding its ligand undergoes conformational changes that initiate MyD88 
signalling pathway. This triggers the activation of a downstream pathway that results in 
translocation of nuclear factor κB (NF-κB) from the cytoplasm to the nucleus and finally 
production of pro-inflammatory cytokines including TNF-α.  
Mature dendritic cells are known to secrete TNF-α through TLR4 signalling. However, the 
reaction of dendritic cells to HAP stimulation is not known. To gain insight into the role of HAP 
in TLR4 signalling in moDCs, and to confirm moDC functionality, aliquots of supernatants were 
analysed by ELISA for the expression of TNF- α. ELISA kit used had a very high sensitivity of 1.7 
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pg/mL. MoDCs were grown with the addition of LPS for up to 72h. Media was then collected and 
secreted TNF-α concentrations measured. The maximum TNF-α secretion detected in the 
supernatant of mature DCs was 7 ng/ml (Fig. 2.11 A), which was observed at 12 h after LPS 
stimulation. This was followed by a gradual decrease at 48 h, lowering to almost 50% of the 
maximum value, and then increasing again after this time point. In the experiment, two controls 
were used. The first one was the culture of moDCs without the addition of LPS to control for any 
compounds found in the culture media that may trigger a response from DCs. The second control 
was RPMI media supplemented with 10% FCS.  
The secretion of TNF-α by moDCs upon HAP stimulation was also examined (Fig. 2.11 B). 
Differentiated moDCs were grown in the presence of sterile HAP powder for 24 h at the variety 
of concentrations. After stimulation, the cell culture media was collected and TNF-α 
concentrations were measured. It was found that HAP does initiate an immune response from 
moDCs (as indicated by an increase in TNF-α secretion). However, secreted TNF-α levels were 
generally lower from cells treated with HAP compared to LPS-activated cells, with the peak of 
350 pg/ml (at 5 mg of HAP per ml of media). With higher concentrations of HAP, TNF- α secretion 
becomes lower again and at 20 mg/ml of HAP almost reached the level of TNF-α secretion of an 
untreated control. Cells untreated with HAP were used as a control and showed 200 pg/ml TNF-
α secretion. This would suggest that even though HAP can activate DCs, the response is not as 
strong as with LPS (Fig. 2.11 B). 
 
Figure 2.11. TNF-α release from moDCs following stimulation with LPS and HAP. MoDCs were 
cultured in RPMI media supplemented 10% FCS. Next cells were stimulated with 100 μg/ml of 
bacterial LPS for up to 72 h (A) or with hydroxyapatite nanopowder for 24 h (B) and TNF-α 
secretion was measured using Human TNF-α ELISA Kit (Life Technologies). p≤0.05 (*), p≤0.01 
(**), p≤0.001 (***). 
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2.4 Discussion 
2.4.1. Morphological characteristic of moDC  
DCs can be directly purified from blood; however, their number is very low at just 0.02-0.06 x 
106 cells/ml of blood. DCs can be also generated in vitro by culturing CD14+ monocytes (Soo et 
al., 2012) or CD34+ bone marrow cells (Tan et al., 2010), with the addition of GM-CSF and IL-4. 
Obtained immature DCs can be then stimulated with antigen to induce maturation. Upon 
maturation, DCs undergo morphological and functional changes, including development of 
extensive cytoplasmic projections in many directions from the cell body. Additional 
characteristics of mature moDCs are the presence of MHC class II and co-stimulatory molecules, 
including CD40, CD80 and CD86 (Reis e Sousa, 2006), as demonstrated through 
immunophenotyping using flow cytometry.  
The DCs used in this chapter were generated from peripheral blood monocytes. Great care was 
taken during cell preparation to maintain cell structure. Therefore, cells were grown directly on 
microscopy coverslips, as attaching cells to the microscopy slide by centrifugation (cytospin) 
could cause severe damage. Microscopy imaging in both bright field and using fluorescence 
antibodies revealed the abundance of characteristic cytoplasmic projections upon LPS-induced 
maturation. Cells were prepared using a well-established protocol (Soo et al., 2012), therefore, 
no further characterisation (immunophenotyping) was done.  
2.4.2. Zinc homeostasis in moDC upon LPS stimulation 
Zinc deficiency causes defects in cellular immunity. Therefore, it is crucial to establish the link 
between zinc homeostasis and dendritic cells function. One of the components of a network 
that build zinc homeostasis are Zip and ZnT transporters. A study by Kitamura et. al. (2006) 
demonstrated that in dendritic cells (DC), stimulation by bacterial LPS induced significant 
alterations in the expression of zinc transporters. In this study, expression was assessed up to 6 
hours after LPS stimulation. The main aim of the current study was to confirm these results and 
extend the timescale of experiment beyond 6 hours post-LPS stimulation. Therefore, mature 
monocyte-derived DCs were treated with 100 ng/μl of bacterial LPS for up to 72 h. The presented 
data show that LPS-induced alterations in zinc transporters expression maintain stable level of 
intracellular free zinc.  
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Stimulation of moDCs with bacterial LPS caused significant changes in zinc transporters 
expression observed for both mRNA transcripts and protein. Firstly, the expression of mRNA 
transcripts encoding for six ZnT (1, 4, 5, 6, 7, 9) and nine Zip (1, 3, 6, 7, 8, 9, 10, 11, 12) 
transporters was verified, until 10 h of LPS induced maturation. Changes in expression differed 
between the transporters. For ZnT4, Zip3, Zip10, and Zip11 the expression reduced gradually 
until 10 h post-LPS treatment. ZnT1, ZnT7, ZnT9, Zip1, and Zip8 mRNA expression increased after 
6 h of maturation, and then decreased between 6-10 h. Zip6 and Zip7 exhibited an abrupt 
increase in expression after treatment with the peak at 2-6 h. Interestingly, LPS treatment did 
not alter the expression of ZnT5, ZnT6 and Zip12. 
These findings are extremely interesting in the context of a study done by Kitamura et al. (2006). 
According to Kitamura (2006), expression of Zip6 slightly decreases, and expression of Zip10 is 
not altered after 6 h of LPS treatment. Though those findings are consistent with current results, 
the most interesting observations start beyond the 6 h time point where the expression of not 
only Zip6 and Zip10, but also Zip1 and Zip9 decreased almost to the basal level. Published results 
also suggest reduction in ZnT1, ZnT4 and ZnT6 mRNA expression after 6 h of treatment (Kitamura 
et al., 2006). The results obtained demonstrate that while expression of ZnT4 decreases over 
time, expression of ZnT6 does not change. Also ZnT1 expression was found to increase over 6 h 
and then decrease.  
To gain more insight into the role of transporters in zinc homeostasis during DC maturation, 
quantitative PCR (qPCR) was used. For this study, two zinc importers (Zip6 and Zip7) and two 
zinc exporters (ZnT1 and ZnT7) were chosen. Zip6 is present on the cell membrane and thus 
transports zinc from the extracellular space into the cytosol. ZnT1 is also present on the cell 
membrane but maintains the transport of zinc in the opposite direction. Zip7 and ZnT7 are both 
located on intracellular organelles and cytoplasmic vesicles, where ZnT7 transports zinc into the 
storage, and Zip7 releases zinc from endoplasmic reticulum (ER) into the cytoplasm. It was 
important that for detailed study of zinc in moDC maturation, transporters either located on the 
cell membrane or on intracellular membranes were characterised.  
The expression of mRNA transcripts encoding for Zip7 increased by ~0.25-fold at 24 h post-LPS 
stimulation. The expression of mRNA transcripts encoding for Zip6 decreased by 0.2-fold at 6 h, 
and then increased by 0.5-fold at 24 h and stabilised. The mRNA expression of ZnT transporters 
(ZnT1 and ZnT7) also increased, but the changes were more rapid and significant than for zinc 
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importers, and appeared after 12 h of LPS treatment (3-fold for ZnT1 and 2.5-fold for ZnT7). 
Additionally, the mRNA expression of zinc exporters decreased gradually until 72h.  
The results of protein expression studies surprisingly did not mirror those observed in the gene 
expression studies. The expression of zinc exporters at the protein level gradually decreased 
until to 72h of LPS stimulation, when compared to the untreated control. The expression of Zip6 
decreased dramatically after 24 h, but then slowly recovered. In contrast, the expression of Zip7 
did not change, but the phosphorylation occurred after 12 h of LPS stimulation.  
The biological explanation of this observation is not immediately obvious, however, chosen time 
points are highly likely to replicate the period of in vivo post-LPS stimulation (i.e. exposure to a 
pathogen) when the DC processes the antigen, leaves the site of pathogen exposure and reaches 
the lymph nodes to initiate an immune response. Immature DCs are located in non-lymphoid 
tissues, where they permanently explore the presence of microorganisms or bacteria products. 
As soon as DCs recognise the pathogen, they undergo a complex process termed “maturation”, 
which changes their morphology and function to enhance the ability of antigen uptake and 
processing (Granucci et al., 1999; Reis e Sousa, 2006). During these developmental changes, the 
expression of MHC class II and co-stimulatory molecules, including CD40, CD80, and CD86 
increases. In addition, the secretion of inflammatory cytokines and chemokines is also increased 
(Reis e Sousa, 2006). The whole process of DC maturation can be divided into three main phases: 
early maturation (0-6 h of stimulation), maturing DCs (7-18 h of stimulation), and fully mature 
DCs (over 18 h of stimulation; Alloatti et al., 2016). The early maturation of DCs starts after an 
antigen is recognised through PRRs, such as TLRs. Antigens can be either pathogen- or damage-
associated molecular pattern molecules, and include bacterial LPS, which is a ligand for TLR4. 
During the early phase of maturation, an antigen is taken up by DCs. In the next phase, antigen 
uptake and the ability to degrade and process antigens is decreased in order to preserve the 
antigen for processing in the lymph node. Throughout the process of maturation, DCs travel to 
the lymph nodes. Fully mature DCs present the antigen to CD4+, but the process of cross-
presentation of newly acquired antigens to CD8+ T-cells is downregulated. It is estimated that 
after 40 h of antigen stimulation, the ability of the cell to present antigen ends or is at least very 
circumscribed (Alloatti et al., 2016; Reis e Sousa, 2006).  
There is a growing evidence that following activation, zinc acts as a second messenger to trigger 
the activation of dendritic cells through MyD88 or TRIF signalling pathways (Kitamura et al., 
2006; Brieger et al., 2013; Haase et al., 2008). MyD88 is the early signalling pathway, where zinc 
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acts as phosphatase inhibitor, resulting in the production of inflammatory cytokines. Later, TRIF 
dependent signalling causes the secretion of IFN-β and expression of surface molecules that 
together are required for T-cell activation during antigen presentation (Brieger et al., 2013). 
Current findings support this observation, as the data now shows that intracellular zinc levels 
are not changing during the whole process of antigen recognition, uptake, and processing. One 
of the mechanisms to ensure sufficient zinc level in the cytoplasm is its release from ER storage, 
through Zip7 transporter.  
Zip7 is an exception amongst zinc transporters. It is ubiquitously expressed among organisms, 
including orthologues in Drosophila (CATSUP) and Arabidopsis (IAR1; Taylor and Nicholson, 
2003; Stathakis et al., 1999); and among cell types (Taylor et al., 2004). Studies on the variety of 
cell types, including erythroleukemia cells, lung fibroblasts and mammary epithelial cells, 
showed that Zip7 subcellular localisation is limited to the membrane of the Golgi or endoplasmic 
reticulum (ER), or both (Kambe, 2011; Huang et al., 2005). Its gene expression and cellular 
localization are not affected by the alterations in zinc levels. Nonetheless, elevated zinc levels 
can extinguish Zip7 protein translation (Huang et al., 2005). 
Zip7 has multiple functions. Activation of Zip7 is essential for the release of zinc from the ER, 
and initiates the signalling cascade, which promotes cell proliferation (Taylor, 2008; Taylor 
2008b). Additional functions include zinc-mediated inactivation of protein phosphatases, which 
results in the activation of tyrosine kinases (Hogstrand et al., 2009).  
As demonstrated with the prokaryotic Zip homologue ZipB, Zip transporters act as ion channels 
(Hogstrand et al., 2009). The mechanisms that regulates zinc transport are not entirely clear; 
however, Zip7 (and other Zips) are known to be activated (at least in part) by phosphorylation. 
There is multiple evidence to support this concept, including presence of phosphorylation sites 
and MAPK-binding motifs located on the cytoplasmic site of the Zip7 transporter (Hogstrand et 
al., 2009). Gated release of zinc from the ER has been observed after phosphorylation of Zip7 by 
protein kinase CK2. As a result, released zinc activates tyrosine kinase, which leads to the 
phosphorylation of AKT and kinases 1 and 2 (ERK1/2) (Taylor et al., 2012).  
The presented data suggest that zinc homeostatic control is an important part of the antigen 
presentation process. The later time points (>6 h) are likely to correspond to the period in vivo 
post-LPS stimulation (i.e. exposure to a pathogen) when the DC has left the site of pathogen 
exposure and is migrating to a local lymph node to initiate an immune response. Collectively, 
the findings help to build a more complete picture of the behaviour of Zip and ZnT transporters 
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that occurs during this crucial period for DCs. Additionally, presented data now implicate zinc 
homeostasis as important in this process and provides a strong background for future functional 
studies of zinc and DCs in the immune system in health and disease. 
2.4.3. HAP and LPS induced TNF-α secretion  
The presented data show that HAP can induce the secretion of pro-inflammatory cytokines by 
DCs, however to a lesser extent than LPS. Calcium phosphate biomaterial particles, typically HAP 
or beta-tricalcium phosphate (b-TCP), are known to trigger an immune response (Velard et al., 
2013) in a number of immune cells studied, including monocytes, macrophages and fibroblasts 
(Nandra et al., 2005). Such responses are usually measured by monitoring the secretion of pro-
inflammatory cytokines, including TNF-α and do not depend on the size, type or shape of 
particles used in the study (Lange et al., 2009; Lange et al., 2011). The cellular pathways involved 
in the response remain unclear (Velard et al., 2013). Production of TNF-a by macrophages 
exposed to HAP particles is partially TLR4 dependent (Grandjean-Laquerrière et al., 2007), which 
would indicate a joint signalling pathway between HAP and LPS stimulation. 
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Chapter 3. Proteomic alterations in maturing dendritic cells  
3.1. Introduction  
3.1.1. Proteomic studies on maturing human dendritic cells 
Tissue-resident immature dendritic cells (iDCs) exhibit very high capacity to capture exogenous 
and cellular antigens through endocytosis and phagocytosis upon activation of surface 
receptors. The antigens are recognised through pattern recognition receptors (PRRs) including 
toll like receptors (TLRs; West et al., 2006). IDCs are highly phagocytic, however their antigen 
presenting ability is very limited. After antigen recognition, iDCs begin a maturation process 
which can be divided into five steps. Firstly, the morphology of DC changes whereby the cell 
grows and develops cytoplasmic projections, a process involving cytoskeleton rearrangement. 
In this first phase cell motility increases by the loss of adhesive molecules (West et al., 2004). In 
the second phase, maturing DCs express T-cell co-stimulatory molecules (CD40, CD54, CD80 and 
CD86) on the cell surface (Ferreira et al., 2010). The third phase is a migration to the lymph 
nodes and spleen and the expression of a lymph-node homing chemokine receptor (CCR7), 
which enables cell to enter lymphatic vessels (Yanagihara, 1998). DCs express MHC class II 
antigen presenting molecules on their cell surface, and in the final phase chemokines and 
cytokines are secreted (Ferreira et al., 2010).  At this point, DCs become fully mature and cannot 
take up new antigens but are ready to present the processed antigens to chemo-attracted, 
antigen-specific T-cells to therefore initiate the immune response (Banchereau et al., 2000). 
Overall DCs are considered as mature when they can activate T-cell through distinct 
mechanisms. The first mechanism of signalling is the interaction of MHC II molecule with T-cell 
receptor (TCR). Second mechanism is the interaction between costimulatory molecules 
CD80/CD86 on the DC cell surface with CD28 on the T cells. DC signalling determines the balance 
between different subsets of T-cells (Ferreira et al., 2010).   
Proteomics can be defined as the simultaneous study of multiple (usually many) proteins in a 
particular cell or tissue at a given time. This can incorporate aspects of cellular localisation, 
interactions between proteins, post-translational modifications and protein functions. Such data 
provides an insight into the biological processes and the functional state of the cell and very 
often is complementary to genomic studies. Most of the proteomics studies performed so far in 
DCs are fairly primitive and based primarily on traditional electrophoresis-based techniques, 
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such as 2-D gel electrophoresis and 2-D DIGE (2-D gel electrophoresis with an internal 
standards). Other non-gel based techniques that have been used to study DCs are liquid 
chromatography combined with mass spectrometry (LC-MS/MS) and multidimensional protein 
identification technology (MudPIT; Ferreira et al., 2010). Several of those studies focused on 
alterations in protein expression during DCs maturation. Those were performed either on the 
whole cell lysate or on the fractionated samples of DCs, including exosome (Andre et al., 2004; 
Thery et al., 2002) and secretome (Gundacker et al., 2009).  
One of the earliest proteomic studies of DCs was carried out by Angenieux et al. (2001). They 
identified 10 proteins (Table 3.1) which expression differed between monocytes and immature 
monocyte derived DCs (moDCs). They identified proteins involved in antigen processing, 
including chaperones, and proteins involved in cytoskeletal remodelling upregulated on protein 
level and mRNA transcript in immature moDCs. Soon another two papers were published 
examining protein and gene expression changes upon differentiation and TNF-α induced 
maturation of moDCs. Richards and colleagues using 2-D gel electrophoresis were able to detect 
a total of 900 distinct proteins, from which expression levels of only 37 were identified to have 
changed (Le Naour et al., 2001; Richards et al., 2002).  Their most interesting observation was 
that during moDC maturation, only a small number of genes were altered at the RNA level, which 
points to importance of post-transcriptional and post-translational modifications. Among the 
identified proteins were chaperones, proteins involved in cell structure and fatty acid-binding 
proteins (Table 3.1), which suggested that protein-folding pathways and alterations in lipid 
metabolism play a role in antigen processing and presentation.  
Another proteomic study confirmed the importance of post-translational modifications in 
moDCs maturation (Pereira et al., 2005). In this study lipopolysaccharide (LPS) was used to 
induce maturation and then combined CBB G-250 stained 2-D gels with LC-MS/MS to identify 
proteins in cell lysates. They observed 50 spots on 2-D gels, which corresponded to 36 separate 
altered proteins upon maturation (note that many spots appear in multiple electrophoretic 
forms). The identified altered proteins were mostly involved in cell structure including multiple 
forms of actin, but also chaperones and MHC class I molecule (Table 3.1). 
A study by Ferreira et al. (2008) used a more sensitive gel electrophoresis technique, 2-D DIGE 
combined with MALDI-TOF/TOF-MS. This allowed identification of 74 proteins exhibiting altered 
expression upon moDC maturation. The authors analysed the protein expression profile of 
immature and mature moDCs. Again, similar to previous studies, they were mostly involved in 
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cytoskeleton remodelling, including gamma actin, fascin and lamin; in signal transduction, 
interferon-induced GTP-binding protein Mx1 and tyrosine-protein phosphatase; and in cellular 
metabolism, pyruvate carboxilase and alpha enolase. In addition proteins involved in MHC II 
antigen processing pathway (cathepsin B, D and S) were also altered. 
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Table 3.1. An overview of various proteomic studies performed on DCs.  
 
Individual proteins differ between described studies, with only few proteins in common. This 
may be due to the sensitivity and accuracy of the methods used as well as the method of sample 
preparation and the protocol used for moDC maturation, which were varied. Ferreira et al. 
(2008) used a combination of LPS and IFN-γ, Pereira et al. (2005) used GM-CSF with IL-4 and LPS 
and Le Naour et al. (2001) used IL-4, GM-CSF and TNFa. It was later shown that the inducer used 
for moDC maturation has great influence on the proteomic profile of matured cells and 
therefore also their functional state (Gundacker et al., 2009). In this study shotgun analysis 
identified 1690 cytoplasmic proteins. The greatest alterations in protein expression were 
observed upon LPS induced maturation.  Activation of moDCs with 1-palmitoyl-2-arachidoyl-sn-
glycerol-3-phosphorylcholin (OxPAPC) or with human rhinovirus (HRV) also induced alterations 
in protein expression, however these were lesser than those observed following LPS-treatemnt 
(Gundacker et al., 2009). Another known inducer of DCs maturation is hydroxyapatite (HAP). 
HAP a calcium phosphate mineral, can induce inflammatory reaction via TLR4 signalling as 
shown in macrophages exposed to HAP particles (Grandjean-Laquerrière et al., 2007). So far no 
studies describing proteomic changes during DCs maturation induced with HAP have been 
reported.  
The proteomic studies of DCs maturation described above highlighted involvement of similar 
groups of proteins, including proteins involved in cytoskeletal remodelling, chaperones and 
antigen processing and presentation proteins. Nevertheless, specific identified proteins differ 
between the studies, which might be due to the technical limitations of proteomic methods 
used, which varied from traditional 2-D electrophoresis to basic mass spectrometry-based 
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approaches. Also the preparation and maturation of cells has a big influence on the proteome 
of mature DCs. The majority of methods used in the studies described above are semi-
quantitative at best. The proteomic technique that will be described next, SWATH is fully 
quantitative and has vast coverage. 
3.1.2. SWATH 
Mass spectrometry (MS)-based proteomic approaches are a quickly developing field of research. 
In comparison to traditional techniques used for protein analysis such as western-blotting or 
enzyme-linked immunosorbent (ELISA) assays, which serve mostly for protein identification, 
(MS)-based proteomics allows higher throughput, specificity and quantitative analysis (Ong and 
Mann, 2005). 
The most commonly used MS-based proteomic technique is quantitative LC-MS/MS, which is a 
combination of liquid chromatography and two or more mass spectrometry based techniques. 
This technique requires the use of isotopically-labelled standards, which show similar 
chromatographic behaviour to the target, but can be discriminated based on the mass. Prior to 
analysis, the analyte is proteolytically cleaved and then the resultant peptides are separated by 
liquid chromatography. Next the sample can be processed in one of the two main strategies 
used for LC-MS/MS. The first is known as shotgun proteomics, where separated peptides are 
analysed by a tandem mass spectrometry (MS/MS). MS/MS involves two steps. The first step 
(MS1) is the formation of ions by the ion source and their separation by mass-to-charge ratio 
and then fragmentation. In the second stage (MS2), fragmented ions are separated and 
detected. It is then possible to assign fragmented ion spectra to their corresponding peptide 
sequences using a database. The second strategy used is a targeted proteomics. In this method 
a set of searched peptides have to be specified prior to experiment. It then allows quantitative 
search of only this limited number of peptides in the sample, by calculating the likelihood that a 
group of transition signals generated by ions are delivered from the searched peptide (Gillet et 
al., 2012). The two described LC-MS/MS techniques have many advantages but also some 
limitations. Shotgun proteomics allows identification of a large number of proteins in a sample, 
but does not suit an accurate quantification (Liu et al., 2004). In contrast, targeted proteomics 
allows an accurate quantification and reproducible detection, but just for a set of specific 
proteins (Picotti et al., 2009). Therefore even a combination of both methods, cannot provide 
simultaneous quantitative identification of a large number of proteins (Gillet et al., 2012). 
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Sequential Window Acquisition of all Theoretical fragment-ion spectra (SWATH) is a label-free 
quantitative, proteomic technique. Samples are quantified by comparison of peak areas 
received for the sample under one or more biological conditions or a biological timeline and 
normalised to one or more internal standards, that are unaffected upon the course of 
experiment. This allows calculation of the fold-change of the identified protein between the 
conditions tested. SWATH can analyse a large number of digested peptides from 1000s of 
proteins simultaneously, collecting the fragmentation spectra by using wide range precursor-
isolation windows (Gillet et al., 2012). In the first quadrupole of a standard SWATH acquisition, 
precursor windows (30 to 50), with variable mass widths are sequentially selected. This allows 
to full coverage of the mass-to-charge range (m/z) 400-1250. In the second quadrupole, 
transmitted ions are fragmented. These fragmented ions are then detected by the ToF (time of 
flight) mass analyser (Fig. 3.1). For each precursor-isolation window, ToF analyser generates a 
3D fragment-ion m/z intensity-retention time map. To identify proteins corresponding to 
fragmented ions, a reference map is generated by information-dependent acquisition (IDA) 
experiment. Peptides are then quantified based on fragmented-ion peaks, using spectral 
libraries, which are generated using SWATH compatible mass spectrometer operated in data 
dependent acquisition mode (Chang et al., 2015). 
Overall, SWATH quantitatively identifies proteins by combining precursor mass, 
chromatography retention and ion transitions. SWATH is the proteomic method that comprise 
both high throughput, and full quantification of proteins in the sample. In addition, it requires 
the minimal sample preparation and much lower costs, compared to other MS techniques such 
as SILAC (stable isotope labelling with amino acids in cell culture), which requires isotopic 
labelling of cells. It provides quantification that is incomparably more accurate than not only 
traditional immunoblotting, but also LC-MS/MS.  
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Figure 3.1. Overview of SWATH acquisition. The first quadrupole (Q1) contains 25 Da windows 
across the entire m/z range of interest. In second quadruple (Q2) ions that pass from Q1 are 
fragmented by collision-induced dissociation. Those fragmented ions are then monitored by ToF 
mass analyser.   
 
SWATH has previously been used to quantitatively characterise proteins in human plasma 
(Haverland, 2016), and to study protein interaction dynamics including synaptosomes, from 
human Alzheimer’s disease autopsy tissue (Chang et al., 2015), human leukocyte antigen (HLA)-
associated proteome (Caron et al., 2015) and of nucleic acid binding and regulatory proteins in 
HIV-1-infected macrophages (Haverland et al., 2014). SWATH proteomics has never been used 
to identify infection-related proteomic changes in the most potent antigen presenting cells – 
DCs. 
The aims of this chapter are to quantitatively describe global proteomic changes in DCs upon 
LPS and HAP induced maturation. In addition, those proteomic changes will be related to specific 
cellular pathways involved in metabolism, protein production and antigen presentation. That 
will allow to characterise for the first time quantitative proteomic changes that occur during 
antigen processing and presentation, which is a crucial time period for DCs.  
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3.2. Methods 
3.2.1. Sample preparation 
3.2.1.1. Cell culture 
Blood was obtained from a healthy donor and purified over a ficoll gradient at room 
temperature to isolate peripheral blood mononuclear cells (PBMC; Histopaque, Sigma Aldrich). 
PBMC were plated on 3 wells of 6 well plate, then monocytes were isolated and differentiated 
into dendritic cells as described before (2.2.1.1.). MoDCs were treated with 4 mg of sterile 
hydroxyapatite nanopowder (Sigma) or with 100 ng/ml of bacterial LPS, or left untreated as 
control. HAP nanopowder was washed twice in 70% ethanol, then washed twice with sterile 
RPMI serum free media and then resuspended 10 µl of RPMI 10% FCS and applied to cell culture 
dish. Cell culture was carried for 24h.  
3.2.1.2. Assessment of Cytokine Production. 
Macrophages and mature dendritic cells are known to secrete TNF-α after TLR4 signalling upon 
LPS stimulation, which indicates that cells are active and functional. The response of dendritic 
cells for hydroxyapatite (HAP) stimulation is not known. To see whether generated moDC are 
functional and to find the amount of HAP that triggers the highest response of DCs, aliquots of 
supernatants were analysed using an enzyme-linked immunosorbent assay (ELISA) for the 
quantitative determination of TNF- α. Differentiated moDCs matured by 4 mg of HAP and 100 
ng/ml of LPS stimulation as described above (3.2.1.1.) for 24 h. Next, the culture media was 
collected and TNF-α concentration measured using the TNF alpha Human ELISA Kit (Invitrogen, 
Thermo Fisher Scientific). This kit is a sandwich ELISA assay, which comes with plates pre-coated 
with specific anti-TNF-α antibody. After addition of the sample to the wells detection involved 
addition of biotinylated anti-TNF-α antibody, followed by streptavidin-HRP conjugate. The plate 
was then washed to remove unbound substances and substrate for HRP was applied. After the 
reaction was stopped, the absorbance at 450 nm was measured using a Dynex MRX microplate 
reader (Dynex Technologies, Worthing, UK). The concentration of TNF-α in the samples was 
determined based on standards supplied with the kit. 
3.2.1.3. Cell lysis and quantification 
Cells were washed on ice with 1x PBS and lysed for 30 min at 55oC with 300 µl of lysis buffer (10 
mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 % Rapi Gest, pH 7.9). Cells were further 
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lysed using syringe. Next cell debris was spun down at 14000 rpm, 4oC, for 5 min, supernatant 
transferred to a fresh Eppendorf tube and protein quantified using the BCA protein assay kit 
(Thermo Fisher Scientific) as described before (2.2.3.3). For the analysis 30 µg of protein per 50 
µl solution was submitted. 
3.2.2. LC-ESI-MSMS analysis 
LC-ESI-MSMS analysis, including library generation and SWATH were carried out by The Mass 
Spectrometry and Proteomics Facility (University of St Andrews) and Dr Swati Arya. Prior to 
analysis 20 µg of proteins were first denatured with 6-8 M Urea and subsequently reduced and 
alkylated with 1 mM tris(2-carboxyethyl)phosphine (TCEP) and 5 mM iodoacetamide. The 
reaction was stopped with 10 mM dithiothreitol (DTT). The resulting samples were then digested 
with trypsin (1:50 ratio (w/w), 0.2 µg/μl trypsin; Promega), overnight at 30°C. To stop the 
digestion, 0.5% (v/v) trifluoroacetic acid was added. Tryptic peptides were desalted using Pierce 
C18 spin column (Thermo Fisher Scientific) and concentrated down, using a SpeedVac (Thermo 
Savant). 
3.2.2.1. Library generation 
For spectral library generation, an AB SCIEX TripleTOF 5600+ System mass spectrometer was 
used. All samples were analysed on an Eksigent nanoLC AS-2/2Dplus system coupled with a 
SWATH-MS-enabled AB SCIEX TripleTOF 5600+ System utilising trap elute methods.  The 
samples were loaded in loading buffer (2% acetonitrile and 0.05% trifluoroacetic acid) and 
bound to an Aclaim pepmap 100 µm x 2 cm trap (Thermo Fisher Scientific), and washed for 10 
min to waste.  The trap was turned in line with the analytical column, Aclaim pepmap RSLC 75 
µm x 15 cm and the peptides eluted. The analytical solvent system consisted of buffer A (2% 
acetonitrile and 0.1% formic acid in water) and buffer B (2% water with 0.1% formic acid in 
acetonitrile) at a flow rate of 300 nl/min with the following gradient: linear 1-20% of buffer B 
over 90 min, linear 20-40% of buffer B for 30 min, linear 40-99% of buffer B for 10 min, isocratic 
99% of buffer B for 5 min, linear 99-1% of buffer B for 2.5 min and isocratic 1% solvent buffer B 
for 12.5 min. The mass spectrometer was operated in DDA top20 positive ion mode, with 250 
and 150 ms acquisition time for the MS1 (m/z 400-1200) and MS2 (m/z 230-1800) scans 
respectively, and 15 s dynamic exclusion. Rolling collision energy with a collision energy spread 
of 15 eV was used for fragmentation. 
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The library of identified 845 proteins was generated using Protein Pilot v5.0.1. The following 
search parameters were used, with urea denaturation as special factors, Homo sapiens as 
species, trypsin as the cleavage enzyme and carbamidomethyl as a fixed modification of 
cysteines. The search was carried out against the Swissprot database downloaded June 2015, 
restricted to Human only species.  The iRT peptides had been added to this fasta database.   
3.2.2.2. Sequential Window Acquisition of all Theoretical fragment-ion spectra (SWATH) mass 
spectrometry  
DIA mass spectrometry (SWATH-MS) 
For SWATH-MS data acquisition, the same mass spectrometer and LC-MS/MS setup was 
operated essentially as described before above, but using 50 windows of variable Da effective 
isolation width (with an additional 1 Da overlap on the left side of the window) and with a dwell 
time of 50 ms to cover the mass range of 400–1,250 m/z in 2.6 s in TOF-MS mode. MS/MS data 
is acquired over a range of 230-1800 m/z with high sensitivity setting. The collision energy for 
each window was set using the collision energy of a 2+ ion centred in the middle of the window 
with a spread of 15 eV 
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3.3. Results  
3.3.1. Cytokine Production. 
Immature DCs were obtained from fresh blood taken from a single donor following culture of 
purified human peripheral blood monocytes with GM-CSF and IL-4. Maturation was induced by 
the addition of either LPS or HAP nanopowder. TLR4 recognise bacterial products present in the 
extracellular space such as LPS. Some non-bacterial particles can also be recognised by TLRs. 
One of them is the mineral HAP, which is a ligand for TLR4 and at least one more TLR (Velard et 
al., 2013). Following activation, TLRs activate signalling pathways that induce the production of 
chemokines, co-stimulatory molecules, and cytokines including TNF-α (Kolanowski et al., 2016). 
DCs matured upon LPS treatment exhibit a strong T cell stimulatory capacity, however the 
functional phenotype of DC matured upon HAP stimulation is not known.  
To confirm cell functionality, aliquots of the culture media were analysed for TNF-α production, 
using a commercial ELISA kit. DCs maturated in response to addition of LPS secreted 5.00±0.86 
ng/ml TNF-α and cells maturated following addition of HAP nanopowder secreted 0.42±0.04 
ng/ml TNF-α. Immature dendritic cells (control) secreted 0.26±0.04 ng/ml TNF-α. (Fig 4.1). These 
results indicate that hydroxyapatite can induce DCs maturation.  
 
Figure 3.2. TNF-α release from moDCs following stimulation with LPS and HAP. MoDCs were 
cultured in RPMI media supplemented 10% FCS. Next cells were stimulated with 100 μg/ml of 
bacterial LPS or 4 mg/ml of HAP for 24 h. TNF-α secretion was measured using Human TNF-α 
ELISA Kit (Life Technologies). p≤0.01 (**), p≤0.001 (***). The experiment was replicated with 
similar results obtained.  
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3.3.2. Identification of proteins upregulated upon moDC maturation 
3.3.2.1. Proteins upregulated upon LPS induced maturation 
SWATH analysis allowed identification of 845 proteins, from which 260 proteins exhibited a 
significant change in expression (p value <0.05) in cell lysates taken from moDCs differentiated 
upon LPS stimulation. From those 260 proteins, 19 (7.3%) were upregulated upon maturation.  
The highest up regulation, of more than 30-fold change, was observed for three proteins: 
Interferon-induced GTP-binding protein, interferon-induced protein with tetratricopeptide 
repeats 3 (IFIT3) and ubiquitin-like protein ISG15 (Table 3.2). The two “interferon-induced” 
proteins are involved in immune defence against a wide range of viruses (Pichlmair et al., 2011). 
Additionally, those proteins act as regulators of apoptosis, IFN-induced GTP binding protein as 
enhancer (Li and Youssoufian, 1997), and IFIT3 as a negative regulator (Stowowczyk et al., 2011). 
Ubiquitin-like protein ISG15 is also involved in immune response to viral (Hsiang et al., 2009) and 
bacterial (Bogunovic et al., 2012) infection. In fact it is a key protein in the innate immune 
response and acts either via binding to a target protein as a tag (ISGylation) or as an 
unconjugated protein. Besides the response against bacterial and viral infection, ISG15 
negatively regulates protein ubiquitination (Okumura et al., 2008) and type I interferon 
production, but induce natural killer cell proliferation, act as a chemotactic factor for 
neutrophils, induce interferon-gamma production and is involved in type I interferon signalling 
pathway playing an essential role in antibacterial immunity (Bogunovic et al., 2012). 
Other proteins with more than 10-fold up regulation upon LPS-induced maturation, were TNF 
receptor-associated factor 1 (TRAF1) and fascin. TRAF1 regulates cells survival and apoptosis as 
part of E3 ubiquitin-protein ligase complex, which promotes ubiquitination of target proteins. 
TRAF1 is also an inducer of nuclear factor-κB (NF-κB), transcription factor that regulates genes 
involved in innate and adaptive immune response including cytokine release (Irmler et al., 2000). 
Additionally, as a TNF binding protein, was involved in the regulation of TNF-mediated signalling 
pathway (Wicovsky et al., 2009). Fascin is a protein involved in maintaining anatomical cell 
structure by organising actin filaments into bundles.  Plays a role in the formation of membrane 
ruffles, positive regulation of filopodium, and podosome assembly, anatomical structure 
morphogenesis and the formation of cell-cell junction involved in cell communication (Chen et 
al., 2010; Yamashiro et al., 1998). Also several keratins were upregulated after LPS induced 
maturation. Similarly, to fascin, they are involved in maintaining cell structure as structural 
constituents of cytoskeleton (Kobayashi et al., 1996; Kobayashi et al., 1999). Furthermore, one 
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of them, keratin, type II cytoskeletal 1, is a part of skin barrier against pathogens and as that 
regulate immune response via activation of lectin complement pathway (Collard et al., 2001). It 
is also possible that those keratins may be contaminating proteins, as those can be found in 
dead skin and dust and although great care is taken during sample preparation it is difficult to 
be absolutely sure these were not introduced during the experiment. Another protein involved 
in cytoskeletal organisation is coronin-1B. It is involved in actin filament branching and in 
filament bundle assembly (Makhov et al., 2008) and also in cell migration (Holoweckyj et al., 
2005).  
Three alleles of α-chain of major histocompatibility complex class I (MHC class I) were identified 
as upregulated proteins. MHC class I is present on antigen presenting cells (including dendritic 
cells) and is involved in the presentation of foreign peptide antigen to CD8+ T-cells, and to 
natural killer (NK) cells. MHC class I is also involved in IFN-γ and type I IFN signalling pathways.  
Additionally, MHC calls I regulates DC differentiation during viral infection (Huang et al., 2009). 
Several enzymes were upregulated upon DC maturation. Creatine kinase catalyses the transfer 
of phosphate from ATP to phosphogens. The activity of this enzyme is crucial to energy 
transduction when energy demands are high. Another catalyst, thioredoxin, catalyses dithiol- 
exchange reactions. Amongst its many functions are cell to cell signalling, cell proliferation, cell 
movement (Miller et al., 2000). Thioredoxin also assists in protein folding and repair. Calpain-1 
is a calcium-regulated protease which is involved in cytoskeletal remodelling and signal 
transduction. Tryptophan-tRNA ligase, regulates activation of ERK, Akt, and endothelial nitric 
oxide synthase (eNOS) signalling pathways, that are associated with angiogenesis, cell 
proliferation and cytoskeletal reorganization (Tzima et al., 2003; Bange et al., 1992). The last 
identified enzyme, with 1.67 fold increase upon DC maturation, was kynureninase. Through its 
enzymatic activity, kynureninase is involved in 'de novo' biosynthetic of nicotinamide adenine 
dinucleotide (NAD) and involved in response to IFN-γ (Walsh and Botting, 2002).  
Finally, there were two proteins with small but significant, 1.3-fold upregulation upon LPS 
induced maturation. Those are CD44 antigen, and WD repeat- and FYVE domain-containing 
protein 4 (WDFY4). CD44 antigen is a receptor for hyaluronic acid (HA) and other ligands 
including collagens and metalloproteinases. Through those interactions, CD44 antigen mediates 
cell-cell interactions and cell migration. It is involved in lymphocyte activation, monocyte 
aggregation (Selbi et al., 2004), IFN-γ signalling pathway and negative regulation of apoptosis 
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(Bourguignon et al., 2009). CD44 antigen also regulates peptidyl-serine and peptidyl-tyrosine 
phosphorylation (Shi et al., 2006).  
 
UNIPROT PROTEIN NAME FOLD 
INCREASE 
P VALUE 
P20591 Interferon-induced GTP-binding protein 37.52 0.001 
O14879 Interferon-induced protein with tetratricopeptide repeats 3  34.16 0.001 
P05161 Ubiquitin-like protein ISG15 30.98 0.001 
Q13077 TNF receptor-associated factor 1 17.87 0.008 
Q16658 Fascin  11.09 0.004 
P30466 Major histocompatibility complex class I, B-18 alpha chain  7.42 0.019 
P35527 Keratin, type I cytoskeletal 9  7.06 0.013 
P12277 Creatine kinase B-type  3.45 0.009 
P01889 Major histocompatibility complex class I, B-7 alpha chain  3.42 0.002 
Q07000 Major histocompatibility complex class I, Cw-15 alpha chain  3.19 0.011 
P10599 Thioredoxin  2.88 0.001 
P04264 Keratin, type II cytoskeletal 1  2.58 0.019 
P07384 Calpain-1 catalytic subunit  2.43 0.036 
P23381 Tryptophan--tRNA ligase, cytoplasmic  2.41 0.009 
Q16719 Kynureninase  1.67 0.008 
Q8NHM4 Putative trypsin-6  1.66 0.036 
Q9BR76 Coronin-1B 1.51 0.048 
P35908 Keratin, type II cytoskeletal 2 epidermal  1.45 0.001 
P16070 CD44 antigen  1.35 0.050 
Q6ZS81 WD repeat- and FYVE domain-containing protein 4  1.30 0.009 
Table 3.2. List of the proteins upregulated, after stimulation of dendritic cells with LPS. 
Calculated p value is the confidence that the fold change described is legitimate across the 
technical and biological replicates, based on the instrumentation and software used.  
 
3.3.2.2. Proteins upregulated upon HAP induced maturation 
SWATH identified 190 proteins (from 845) that significantly changed in expression level (p value 
<0.05) in cell lysates from moDCs upon HAP stimulation. From those 190 proteins, only 5 (2.6 %) 
were upregulated upon maturation (Table 3.3). Two of the proteins, Interferon-induced protein 
with tetratricopeptide repeats 3 and WD repeat- and FYVE domain-containing protein 4 were 
also upregulated upon LPS-induced maturation.  
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Second highest fold-change was observed integrin beta-3 (ITGB3), a receptor for vast array of 
ligands, including cytotactin, fibronectin, fibrinogen, laminin, plasminogen, prothrombin, 
thrombospondin and vitronectin. ITGB3 is involved in numerous process, including cell adhesion 
(Longhurst et al., 1999), migration and growth (Lee et al., 2012), and also negatively regulates 
chemotaxis (Riches et al., 2013). 
Thymidine phosphorylase provides energy for nucleotide synthesis by catalysing the reversible 
phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy 
sources (Usuki et al., 1992). Thymidine phosphorylase is also involved in cell differentiation.  
Finally, the last protein upregulated upon HAP induced maturation was ubiquitin thioesterase, 
an enzyme involved in adaptive immune response by regulating CD4+ T-cell energy via 
interaction with RNF128. Ubiquitin thioesterase is also involved in cellular response to DNA 
damage (Nakada et al., 2010) and response to IL- 1.    
 
UNIPROT PROTEIN NAME FOLD 
CHANGE 
P VALUE 
O14879 Interferon-induced protein with tetratricopeptide repeats 3  2.46 0.040 
Q6ZS81 WD repeat- and FYVE domain-containing protein 4  1.34 0.021 
P05106 Integrin beta-3 1.27 0.038 
P19971 Thymidine phosphorylase 1.19 0.018 
Q96FW1 Ubiquitin thioesterase 1.17 0.049 
Table 3.3. List of the proteins upregulated, after stimulation of dendritic cells with HAP 
nanopowder. 
 
3.3.3. Identification of proteins down-regulated upon moDC maturation 
3.3.3.1. Proteins that exhibit reduced expression following LPS induced maturation of moDC 
Upon LPS induced maturation of DCs, the majority of proteins detected in cell lysate were down-
regulated. This accounts for as much as 92.7% of the total proteins detected (Table 3.4). Those 
proteins are involved in many cellular processes including cell metabolism, antigen presentation 
and protein production. Proteins were therefore grouped into specific pathways, using KEGG 
database: Kyoto Encyclopedia of Genes and Genomes – GenomeNet (www.genome.jp/kegg).  
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UNIPROT PROTEIN NAME 
FOLD 
DECREASE 
P 
VALUE 
Q9BVJ7 Dual specificity protein phosphatase 23 13.40 0.001 
Q15717 ELAV-like protein 1  10.98 0.001 
Q6NUK1 Calcium-binding mitochondrial carrier protein SCaMC-1 9.53 0.009 
P38571 Lysosomal acid lipase/cholesteryl ester hydrolase  7.63 0.001 
P36543 V-type proton ATPase subunit E 1  6.12 0.012 
P00390 Glutathione reductase, mitochondrial  5.09 0.001 
P07339 Cathepsin D  4.91 0.003 
P55263 Adenosine kinase  4.43 0.000 
P17900 Ganglioside GM2 activator  4.29 0.042 
Q96CN7 Isochorismatase domain-containing protein 1  4.11 0.019 
P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit  3.88 0.026 
Q8IV08 Phospholipase D3  3.82 0.025 
P35270 Sepiapterin reductase  3.62 0.025 
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1  3.47 0.011 
P62805 Histone H4  3.38 0.012 
Q9Y5X3 Sorting nexin-5  3.32 0.008 
P24666 Low molecular weight phosphotyrosine protein phosphatase  3.25 0.049 
P60891 Ribose-phosphate pyrophosphokinase 1  3.23 0.022 
P34897 Serine hydroxymethyltransferase, mitochondrial  3.22 0.024 
P61916 Epididymal secretory protein E1 3.22 0.012 
Q99880 Histone H2B type 1-L  3.15 0.002 
P07858 Cathepsin B  3.14 0.001 
P11310 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial  3.10 0.034 
P09622 Dihydrolipoyl dehydrogenase, mitochondrial  3.10 0.032 
P22102 Trifunctional purine biosynthetic protein adenosine-3  3.08 0.029 
Q96HC4 PDZ and LIM domain protein 5  2.99 0.052 
Q9Y3F4 Serine-threonine kinase receptor-associated protein  2.85 0.040 
O75369 Filamin-B  2.83 0.003 
P15090 Fatty acid-binding protein, adipocyte  2.82 0.001 
P07910 Heterogeneous nuclear ribonucleoproteins C1/C2  2.81 0.015 
P01034 Cystatin-C  2.81 0.021 
P06748 Nucleophosmin  2.78 0.012 
Q9BTM1 Histone H2A.J  2.72 0.004 
P08697 Alpha-2-antiplasmin  2.70 0.016 
P17844 Probable ATP-dependent RNA helicase DDX5  2.65 0.032 
Q9UBR2 Cathepsin Z 2.64 0.001 
P61960 Ubiquitin-fold modifier 1  2.64 0.004 
P19878 Neutrophil cytosol factor 2  2.58 0.021 
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P10253 Lysosomal alpha-glucosidase  2.53 0.013 
P15531 Nucleoside diphosphate kinase A  2.52 0.006 
P00505 Aspartate aminotransferase, mitochondrial  2.50 0.048 
Q92945 Far upstream element-binding protein 2  2.44 0.030 
O00764 Pyridoxal kinase  2.42 0.010 
P52790 Hexokinase-3  2.41 0.019 
P46776 60S ribosomal protein L27a 2.38 0.033 
P63173 60S ribosomal protein L38  2.30 0.022 
P28676 Grancalcin  2.30 0.001 
P02774 Vitamin D-binding protein  2.27 0.036 
P30043 Flavin reductase (NADPH)  2.27 0.042 
Q13838 Spliceosome RNA helicase DDX39B  2.27 0.025 
P62136 Serine/threonine-protein phosphatase PP1-alpha  2.24 0.049 
Q99536 Synaptic vesicle membrane protein VAT-1 homolog  2.23 0.002 
Q09666 Neuroblast differentiation-associated protein AHNAK  2.23 0.004 
O00757 Fructose-1,6-bisphosphatase isozyme 2  2.22 0.003 
P08670 Vimentin  2.20 0.001 
P20036 HLA class II histocompatibility antigen, DP alpha 1 chain  2.20 0.035 
P06703 Protein S100-A6  2.14 0.040 
Q13510 Acid ceramidase  2.12 0.034 
O00154 Cytosolic acyl coenzyme A thioester hydrolase  2.09 0.040 
P11215 Integrin alpha-M  2.07 0.013 
P24844 Myosin regulatory light polypeptide 9  2.07 0.001 
Q92598 Heat shock protein 105 kDa  2.07 0.007 
P07686 Beta-hexosaminidase subunit beta 2.06 0.000 
P07954 Fumarate hydratase, mitochondrial  2.06 0.032 
P26599 Polypyrimidine tract-binding protein 1  2.00 0.016 
P04080 Cystatin-B  1.96 0.013 
P22897 Macrophage mannose receptor 1  1.96 0.050 
P35268 60S ribosomal protein L22  1.91 0.001 
P42765 3-ketoacyl-CoA thiolase, mitochondrial  1.88 0.047 
Q9H4A4 Aminopeptidase B  1.87 0.041 
Q13075 Baculoviral IAP repeat-containing protein 1  1.87 0.027 
Q99798 Aconitate hydratase, mitochondrial  1.85 0.006 
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic  1.85 0.005 
P55084 Trifunctional enzyme subunit beta, mitochondrial  1.85 0.038 
P05107 Integrin beta-2  1.84 0.000 
P25788 Proteasome subunit alpha type-3  1.83 0.050 
P31946 14-3-3 protein beta/alpha  1.82 0.014 
P15586 N-acetylglucosamine-6-sulfatase  1.82 0.016 
Q01469 Fatty acid-binding protein, epidermal  1.81 0.000 
P06576 ATP synthase subunit beta, mitochondrial  1.81 0.050 
O75368 SH3 domain-binding glutamic acid-rich-like protein  1.81 0.015 
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P21980 Protein-glutamine gamma-glutamyltransferase 2  1.80 0.006 
Q86TI2 Dipeptidyl peptidase 9  1.79 0.024 
P23469 Receptor-type tyrosine-protein phosphatase epsilon  1.78 0.012 
P51659 Peroxisomal multifunctional enzyme type 2  1.77 0.019 
P23526 Adenosylhomocysteinase  1.77 0.018 
P18510 Interleukin-1 receptor antagonist protein  1.76 0.005 
P34932 Heat shock 70 kDa protein 4  1.76 0.000 
Q14103 Heterogeneous nuclear ribonucleoprotein D0  1.76 0.019 
Q9NNX6 CD209 antigen  1.75 0.004 
Q9ULV4 Coronin-1C  1.75 0.019 
P45974 Ubiquitin carboxyl-terminal hydrolase 5 1.74 0.029 
P48735 Isocitrate dehydrogenase [NADP], mitochondrial  1.74 0.030 
P83731 60S ribosomal protein L24  1.74 0.020 
P62913 60S ribosomal protein L11  1.72 0.029 
P40939 Trifunctional enzyme subunit alpha, mitochondrial  1.71 0.018 
P09467 Fructose-1,6-bisphosphatase  1.70 0.013 
Q15257 Serine/threonine-protein phosphatase 2A activator  1.68 0.050 
O95571 Persulfide dioxygenase ETHE1, mitochondrial  1.68 0.009 
Q8N392 Rho GTPase-activating protein 18  1.67 0.050 
P50995 Annexin A11  1.66 0.006 
Q9Y6N5 Sulfide:quinone oxidoreductase, mitochondrial  1.65 0.019 
P01903 HLA class II histocompatibility antigen, DR alpha chain  1.65 0.016 
Q9NTK5 Obg-like ATPase 1  1.65 0.046 
P68032 Actin, alpha cardiac muscle 1  1.65 0.040 
Q96G03 Phosphoglucomutase-2  1.64 0.016 
P30044 Peroxiredoxin-5, mitochondrial  1.64 0.030 
P62917 60S ribosomal protein L8 1.63 0.013 
P21281 V-type proton ATPase subunit B, brain isoform 1.63 0.000 
P29350 Tyrosine-protein phosphatase non-receptor type 6  1.63 0.019 
P62158 Calmodulin  1.63 0.001 
P19823 Inter-alpha-trypsin inhibitor heavy chain H2  1.63 0.000 
Q15582 Transforming growth factor-beta-induced protein ig-h3  1.62 0.011 
P31948 Stress-induced-phosphoprotein 1  1.62 0.003 
Q9UBQ7 Glyoxylate reductase/hydroxypyruvate reductase  1.60 0.017 
P38117 Electron transfer flavoprotein subunit beta  1.60 0.015 
P14550 Alcohol dehydrogenase [NADP(+)]  1.60 0.014 
P38646 Stress-70 protein, mitochondrial  1.59 0.006 
O15143 Actin-related protein 2/3 complex subunit 1B  1.59 0.008 
P61160 Actin-related protein 2  1.59 0.001 
O14773 Tripeptidyl-peptidase 1  1.59 0.003 
P60842 Eukaryotic initiation factor 4A-I  1.58 0.021 
P18124 60S ribosomal protein L7  1.57 0.028 
P62269 40S ribosomal protein S18  1.57 0.005 
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P40925 Malate dehydrogenase, cytoplasmic  1.57 0.002 
P38606 V-type proton ATPase catalytic subunit A  1.54 0.004 
P30046 D-dopachrome decarboxylase  1.54 0.020 
P63244 Guanine nucleotide-binding protein subunit beta-2-like 1  1.53 0.000 
Q96TA1 Niban-like protein 1  1.53 0.036 
P26447 Protein S100-A4 1.53 0.044 
P50502 Hsc70-interacting protein  1.52 0.023 
Q9BRA2 Thioredoxin domain-containing protein 17  1.52 0.016 
P62424 60S ribosomal protein L7a  1.51 0.022 
P14314 Glucosidase 2 subunit beta  1.51 0.041 
P06744 Glucose-6-phosphate isomerase  1.50 0.010 
P84077 ADP-ribosylation factor 1  1.50 0.000 
P09960 Leukotriene A-4 hydrolase  1.49 0.014 
P06753 Tropomyosin alpha-3 chain  1.49 0.039 
P62826 GTP-binding nuclear protein Ran  1.49 0.029 
P31146 Coronin-1A  1.49 0.030 
Q16698 2,4-dienoyl-CoA reductase, mitochondrial  1.49 0.018 
P40121 Macrophage-capping protein  1.49 0.007 
Q9BUF5 Tubulin beta-6 chain  1.48 0.001 
P50990 T-complex protein 1 subunit theta  1.48 0.022 
O75608 Acyl-protein thioesterase 1  1.47 0.034 
P25787 Proteasome subunit alpha type-2  1.47 0.029 
P02768 Serum albumin  1.47 0.017 
Q04917 14-3-3 protein eta  1.47 0.044 
Q9Y2Q3 Glutathione S-transferase kappa 1  1.46 0.001 
Q06830 Peroxiredoxin-1  1.45 0.011 
P04406 Glyceraldehyde-3-phosphate dehydrogenase  1.45 0.025 
P47756 F-actin-capping protein subunit beta  1.44 0.001 
Q9BSJ8 Extended synaptotagmin-1  1.44 0.006 
P61088 Ubiquitin-conjugating enzyme E2 N  1.44 0.001 
P51149 Ras-related protein Rab-7a  1.43 0.010 
P27797 Calreticulin  1.43 0.005 
Q7Z4W1 L-xylulose reductase  1.43 0.014 
P52566 Rho GDP-dissociation inhibitor 2  1.42 0.062 
Q9NY33 Dipeptidyl peptidase 3  1.42 0.024 
P52209 6-phosphogluconate dehydrogenase, decarboxylating  1.41 0.001 
P10809 60 kDa heat shock protein, mitochondrial  1.41 0.008 
P12081 Histidine--tRNA ligase, cytoplasmic  1.41 0.002 
P28072 Proteasome subunit beta type-6  1.41 0.008 
P37837 Transaldolase  1.40 0.002 
P13489 Ribonuclease inhibitor  1.40 0.044 
P09382 Galectin-1 1.39 0.002 
Q969H8 Myeloid-derived growth factor  1.39 0.021 
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P04040 Catalase  1.39 0.001 
P11413 Glucose-6-phosphate 1-dehydrogenase  1.39 0.013 
P00918 Carbonic anhydrase 2  1.38 0.009 
P49411 Elongation factor Tu, mitochondrial  1.38 0.005 
Q02878 60S ribosomal protein L6  1.38 0.005 
O60664 Perilipin-3  1.38 0.021 
P62277 40S ribosomal protein S13  1.38 0.016 
O14818 Proteasome subunit alpha type-7  1.38 0.045 
P07741 Adenine phosphoribosyltransferase  1.38 0.007 
P62851 40S ribosomal protein S25  1.37 0.017 
P50226 Sulfotransferase 1A2  1.37 0.031 
P40926 Malate dehydrogenase, mitochondrial  1.37 0.001 
Q15121 Astrocytic phosphoprotein PEA-15  1.37 0.004 
P61981 14-3-3 protein gamma  1.37 0.011 
P61313 60S ribosomal protein L15  1.37 0.013 
O43399 Tumor protein D54  1.36 0.029 
P28482 Mitogen-activated protein kinase 1  1.36 0.007 
O00754 Lysosomal alpha-mannosidase  1.36 0.045 
P05387 60S acidic ribosomal protein P2  1.36 0.007 
P07355 Annexin A2  1.36 0.035 
O75083 WD repeat-containing protein 1  1.35 0.004 
P30041 Peroxiredoxin-6  1.35 0.002 
P62888 60S ribosomal protein L30  1.35 0.026 
P30040 Endoplasmic reticulum resident protein 29  1.35 0.013 
P62829 60S ribosomal protein L23  1.34 0.022 
P06737 Glycogen phosphorylase, liver form  1.34 0.033 
P14618 Pyruvate kinase PKM  1.34 0.013 
P47755 F-actin-capping protein subunit alpha-2  1.33 0.004 
Q15084 Protein disulfide-isomerase A6 1.33 0.016 
Q9NUQ9 Protein FAM49B  1.33 0.001 
P01911 HLA class II histocompatibility antigen, DRB1-15 beta chain  1.32 0.030 
Q9Y3Z3 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1  1.32 0.028 
O43707 Alpha-actinin-4  1.32 0.020 
P19105 Myosin regulatory light chain 12A  1.32 0.005 
P14174 Macrophage migration inhibitory factor 1.32 0.001 
P00558 Phosphoglycerate kinase 1  1.32 0.010 
P07237 Protein disulfide-isomerase  1.31 0.017 
P11142 Heat shock cognate 71 kDa protein 1.31 0.001 
O15144 Actin-related protein 2/3 complex subunit 2  1.31 0.018 
P62937 Peptidyl-prolyl cis-trans isomerase A  1.30 0.040 
P14625 Endoplasmin  1.29 0.023 
P13716 Delta-aminolevulinic acid dehydratase 1.29 0.019 
P62258 14-3-3 protein epsilon 1.29 0.029 
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P11021 78 kDa glucose-regulated protein  1.28 0.020 
O95336 6-phosphogluconolactonase  1.28 0.041 
P78417 Glutathione S-transferase omega-1  1.28 0.006 
P00488 Coagulation factor XIII A chain  1.28 0.007 
P13796 Plastin-2  1.27 0.026 
Q01105 Protein SET  1.27 0.018 
P35237 Serpin B6  1.27 0.037 
P55786 Puromycin-sensitive aminopeptidase  1.26 0.019 
P46940 Ras GTPase-activating-like protein IQGAP1  1.26 0.000 
Q00610 Clathrin heavy chain 1  1.25 0.043 
P30101 Protein disulfide-isomerase A3  1.25 0.061 
O60749 Sorting nexin-2  1.25 0.033 
Q01813 ATP-dependent 6-phosphofructokinase, platelet type  1.25 0.039 
P28066 Proteasome subunit alpha type-5  1.24 0.010 
P36578 60S ribosomal protein L4  1.23 0.037 
P04075 Fructose-bisphosphate aldolase A  1.23 0.009 
P06396 Gelsolin  1.21 0.032 
P06733 Alpha-enolase  1.21 0.016 
P05388 60S acidic ribosomal protein P0 1.19 0.024 
P55072 Transitional endoplasmic reticulum ATPase  1.19 0.047 
O75390 Citrate synthase, mitochondrial  1.14 0.032 
P26641 Elongation factor 1-gamma  1.14 0.005 
P50914 60S ribosomal protein L14  1.08 0.028 
Table 3.4. List of the proteins exhibiting reduced expression in dendritic cells stimulated with 
LPS. 
 
Cell metabolism 
From the identified, down regulated proteins, 15 were assigned as being involved in the 
glycolysis/gluconeogenesis pathway. Glycolysis is a sequence of enzymatic reactions that result 
in the conversion of glucose into pyruvate. The energy produced in this process is used to form 
adenosine triphosphate (ATP) and reduced nicotinamide adenine dinucleotide (NADH). 
Gluconeogenesis, is a process of generation of glucose from non-carbohydrate carbon 
substrates like glucogenic amino acids, glycerol, pyruvate and lactate (Berg et al., 2012). 
LPS-induced maturation inhibits a number of enzymatic reaction in glycolysis and 
gluconeogenesis pathway (downregulated enzymes are highlighted in red, Fig. 3.3). Starting with 
the first step of glycolysis, phosphorylation of glucose to form glucose 6-phosphate (G6P), where 
two enzymes are downregulated, phosphoglucomutase-2 (5.4.2.2) and hexokinase 1 (2.7.1.1). 
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This is an energy consuming reaction, which stimulates continuous influx of glucose into the cell. 
G6P is then converted into fructose 6-phosphate (F6P) by glucose-6-phosphate isomerase 
(5.3.1.9). This reaction is reversible in case of high concentration of F6P, however normally the 
glycolysis moves to the next step, which is phosphorylation of F6P. This second phosphorylation 
is catalysed by a phosphofructokinase-1 (2.7.1.11) and results in the production of β-D-Fructose 
1,6-bisphosphate (F1,6BP) and energy use by ATP hydrolysis. This pathway is irreversible and 
therefore during gluconeogenesis, alternative pathway with fructose-bisphosphatase 1 
(3.1.3.11) for dephophorylation of F1,6BP to F6P. Next the hexose ring of F1,6BP is split by 
fructose-bisphosphate (4.1.2.13) into two triose sugars, glyceraldehyde 3-phosphate (GADP) 
and glycerine phosphatase which is rapidly converted to a second GADP. This is the end of the 
first phase of glycolysis, the energy consuming process, where is converted into two triose 
sugars (Berg et al., 2012). Enzymes catalysing all described steps were downregulated upon LPS 
induced maturation of DCs.  
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Figure 3.3. Glycolysis/gluconeogenesis pathway. Proteins down regulated during LPS induced 
maturation of moDC are highlighted in red. Both proteins highlighted in red and in green are 
members of human pathway. Pathway was plotted using KEGG Orthology Based Annotation 
System (www.genome.jp/kegg).  
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In the second phase of glycolysis is an energy gaining process where for each of the trio sugars, 
two ATP molecules and one NADH molecule are gained.  GADP sugars are oxidised and 
phosphorylated by glyceraldehyde phosphate dehydrogenase (GAPDH; 1.2.1.12) giving two 
molecules of glycerate-1,3-phosphatase and also releasing two molecules of NADH. In the next 
step phosphate group is being transferred from glycerate-1,3-phosphatase to ADP by 
phosphoglycerate kinase 1 (2.7.2.3), forming ATP and 3-phosphoglycerate. This is followed by 
de-phosphorylation of 3-phosphoglycerate into 2-phosphoglycerate by phosphoglycerate 
mutase (5.4.2.11) an enzyme that is not downregulated by DC maturation. Enolase (4.2.1.11) 
then forms phosphoenolpyruvate from 2-phosphoglycerate. In the final step, pyruvate kinase 
(2.7.1.40) de-phosphorylates phosphoenolpyruvate to pyruvate and phosphorylates a molecule 
of ADP to ATP (Berg et al., 2012). 
In the post glycolytic processes, NADH is oxidised back to NAD+. In nonaerobic conditions this is 
done by pyruvate converting to lactate or by the pyruvate first converting to acetaldehyde and 
then by aldo-keto reductase (1.1.1.2) to ethanol. In aerobic conditions, NADH generated in 
glycolysis, is transferred to mitochondria where it is converted to acetyl-CoA, which then enters 
citric acid cycle.  
The citric acid cycle (or Krebs cycle) is another metabolic pathway negatively affected by LPS 
induced maturation of moDCs.  In this cycle, energy is generated through the oxidation of acetyl-
CoA in the reactions carried out by 8 enzymes. Five of those enzymes are downregulated upon 
DC maturation (Fig. 3.4, highlighted in red).  
Acetyl-CoA can be provided from glycolysis, or as a product of fatty acid oxidation or amino acid 
metabolism. The cycle begins with the transfer of carbon groups by citrate synthase (2.3.3.1) 
from acetyl-CoA to oxaloacetate, to form citrate. Citrate then undergoes isomerisation catalysed 
by aconitase (4.2.1.3) to form isocitrate. Then isocitrate is converted to 2-oxoglutaratein in two 
reactions catalysed by isocitrate dehydrogenase (1.1.1.42). Firstly, oxidation of isocitrate to 
oxalosuccinate occurs with the production of NADPH molecule, followed by decarboxylation of 
oxalosuccinate to 2-oxoglutarate. It is then oxidised to succinyl-CoA with the release of another 
NADH molecule. Subsequently succinyl-CoA is dephosphorylates into sonicate which is oxidised 
to form fumarate. Another downregulated enzyme, fumarate hydratase (4.2.1.2) is then 
hydrating a C-C double bond of fumarate, which results in the formation of L-malatate. In the 
last reaction of the citric cycle, L-malatate is oxidised by malate dehydrogenase (1.1.1.37) to give 
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oxaloacetate and release another NADPH. The next step is again step one, where acetyl-CoA 
donates carbon group to oxaloacetate (Berg et al., 2012). 
 
Figure 3.4. The citric acid cycle. Proteins down regulated during LPS induced maturation of 
moDC are highlighted in red. Both proteins highlighted in red and in green are members of 
human pathway. Pathway was plotted using KEGG Orthology Based Annotation System 
(www.genome.jp/kegg).  
 
Another metabolic pathway affected by LPS induced moDC maturation is the pentose-
phosphate pathway, where 11 enzymes are downregulated. In this sequence of biochemical 
reactions glucose-6-phosphate is oxidised to ribulose-5-phosphate and NADPH is produced. 
NADPH production is the main objective of this pathway, as it is necessary to carry out the 
reduction reaction in the cytoplasm and the synthesis of pentose sugars. The pentose phosphate 
pathway is divided into two phases, the oxidative phase where two molecules of NADP+ are 
reduced to NADPH and the non-oxidative phase (Fig. 3.5; Berg et al., 2012).   
Firstly, glucose 6-phosphate, through dehydrogenation with glucose-6-phosphate 
dehydrogenase (1.1.1.49), is converting to glucono-1,5-phospholactone releasing one NADPH 
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molecule. Glucono-1,5-phospholactone is then hydrolysed to 6-phosphogluconate by 6-
phosphogluconolactonase (3.1.1.31), which is then converted to ribulose-5-phosphate by 
donating electron to NADP+ and as a result generating another molecule of NADPH, and CO2. 
The enzyme catalysing this reaction is phosphogluconate dehydrogenase (1.1.1.44).  
The non-oxidative phase begins with the isomerisation of ribulose-5-phosphate, either to 
ribulose-5-phosphate by ribose 5-phosphate isomerase (5.3.1.6) or to xylulose 5-phosphate by 
ribulose-5-phosphate-3-epimerase (5.1.3.1). xylulose 5-phosphate and ribose 5-phosphate 
together undergo a reaction catalysed by transketolase (2.2.1.1) that gives glyceraldehyde 3-
phosphate and sedoheptulose 7-phosphate which then together undergo a reaction performed 
by transaldolase 1 (2.2.1.2) and gives erythrose 4-phosphate and fructose 6-phosphate. Other 
enzymes form pentose phosphate pathway down-regulated upon LPS induced maturation were 
fructose-bisphosphate aldolase (4.1.2.13) converting glyceraldehayde to fructose-1,6-
phosphate, which is then dephosphorylated to fructose 6-phosphate by fructose-
bisphosphatase (3.1.3.11) which can be reversed by 6-phosphofructokinase (2.7.1.11); fructose 
6-phosphate is be reversibly converted to glucose-6-phosphate by glucose-6-phosphate 
isomerase (Fig. 3.4; 5.3.1.9). Also two enzymes from post pentose phosphate reaction were 
downregulated; phosphoribosyl pyrophosphate synthetase 1-like (2.7.6.1) and 
phosphoglucomutase 2 (5.4.2.2 and 5.4.2.7). 
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Figure 3.5. The pentose phosphate cycle. Proteins down regulated during LPS induced 
maturation of moDC are highlighted in red. Both proteins highlighted in red and in green are 
members of human pathway. Pathway was plotted using KEGG Orthology Based Annotation 
System (www.genome.jp/kegg).  
 
Antigen presentation  
DCs are the most potent antigen presenting cells and proteomic studies identified expression 
changes in several proteins involved in antigen processing and presentation. Proteins 
downregulated upon LPS-induced moDCs maturation were identified in both MHC class I and 
MHC class II pathways. After antigen presentation by MHC class I and II, T-cells, can establish the 
tolerance for self-antigen, and adaptive immunity against exogenous antigens. Additionally MHC 
I presents antigens produced by the cell itself, and MHC II presents foreign antigens.  
Antigen processing by MHC I starts with the protein degradation by proteasome. Cytosolic 
proteins are then cut into 8-10 amino acid (aa) peptides, which are stabilised and directed 
towards endoplasmic reticulum (ER) by two chaperones, heat shock protein 70 (Hsp70; Fig. 3.6) 
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and heat shock protein 90 (Hsp90). Peptides are then being transferred into the endoplasmic 
reticulum (ER) by transporter associated with antigen processing (TAP). The TAP structure is 
formed of two proteins: TAP-1 and TAP-2 (TAP1/2). The TAP transporter can be also found in the 
lumen where it is linked to the large multimeric peptide-loading complex (PLC). PLC is formed 
by TAP, β2 microglobulin (β2M), calreticulin (CALR), ERp57 and tapasin (TAPBP), and MHC I and 
holds MHC I molecules until they have been fully loaded with peptides (Antoniou et al., 2003). 
When MHC I is loaded (on the Fig 3.6 shown together with its component β2M), the PLC 
dissociates, and MHC I leaves ER through the secretory pathway to reach the cell surface. It then 
interacts via α3 domain with the extracellular IgV-like domain of CD8-α on CD8+ T-cells (Devine 
et al., 1999), or with killer-cell immunoglobulin-like receptor (KIR) on the surface of NK-cells. 
Current results show, that Hsp70, ERp57, CALR and heat shock protein family A member 5 
(Hsp70A5; BiP on Fig. 3.6) are downregulated after LPS-induced DCs maturation. 
Exogenous antigens are endocytosed and cleaved by cathepsin B (CATB), gamma-interferon-
inducible lysosomal thiol reductase (GILT), legumin (AEP) and other endo/lysosomal proteases 
into small peptides of 14-20 aa (Blum et al., 2013). MHC II molecules are being synthetised in ER 
from α and β chains complexed with an invariant chain (Ii). Ii chai, blocks antigen binding site on 
MHC II until it is fused with late endosome, containing antigenic peptides. Ii the helps in the 
export of MHC II fused with endosomes into the Golgi and then Ii chain is degraded by 
cathepsins, including CATB, which is downregulated upon LPS-induced DC maturation. MHC II is 
then stabilised and transported in vesicles to the cell surface, where it presents the antigen to 
CD4+ T-cells.  
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Figure 3.6. Antigen processing and presentation by DCs. Proteins down regulated during LPS 
induced maturation of moDC are highlighted in red. Both proteins highlighted in red and in green 
are members of human pathway. Pathway was plotted using KEGG Orthology Based Annotation 
System (www.genome.jp/kegg). 
 
It was mentioned previously that exogenous antigens, prior to processing and presentation, are 
internalised by endocytosis. Endocytosis can be subdivided into two main subcategories, 
clathrin-mediated and clathrin-independent endocytosis. Several proteins from the clathrin-
dependent pathway were down-regulated upon LPS induced maturation. The first identified 
protein was clathrin itself, which together with associated proteins plays critical role in the 
shaping of rounded vesicles for intracellular trafficking. Following clathrin, another 
downregulated protein was Arp2/3 complex, responsible for maintaining intracellular motility 
of endosomes and other intracellular vesicles (Fig. 3.7).  Another downregulated protein was 
the heat shock cognate 70 (Hsc70), which together with the phosphatase auxilin is involved in 
removal of clathrin and associated protein from the surface of vesicles, prior to formation of 
early endosomes. Also two proteins associated with early endosomes, F-actin-capping protein 
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subunit beta and alpha (CAPZA and CAPZB), which function is to stabilise actin filaments were 
down-regulated.  
Down-regulated proteins associated with late endosomes were Rab7 and sorting nexins 1/2 and 
5 (SNX 1/2 and 5). Rab7 plays central role in the endocytosis, by participating in in multiple 
regulation mechanisms in endosomal sorting, biogenesis of lysosome and phagocytosis (Zhang 
et al., 2009). The role of SNX 1/2 and 5 proteins is protein sorting from endosomes to lysosomes. 
 
 
Figure 3.7. Endocytic pathway. Proteins down regulated during LPS induced maturation of moDC 
(highlighted in red) belong to clathrin dependent endocytic pathway. Both proteins highlighted 
in red and in green are members of human pathway. Pathway was plotted using KEGG Orthology 
Based Annotation System (www.genome.jp/kegg). 
 
Lysosomal and phagosome protein 
Several lysosomal enzymes were also down-regulated upon LPS-induced maturation. Those 
include proteases: cathepsins and tripeptidyl-peptidase 1 (TTP1), glycosidases: acid alpha-
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glucosidase (GAA), hexosaminidase subunit alpha and beta (HEX A/B), and lysosomal alpha-
mannosidase (LEMAN). Also sulfatase, glucosamine (N-acetyl)-6-sulfatase (GNS), lipase, 
lysosomal acid lipase/cholesteryl ester hydrolase (LIPA), ceramidase, N-acylsphingosine 
amidohydrolase 1 (ASAH1) and ganglioside GM2 activator (GM2A) were down-regulated. In 
addition, adaptor related protein complex 1 mu 2 subunit (AP-1) and clathrin, both involved in 
the transport of synthetised lysosomal enzymes are downregulated. 
Upon LPS-induced maturation several proteins involved in phagosome function were 
downregulated. Those proteins were: coronin, ATPase H+ transporting V0, ras-related protein 
(Rab-7), tubulin β and calreticulin (CALR). In addition four phagocytosis promoting receptors 
were also downregulated: complement C3r receptor (CR3), integrin alpha M (αMβ), 
phospholipase A2 receptor and C-type lectin domain family 4 member M.  
Protein synthesis and processing 
The process of protein biosynthesis can be divided into three main parts; transcription of 
genomic DNA into mRNA occurring in the nucleus, translation of mRNA into amino acids by 
ribosomes and finally post-translational modifications, which involves covalent and enzymatic 
reactions, modifying polypeptide chain, to form mature protein.   
Upon LPS-induced DCs maturation, 19 ribosomal proteins and 11 proteins involved in protein 
processing in ER, were found to be down-regulated. This indicates that maturation not only 
affects metabolic pathways and antigen presentation, as described above but also inhibits the 
synthesis of new proteins by DCs.  
Ribosomal proteins downregulated upon LPS-induced maturation have different functions 
during translation, like initiation, elongation and termination. They are a components of either 
large 60S or small 40S ribosomal subunit, which together consist of around 80 proteins. 
Downregulated proteins from large ribosomal subunit are elongation factors thermo-unstable 
(ET-Tu): L4e, L8e, L23e, L11e, L7e, L14e and L27Ae; elongation factor thermos-unstable G (ET-
Tu,G): L30e and L7Ae. Also proteins that were considered stable irrespectively of the cell 
treatment and are frequently used as housekeeping genes during PCR, were found to be 
downregulated upon LPS-treatment. These were the neutral phosphoprotein ribosomal protein 
P0 (RPLP0; LP0 on Fig. 3.8) and ribosomal phosphoproteins P1 and P2 (RPLP1 and RPLP2; LP1 
and LP2 on Fig. 3.8).  Other downregulated proteins from large ribosomal subunit were L15e, 
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L24e, L6e, L22e and L38e. Only three proteins belonging to small ribosomal subunit were 
downregulated. These were S18e, S13e involved in the initiation of translation and S25e. 
  
Figure 3.8. The structure of large and small subunit of ribosome. (A) Protein composition of large 
and small subunits of ribosome. (B) A list of ribosomal proteins with the proteins downregulated 
during LPS induced maturation of moDC highlighted in red. Both proteins highlighted in red and 
in green are components of human ribosome.  Pathway was plotted using KEGG Orthology Based 
Annotation System (www.genome.jp/kegg). 
 
Once a protein is translated from mRNA, the polypeptide chain is directed into the ER by signal 
recognition particle (SRP; Fig. 3.9). Once the protein enters ER, it is recognised by molecular 
chaperones including the downregulated proteins, binding immunoglobulin protein (BiP) and 
heat shock protein 90 kDa beta member 1 (GRP94). In addition to protein recognition, they are 
crucial for proper protein folding and Bip is also required to transport protein into ER lumen. 
Another downregulated protein, an enzyme alpha 1,3-glucosidase (GlcII) which catalyses N-
glycosylation and also de-glycosylation during protein processing in endoplasmic reticulum. 
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Other downregulated endosomal proteins are protein disulfide isomerase family A member 3 
(ERP57), calreticulin (CRT) and protein disulfide isomerase family A member 6 (PDIs).  
In addition to ER proteins, also three proteins involved in ER-associated protein degradation 
(ERAD) pathway were downregulated; heat shock protein family A (Hsp70), heat shock protein 
family H (NEF) and valosin containing protein (p97). The function of ERAD is targeting of 
misfolded proteins for ubiquitination and later degradation by phagosome.  
 
 
Figure 3.9. Protein processing in ER. Proteins down regulated during LPS induced maturation of 
moDC are highlighted in red. Both proteins highlighted in red and in green are members of 
human pathway. Pathway was plotted using KEGG Orthology Based Annotation System 
(www.genome.jp/kegg). 
 
3.3.3.1. Proteins that exhibit reduced expression following HAP-induced maturation of moDC  
Upon HAP-induced maturation of DCs, the majority of proteins in cell lysates which exhibited 
alterations in protein expression were down-regulated. This accounts for more than 97% of 
these proteins (Table 3.5). Among these, are proteins involved in many cellular processes 
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including cell metabolism, antigen presentation and protein synthesis. Proteins were therefore 
grouped into specific pathways using KEGG – GenomeNet (www.genome.jp/kegg).  
 
UNIPROT PROTEIN NAME 
FOLD 
DECREASE 
P 
VALUE 
Q01105 Protein SET  57.25 0.000 
Q92882 Osteoclast-stimulating factor 1 44.00 0.001 
P13667 Protein disulfide-isomerase A4  25.62 0.016 
Q92945 Far upstream element-binding protein 2  24.77 0.006 
Q13075 Baculoviral IAP repeat-containing protein 1  22.08 0.002 
P27797 Calreticulin  20.67 0.003 
O95379 Tumor necrosis factor alpha-induced protein 8  19.67 0.037 
P05455 Lupus La protein  18.58 0.000 
Q9Y5X3 Sorting nexin-5  16.04 0.017 
P61923 Coatomer subunit zeta-1  15.49 0.001 
Q15435 Protein phosphatase 1 regulatory subunit 7  14.02 0.017 
P08238 Heat shock protein HSP 90-beta  13.95 0.053 
P08697 Alpha-2-antiplasmin  13.12 0.002 
P19338 Nucleolin  11.71 0.000 
P06748 Nucleophosmin  11.09 0.005 
Q16543 Hsp90 co-chaperone Cdc37  10.89 0.001 
P36543 V-type proton ATPase subunit E 1  10.53 0.026 
Q6DKI2 Galectin-9C  9.83 0.009 
O60234 Glia maturation factor gamma  9.76 0.027 
Q13838 Spliceosome RNA helicase DDX39B  9.15 0.034 
Q9Y315 Deoxyribose-phosphate aldolase  8.98 0.027 
O60763 General vesicular transport factor p115  8.57 0.021 
P16403 Histone H1.2  8.02 0.002 
P07237 Protein disulfide-isomerase  7.65 0.000 
P07437 Tubulin beta chain  7.57 0.000 
P07910 Heterogeneous nuclear ribonucleoproteins C1/C2  6.97 0.001 
Q9Y3F4 Serine-threonine kinase receptor-associated protein  6.85 0.000 
P08758 Annexin A5  6.62 0.004 
P52566 Rho GDP-dissociation inhibitor 2  6.26 0.020 
Q00839 Heterogeneous nuclear ribonucleoprotein U  5.69 0.050 
Q13451 Peptidyl-prolyl cis-trans isomerase FKBP5  5.58 0.025 
Q15084 Protein disulfide-isomerase A6  5.23 0.003 
P15090 Fatty acid-binding protein, adipocyte  5.02 0.003 
P06702 Protein S100-A9  4.94 0.004 
P14317 Hematopoietic lineage cell-specific protein  4.88 0.044 
P61956 Small ubiquitin-related modifier 2  4.88 0.048 
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P55209 Nucleosome assembly protein 1-like 1  4.81 0.000 
P14314 Glucosidase 2 subunit beta  4.68 0.028 
P62136 Serine/threonine-protein phosphatase PP1 4.61 0.048 
P30040 Endoplasmic reticulum resident protein 29  4.61 0.009 
P19823 Inter-alpha-trypsin inhibitor heavy chain H2  4.52 0.002 
P51572 B-cell receptor-associated protein 31  4.52 0.035 
Q9BUF5 Tubulin beta-6 chain  4.50 0.002 
P55084 Trifunctional enzyme subunit beta, mitochondrial  4.50 0.040 
P60866 40S ribosomal protein S20  4.50 0.050 
P63173 60S ribosomal protein L38  4.48 0.006 
P02774 Vitamin D-binding protein  4.38 0.013 
Q9H0E2 Toll-interacting protein  4.08 0.040 
P05109 Protein S100-A8  3.87 0.022 
Q9H4B7 Tubulin beta-1 chain  3.86 0.015 
P23284 Peptidyl-prolyl cis-trans isomerase B  3.80 0.049 
Q9UBR2 Cathepsin Z  3.77 0.046 
P19105 Myosin regulatory light chain 12A 3.53 0.005 
P30101 Protein disulfide-isomerase A3 3.40 0.018 
P50502 Hsc70-interacting protein 3.39 0.022 
P07858 Cathepsin B  3.33 0.019 
Q9Y6N5 Sulfide:quinone oxidoreductase, mitochondrial  3.14 0.019 
Q9NQC3 Reticulon-4  3.07 0.009 
P09382 Galectin-1  3.03 0.018 
P15880 40S ribosomal protein S2  2.97 0.028 
O43396 Thioredoxin-like protein 1  2.96 0.020 
P68366 Tubulin alpha-4A chain  2.93 0.025 
P26599 Polypyrimidine tract-binding protein 1  2.90 0.024 
Q8N392 Rho GTPase-activating protein 18  2.88 0.050 
P62847 40S ribosomal protein S24  2.84 0.032 
Q9H223 EH domain-containing protein 4  2.83 0.048 
O00560 Syntenin-1  2.81 0.009 
P07355 Annexin A2  2.75 0.001 
P21980 Protein-glutamine gamma-glutamyltransferase 2  2.68 0.007 
P68371 Tubulin beta-4B chain  2.65 0.055 
P07339 Cathepsin D  2.63 0.021 
P51659 Peroxisomal multifunctional enzyme type 2  2.59 0.001 
P26447 Protein S100-A4  2.58 0.030 
P62913 60S ribosomal protein L11  2.55 0.010 
Q99536 Synaptic vesicle membrane protein VAT-1 homolog  2.53 0.016 
Q71U36 Tubulin alpha-1A chain  2.52 0.032 
P60660 Myosin light polypeptide 6  2.50 0.006 
P41240 Tyrosine-protein kinase CSK  2.46 0.047 
P30050 60S ribosomal protein L12  2.46 0.035 
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P49411 Elongation factor Tu, mitochondrial  2.42 0.020 
P54920 Alpha-soluble NSF attachment protein 2.40 0.019 
P19878 Neutrophil cytosol factor 2  2.39 0.014 
P14625 Endoplasmin  2.38 0.013 
P18124 60S ribosomal protein L7  2.38 0.013 
P11021 78 kDa glucose-regulated protein  2.28 0.003 
P60842 Eukaryotic initiation factor 4A-I  2.27 0.032 
Q9Y3Z3 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1  2.24 0.034 
P28676 Grancalcin  2.22 0.028 
P31948 Stress-induced-phosphoprotein 1  2.21 0.010 
P62241 40S ribosomal protein S8  2.19 0.039 
P53621 Coatomer subunit alpha  2.19 0.025 
P61978 Heterogeneous nuclear ribonucleoprotein K  2.18 0.014 
P05387 60S acidic ribosomal protein P2  2.16 0.002 
P35579 Myosin-9  2.14 0.024 
P02776 Platelet factor 4  2.12 0.009 
P62906 60S ribosomal protein L10a  2.12 0.009 
P62081 40S ribosomal protein S7  2.11 0.002 
P52790 Hexokinase-3  2.09 0.015 
P62269 40S ribosomal protein S18  2.09 0.003 
P26641 Elongation factor 1-gamma  2.08 0.004 
Q9UBW5 Bridging integrator 2  2.06 0.040 
O94925 Glutaminase kidney isoform, mitochondrial  2.05 0.048 
O14773 Tripeptidyl-peptidase 1  2.05 0.008 
P07686 Beta-hexosaminidase subunit beta 2.04 0.052 
Q13177 Serine/threonine-protein kinase PAK 2  2.00 0.031 
P05388 60S acidic ribosomal protein P0  2.00 0.002 
Q9NTK5 Obg-like ATPase 1  1.99 0.001 
P08865 40S ribosomal protein SA  1.98 0.039 
P18510 Interleukin-1 receptor antagonist protein  1.96 0.020 
Q14103 Heterogeneous nuclear ribonucleoprotein D0  1.95 0.019 
Q02878 60S ribosomal protein L6  1.89 0.019 
P12956 X-ray repair cross-complementing protein 6  1.89 0.019 
P62280 40S ribosomal protein S11  1.89 0.031 
P23396 40S ribosomal protein S3  1.88 0.049 
P26373 60S ribosomal protein L13  1.88 0.041 
Q13510 Acid ceramidase 1.85 0.018 
P83731 60S ribosomal protein L24  1.85 0.011 
P46783 40S ribosomal protein S10  1.84 0.052 
P62888 60S ribosomal protein L30  1.84 0.000 
P63244 Guanine nucleotide-binding protein subunit beta-2-like 1  1.80 0.036 
P15153 Ras-related C3 botulinum toxin substrate 2  1.80 0.045 
P62158 Calmodulin  1.77 0.047 
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O75915 PRA1 family protein 3  1.77 0.043 
P51148 Ras-related protein Rab-5C  1.74 0.059 
P38646 Stress-70 protein, mitochondrial  1.73 0.042 
P23526 Adenosylhomocysteinase  1.69 0.057 
P23526 Adenosylhomocysteinase  1.69 0.057 
P36578 60S ribosomal protein L4  1.68 0.033 
Q14697 Neutral alpha-glucosidase AB 1.68 0.058 
P62829 60S ribosomal protein L23  1.68 0.031 
P05386 60S acidic ribosomal protein P1  1.68 0.042 
Q01469 Fatty acid-binding protein, epidermal  1.67 0.013 
P62277 40S ribosomal protein S13  1.67 0.011 
P46777 60S ribosomal protein L5  1.67 0.033 
P01911 HLA class II histocompatibility antigen, DRB1-15 beta chain  1.67 0.006 
O43488 Aflatoxin B1 aldehyde reductase member 2  1.66 0.030 
P04080 Cystatin-B  1.62 0.051 
Q9UI12 V-type proton ATPase subunit H  1.61 0.050 
P61916 Epididymal secretory protein E1  1.60 0.038 
Q9ULV4 Coronin-1C  1.60 0.011 
P46782 40S ribosomal protein S5  1.59 0.020 
Q9Y2Q3 Glutathione S-transferase kappa 1  1.58 0.010 
Q9BTM1 Histone H2A.J  1.58 0.026 
O75347 Tubulin-specific chaperone A  1.56 0.007 
P12081 Histidine--tRNA ligase, cytoplasmic  1.56 0.027 
Q9P0L0 Vesicle-associated membrane protein-associated protein A  1.55 0.010 
P00918 Carbonic anhydrase 2  1.55 0.029 
P61353 60S ribosomal protein L27  1.53 0.022 
Q8WUM4 Programmed cell death 6-interacting protein  1.53 0.008 
Q99798 Aconitate hydratase, mitochondrial  1.51 0.055 
O15143 Actin-related protein 2/3 complex subunit 1B  1.47 0.018 
P61026 Ras-related protein Rab-10  1.46 0.024 
P10809 60 kDa heat shock protein, mitochondrial  1.46 0.018 
Q86VP6 Cullin-associated NEDD8-dissociated protein 1  1.45 0.023 
P47755 F-actin-capping protein subunit alpha-2  1.42 0.042 
P61163 Alpha-centractin 1.41 0.028 
P28482 Mitogen-activated protein kinase 1  1.39 0.008 
P38606 V-type proton ATPase catalytic subunit A  1.39 0.023 
P17987 T-complex protein 1 subunit alpha  1.38 0.040 
P67936 Tropomyosin alpha-4 chain  1.38 0.014 
P14550 Alcohol dehydrogenase [NADP(+)]  1.38 0.028 
Q96TA1 Niban-like protein 1  1.37 0.036 
P40121 Macrophage-capping protein  1.34 0.050 
P50395 Rab GDP dissociation inhibitor beta  1.32 0.001 
P21281 V-type proton ATPase subunit B, brain isoform  1.31 0.042 
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O75874 Isocitrate dehydrogenase [NADP] cytoplasmic  1.30 0.043 
P52209 6-phosphogluconate dehydrogenase, decarboxylating  1.29 0.011 
P09467 Fructose-1,6-bisphosphatase 1  1.27 0.049 
O14818 Proteasome subunit alpha type-7  1.26 0.055 
P40925 Malate dehydrogenase, cytoplasmic  1.26 0.007 
P51452 Dual specificity protein phosphatase 3  1.25 0.011 
P13639 Elongation factor 2  1.24 0.063 
P16050 Arachidonate 15-lipoxygenase 1.24 0.045 
O60664 Perilipin-3  1.23 0.015 
P28066 Proteasome subunit alpha type-5  1.19 0.025 
P06744 Glucose-6-phosphate isomerase  1.19 0.031 
P50990 T-complex protein 1 subunit theta  1.17 0.004 
P37837 Transaldolase  1.15 0.032 
P84077 ADP-ribosylation factor 1  1.15 0.015 
Table 3.4. List of the proteins downregulated, after stimulation of dendritic cells with HAP. 
 
Cell metabolism 
HAP induced maturation affected cellular metabolism but to a much lower extent than LPS-
induced maturation. Only four components of glycolysis and six proteins from the pentose 
phosphate pathway were downregulated.  
Downregulated proteins involved in glycolysis, were also found to be downregulated upon LPS 
stimulation, those proteins are: glucose-6-phosphate isomerase (Fig. 3.3 5.3.1.9), an enzyme 
converting glucose 6-phosphate into fructose 6-phosphate (F6P); hexokinase 1 (2.7.1.1); 
fructose-bisphosphatase 1 (3.1.3.11) which dephophorylates β-D-fructose 1,6-bisphosphate to 
F6P. Also one protein involved in the post glycolytic processes is downregulated. Aldo-keto 
reductase (1.1.1.2) is involved in the oxidation of NADH to NAD+ under non-aerobic conditions.  
Another metabolic pathway affected by HAP-induced moDC maturation is the pentose-
phosphate pathway where four of the downregulated enzymes correspond to enzymes 
downregulated upon LPS stimulation. Those enzymes are: phosphogluconate dehydrogenase 
(Fig. 3.5 1.1.1.44), transaldolase 1 (2.2.1.2), fructose-bisphosphatase (3.1.3.11) and glucose-6-
phosphate isomerase (5.3.1.9). There are also several downregulated enzymes involved in 
pentose phosphate pathway that were not downregulated upon LPS induced maturation. Those 
enzymes are glucose 1-dehydrogenase (H6PD), which belongs to oxidoreductases and catalyses 
conversion of β-D-glucose- 6 phosphate to D-gluconate-6 phosphate; and deoxyribose-
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phosphate aldolase (4.1.2.4), which produces D-glyceraldehyde 3-phosphate and acetaldehyde 
from 2-deoxy-D-ribose 5-phosphate. 
Antigen presentation 
Proteins involved in antigen presentation that were downregulated upon HAP induced moDCs 
maturation were identified in both MHC class I and MHC class II pathways. In general 
downregulated proteins corresponded to the ones identified upon LPS induced DC maturation. 
For MHC I pathway those were HSP90, ERp57, CALR and BiP, for MHC II pathway CTSB and 
CTSB/LiS. However in contrast to LPS induced maturation, MHC II molecule itself was not 
downregulated upon HAP stimulation. 
Protein biosynthesis 
The biggest difference in the protein expression between LPS and HAP induced moDC 
maturation, were observed in protein biosynthesis. Upon HAP-induced DCs maturation, 27 
ribosomal proteins and 9 proteins involved in protein processing in ER, were found to be down-
regulated. From the downregulated ribosomal proteins 12 correspond to the ones identified 
upon LPS induced maturation, these proteins are L4e, L6e, L7e, L11e, L23e, L24e, L30e, L38e, 
RPLP0, LP1/2, S13e and S18e. Other proteins downregulated upon HAP induced maturations 
were EF-Tu proteins: S20e, S3e, S11e, S2e and L5e, and EF-Tu,G proteins S5e and L30e (Fig. 3.10). 
In addition down-regulated proteins belonging to the large subunit were: L10Ae, L12e, L13e and 
L27e; and belonging to small ribosomal subunit: Sae, S8e, S24e, S7e and S10e.  
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Figure 3.10. The structure of large and small subunit of ribosome. (A) Protein composition of 
large and small subunits of ribosome. (B) A list of ribosomal proteins with the proteins 
downregulated during HAP-induced maturation of moDC highlighted in red. Both proteins 
highlighted in red and in green are components of human ribosome.  Pathway was plotted using 
KEGG Orthology Based Annotation System (www.genome.jp/kegg). 
 
Upon HAP-induced maturation, downregulated ER proteins involved in posttranslational 
processing, correspond to the proteins downregulated upon LPS stimulation, namely Bip, 
GRP94, GlcII, ERP57, CRT and PDIs. The difference was observed for ERAD pathway, where only 
heat shock protein 90 alpha (Hsp90) and B-cell receptor-associated protein 31 (Bap31), leading 
to ERAD were downregulated.  
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3.4. Discussion 
DCs are initiators of immune response and inflammation processes. However, to fulfil this role 
they need to be activated upon contact with an antigen and undergo a process called 
maturation, which comprises multiple cellular changes. The aims of maturation are, to allow 
morphological and physiological changes of DCs that aid antigen processing and the subsequent 
migration to the lymphatic organ for antigen presentation. Here we performed a novel 
proteome profiling study of human DCs during the maturation induced with LPS and HAP. 
Although there were numerous proteomic studies performed previously examining DCs in 
different functional states (Angenieux et al., 2001; Le Naour et al., 2001; Richards et al., 2002; 
Pereira et al., 2005; Ferreira et al., 2008; Gundacker et al., 2009), the tool used for this study, 
SWATH proteomics has never used before to characterise DCs proteome. Due to its accuracy 
and sensitivity, the current study can for the first time provide detail of maturation-induced 
proteomic changes in a comprehensive and fully quantitative manner and would be impossible 
using traditional techniques such as 2-D gel electrophoresis or shotgun proteomics. In addition, 
this study for the first time uses HAP to induce DC maturation and provides quantitative analysis 
of subsequent proteomic changes. This can bring important insight into the pathology of 
inflammatory diseases associated with tissue calcification, such as age-related macular 
degeneration, atherosclerosis and Alzheimer’s disease and, or into the mechanisms of bone 
graft rejection.  
SWATH analysis allowed identification of 845 proteins in cell lysates from moDCs from which 
260 proteins and 190 proteins were significantly altered when DCs were differentiated upon LPS 
stimulation and HAP stimulation, respectively. From those, twenty (7.7%) were upregulated 
upon LPS-induced maturation and only six (3.2%) upon HAP induced maturation (Fig. 3.11). 
Proteins that exhibited the largest, more than 30-fold increase upon LPS induced maturation 
were three interferon induced proteins, IFN-induced GTP binding protein, IFN-induced protein 
with tetratricopeptide repeat 3 and ubiquitin-like protein ISG15. These observation match 
exactly to the previously published results by Gundacker et al. (2009). Using shotgun proteomics, 
they also identified those three particular proteins as being the main upregulated proteins upon 
LPS-induced maturation of DCs. Nevertheless, in contrast to Gundacker’s study, current results 
are fully quantitative. In addition, one of those proteins, IFN-induced protein with 
tetratricopeptide repeats 3, was also the most upregulated upon HAP-induced maturation, 
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albeit the increase was just 2.5-fold. Those proteins are involved in antiviral and antibacterial 
defence and ubiquitin like protein serves additionally as a negative regulator of ubiquitination.  
 
 
Figure 3.11. Schematic summary of protemic data, demonstrating differences and similarities 
between dendritic cells (DC) activated with LPS (orange) and HAP (blue). 260 proteins and 190 
proteins were significantly altered when DCs were differentiated upon LPS stimulation and HAP 
stimulation, respectively.  
 
Other proteins identified to be upregulated upon LPS-induced maturation, can be assigned into 
functional groups. Firstly, a group of proteins identified are known to be involved in the positive 
regulation of ubiquitination. Ubiquitination targets protein for destruction and is an important 
post-translational regulator of the immune response on many levels including innate and 
adaptive immunity and antimicrobial defence (Jiang and Chen, 2011). Ubiquitination also 
regulates the antigen presenting function of DCs by influencing TLR4 signalling in multiple ways.  
The TLR4 pathway is activated after binding LPS or HAP and follows either MyD88 or TRIF route, 
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which was described in detail in the introduction. Ubiquitination is involved in the regulation of 
both routes by activation NF-κB and MAPK cascade downstream of both routes (Kayagaki et al., 
2007) and also ubiquitination of TRAF3, which leads to INF secretion (Kagan et al., 2008). 
Ubiquitination is also crucial for antigen presentation by both MHC class I and II (Oh and Shin, 
2015). In DCs, MHC II is ubiquitinated via lysine of of the β subunit (Shin et al., 2006), which is 
mediated by the ubiquitin ligase, membrane-associated RING-CH1 (MARCH1; Nice et al., 2010). 
The role of MHC II ubiquitination is reduction of MHC II surface expression and therefore antigen 
presentation as a response to IL-10 and regulatory T-cells. In addition, it promotes cytokine 
production and aids the ability of DCs to activate CD4+ T-cells, even when less antigen is being 
presented (Oh and Shin, 2015). The ubiquitination of MHC I is also mediated via MARCH1 and 
leads to rapid endocytosis and degradation (Lang et al., 2013).  
Another group of proteins up-regulated upon LPS-induced maturation consisted of proteins 
involved in stabilising cell structure and cytoskeletal remodelling. These include fascin, keratin 
type I and II, calpain and actin binding coronin 1B. Upon maturation, DCs undergo morphological 
and functional changes, including development of extensive cytoplasmic projections in many 
directions from the cell body (Tan et al., 2010; Verdijk et al., 2004). This process involves 
cytoskeletal remodelling; therefore, it was expected to find upregulated proteins involved in this 
process. Fascin (Al-Alwan et al., 2001) and calpain (Gundacker et al., 2008) were previously 
reported to be highly expressed during DC maturation. In addition coronin 1B is required for 
efficient cell migration of maturing DCs to the lymphatic organs (Cai, et al., 2005). Also one 
protein up-regulated during HAP induced DCs maturation ITGB3 is involved in migration and 
growth (Lee et al., 2012). 
The SWATH analysis identified a massive decrease in global protein expression upon DC 
maturation. This accounts for as much as 92% of altered proteins for LPS activated cells and 
almost 97% of altered proteins for HAP activated DCs. For LPS activated cells, 55 proteins (23% 
of the total downregulated proteins) are involved in cellular metabolism. For HAP activated cells, 
23 proteins involved in metabolism are downregulated (12.5% of the total downregulated 
proteins). The pathways that are mostly affected, are the ones involved in carbon metabolism: 
glycolysis, gluconeogenesis, pentose phosphate pathway and citrate cycle. Interestingly, 
proteins involved in fatty acid metabolism and biosynthesis of amino acids are not affected at 
24 h of maturation.  
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The groups of proteins most affected by DC maturation were ribosomal proteins and proteins 
involved in protein processing in ER. Upon LPS-induced maturation 19 ribosomal and 11 ER 
proteins were downregulated and upon HAP-induced maturation, 27 and 9 proteins were 
downregulated, respectively. This suggests that protein translation and post-translational 
modifications are very important for DC-directed immune response. There are multiple studies 
linking inflammation, innate immunity, and post-transcriptional regulation (Todd et al., 2008).  
Ribosomal proteins together with some of the ER components make a complex cellular 
machinery responsible for protein synthesis through translation and post-translational 
modifications. For a long time ribosomal proteins were considered only to be important 
collectively, but now it is clear that many of those proteins are multifunctional and play an 
important role in the regulation of cell growth and death (Warner and McIntosh, 2009).  
Global protein synthesis is increased between 8 to 12h of LPS induced maturation followed by a 
gradual decrease (Ceppi et al., 2009).  This increased protein synthesis is tightly controlled during 
DC activation as it correlates to activation of translational proteins, eIF4E-binding proteins (4E-
BPs) and S6 ribosomal protein (S6) and dephosphorylation of negative regulator of translation, 
alpha-subunit of eukaryotic translation initiation factor 2 (eIF2α; Ceppi et al., 2009). This sudden 
activation of the translational process then reverted back to the steady state, which correlated 
with the global protein synthesis pattern. Nonetheless, the authors observed that relative 
transcription and translation intensity was maintained even at 16 h of maturation. Current 
results now extended the observation of translational machinery to 24 h of maturation.  
Downregulation of translational machinery at 24 h post LPS activation, is also in agreement with 
the large number of proteins to which a decrease in expression was observed. Current results 
also revealed for the first time that HAP-induced maturation of DCs can lead to changes in 
protein translation and post-translational modifications. With many identified proteins being 
downregulated after 24 h post HAP stimulation.  
Upon DC maturation it was found that MHC class I molecules, which are known to be involved 
in antigen presentation, were up-regulated. Three subunits of MHC class I molecules were 
identified with 3 to 7-fold increase in expression after LPS stimulation. MHC I presents self-
antigens, which are either partially degraded proteins, proteins that were previously functional 
or newly synthesised but defective proteins (Apcher et al., 2012; Rock et al., 2014). Activated 
DCs are known to secrete type-I IFN and other cytokines (Liu et al., 2005), which in return 
potentiate MHC I mediated antigen presentation. Most of the proteins involved in antigen 
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presentation in either LPS- or HAP-activated DCs were downregulated during cell maturation. 
This includes MHC class II antigen presenting molecule, but also proteins from MHC I and II 
pathways, involved in antigen processing and loading. It is therefore possible that there is other, 
unexpected source of antigen, which are then presented on MHC I, but are not involved in 
traditional antigen processing and presentation pathway. It was postulated by Apcher et al. 
(2012) that prematurely terminated full length peptides generated from defective mRNA and 
rejected by the non-sense mediated decay pathway after first round of translation are rapidly 
degraded in the cytosol and presented via MHC I. There is also growing evidence suggesting that 
the translation of immature mRNA can occur in the nucleolus (Apcher et al., 2013; Rugjee et al., 
2013). This could be another potential source of antigen for MHC I presentation, which can be 
loaded obviating traditional pathway.  
Another explanation for only MHC class I being upregulated during DC maturation may be 
increased presentation of exogenous antigen by MHC I even though it is usually maintained by 
MHC class II molecules (Lelouard et al., 2007). We have shown that upon LPS- and HAP-induced 
activation of human DCs, expression of a great number of ribosomal proteins is decreased. It is 
very likely caused by type-I IFN stimulation as it was shown before to induce decrease in mRNA 
encoding for ribosomal proteins (Taylor et al., 2004c; Taylor et al., 2007), but the same effect 
was observed on the protein level upon LPS stimulation (Lelouard et al., 2007). Also the 
increased expression of positive regulators of ubiquitination after DC stimulation (e.g. creatine, 
TNF receptor-associated factor 1) supports this concept. It was observed that in response to 
microbe stimulation (LPS), aggregates made of newly synthesised but ubiquitinated proteins are 
formed in the DC cytoplasm (Lelouard et al., 2002; Lelouard et al., 2004). This aggregation is 
probably the result of protein overproduction at 8 to 12 h of maturation (Ceppi et al., 2009). 
Those aggregates are protected from degradation and stabilised for up to 16 h. The highest 
ability of antigen presentation by MHC class I occurs several hours after DCs activation, thus this 
aggregates serve as important store of antigens for delayed antigen presentations (Lelouard et 
al, 2004). 
In summary, SWATH proteomics enabled the identification of a large number of proteins during 
DCs maturation. Results presented in this chapter provided for the first time a fully quantitative 
analysis of proteins during this process. In addition, proteomic changes in maturing DCs induced 
by HAP were observed for the first time.   
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Chapter 4. The role of zinc in complement protein interactions 
4.1 Introduction 
4.1.1. Complement proteins  
The human complement system forms part of the innate immune system and comprises more 
than 35 plasma and cell membrane bound proteins (Nan et al., 2013). There are three 
complement pathways, which lead to the elimination of pathogens and cytotoxic complexes: 
classical, alternative and lectin (Collard et al., 2001). The first components of complement 
pathways are C1q for the classical pathway and C3 for the alternative pathway. 
The complement pathways are very carefully regulated and play key roles in in tissue 
regeneration (Clark et al., 2008), blood clotting, the clearance of cellular debris (Pickering and 
Walport, 2000) and are implicated in the pathophysiology of many diseases (Alchi and Jayne, 
2010; Sweigard et al., 2014). One of the most important regulators is complement Factor H (FH), 
the major regulator of C3b. Polymorphisms in FH can cause or contribute to various diseases. 
One of them is the life-threatening kidney disease, haemolytic uremic syndrome (HUS), where 
the majority of patients demonstrate dysfunctional FH due to mutations or FH autoantibodies 
(Brandstatter et al., 2012). Addition of zinc to FH causes it to form oligomers containing 4-10 
monomers, which inhibit its activity. FH-zinc oligomer formation is relevant to age-related 
macular degeneration (AMD) and occurs when zinc levels increase to above 60 μM (Perkins et 
al., 2010).  
4.1.2. The role of zinc, complement proteins and histidine-rich 
glycoprotein (HRG) in AMD development 
AMD is the leading cause of irreversible central vision loss in elderly people. It is associated with 
the development of drusen between retinal pigment epithelium (RPE) and Bruch's membrane. 
Drusen are pathological extracellular deposits primarily containing glycolipids, proteins, and 
cellular debris (Liu et al., 2012), which block exchange of nutrients from the vasculature leading 
to cell death and sensory loss within the central visual field. Recent work has shown that drusen 
contains cholesterol-containing droplets, coated with insoluble hydroxyapatite (HAP) known as 
HAP spherules. It has been shown in AMD-affected individuals that these spherules bind 
proteins, including amyloid β, vitronectin, FH and HRG (Fig. 4.1) (Thompson et al., 2015). It is 
118 
 
thought that the binding of such proteins to HAP spherules is a primary mechanism leading to 
deposit formation.  
 
 
Figure 4.1. Molecular constituents of the outer surface of HAP spherules, identified in eyes of 
individuals with AMD. Immunohistochemical fluorescent-labelling with protein-specific 
antibodies, showed HAP spherules (A-E, magenta) to be coated with amyloid beta (A, red), 
vitronectin (B, yellow), and FH (C, green), colabelled by a combination of amyloid beta (red) and 
FH (green) (D) or HRG (E, cyan). Scale bars: 2 μm. Figure adapted from Thompson et al., 2015, 
with new data (part E) from Dr Imre Lengyel, UCL Instiute of Ophthalmology. 
 
Given its role as an important regulator of the classical complement pathway, the introduction 
of endogenous FH is being considered as an alternative or supplementary strategy to correct 
complement dysregulation in AMD. Purified human FH has been used in vivo as an experimental 
treatment in an animal model (Fakhouri et al., 2010). Whether such an approach may be useful 
clinically is still to be established. 
Zinc also appears to play a role in AMD development. In the healthy eye, the Bruch’s membrane 
contains 47 ppm of zinc. However, in AMD the amount increases to 137 ppm in the membrane 
and approximately 232 ppm in deposits (Dr Imre Lengyel, personal communication). It is feasible 
that together FH-zinc oligomer formation (Perkins et al., 2010), FH-HRG binding and the 
interaction between HRG, complement proteins and HAP are essential for drusen formation and 
occurs when zinc levels are elevated (Perkins et al., 2010). 
4.1.3. The role of HRG in the immune system 
Human histidine rich glycoprotein (HRG) is an abundant plasma protein with a multi-domain 
structure, composed of 507 amino acids, with six predicted N-linked glycosylation sites (Poon et 
al., 2010a). It consists of two cystatin like N-terminal domains (N1 and N2), a central histidine 
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rich region (HRR) flanked by two proline rich regions (bigger PRRI and smaller PRR2) and a C-
terminal domain (C) (Jones et al., 2005a). 
Through its ability to interact with numerous ligands (mainly through the N- and C-terminal 
domains), HRG serves as a positive (Simantov et al., 2001, Klenotic et al., 2010) and negative 
(Dixelius et al., 2006) regulator of physiological processes including angiogenesis through a 
variety of mechanisms. It has been also shown that HRG acts in the coagulation system as an 
anticoagulant and antifibrinolytic agent (Tsuchida-Straeten et al., 2005) by interaction with 
many molecules including: haem, plasminogen (Lijnen et al., 1980), heparanase (Poon et al., 
2010b), fibrinogen (Leung et al., 1983) and heparins (Koide et al., 1989).  
In the immune system, HRG plays an important role. It modulates the formation and function of 
immune complexes (IC) but also prevents the build-up of IC deposits, which are detrimental to 
small blood vessels. Those deposits can lead to pathologies such as rheumatoid arthritis, 
vasculitis or glomerulonephritis. HRG, through binding to various components of the immune 
system including the complement proteins (within both classical and alternative pathways), 
antibodies and Fc receptors on immunoglobulins, maintains streamline transport of the immune 
complexes to the liver and spleen (Gorgani et al., 1997; Gorgani et al., 1999). 
Another role of HRG in the immune system is modulation of complement function by 
augmentation or inhibition through interactions with C8, C9, D and S-protein. It also binds 
strongly to C1q, FH, C4b -binding protein, C3, C4 and IgG (Manderson et al., 2009; Chang et al., 
1992). It is thought that the binding between HRG and complement proteins, occurs via N-
terminus. Through those interactions HRG is involved in elimination of necrotic (Jones et al., 
2005b, Jones et al., 2005c) and apoptotic (Gorgani et al., 2002) cells from the immune system in 
two ways. HRG can either bind heparan sulfate (HS) on the surface of phagocytes, to promote 
necrotic cell uptake (Poon et al., 2010), or regulate activation of complement on necrotic cells, 
via interactions with C1q. This interaction occurs in the late stage of cell death when the cell 
membrane becomes permeable (Manderson et al., 2009). Zinc is thought to inhibit the 
interaction of HRG with C1q (Gorgani et al., 1997b) and to affect many other proteins within the 
complement system. For example in guinea pig, concentrations of zinc between 25 to 500 µM 
inhibit most of the complement factors and affects overall complement activity (Montgomery 
et al., 1979). The inhibitory effects of zinc were also observed on C9 (Yamamoto and Takahashi, 
1975), C3-convertase, FH, C1q and C4b functions (Blom et al., 2003). On the other hand, zinc has 
stimulatory effect on C3 (Downing et al., 1989). 
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The aims of this chapter are to characterise HRG–complement interactions, using an ELISA based 
method, and to determine whether these interactions occur via N terminus of HRG, a common 
ligand-binding region. In addition, the role of zinc in regulating the interaction of HRG with 
complement proteins and heparin will be examined. Second aim of this chapter is to investigate 
whether zinc and pH alterations may contribute to AMD development by promoting HRG-
hydroxyapatite interactions. Those interactions will be studied using, newly established, 
magnetic beads binding assay.  
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4.2. Materials and methods 
4.2.1. Purification of human and rabbit HRG  
HRG was purified from either human or rabbit plasma using immobilised-metal affinity 
chromatography (IMAC). A HisTrap HP column (GE Healthcare) was equilibrated with binding 
buffer (10 mM Tris, 150 mM NaCl, 5 mM imidazole, pH 8) and then loaded with filtered serum 
following addition of 5 mM imidazole. For elution, the imidazole concentration was increased 
across linear gradient of 0-30% of 500 mM imidazole over 5 min and then 30-100% over another 
5 min. Fractions were collected and analysed using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). For the final purification step, a size exclusion HiLoad 26/600 
Superdex 200 pg column (GE Healthcare) was used with 10 mM Tris, 150 mM NaCl, pH 8 as the 
running buffer, and with a flow rate of 0.5 ml per minute. Eluted fractions were again analysed 
using SDS-PAGE. Human and rabbit HRG were concentrated using a Vivaspin 20 concentrator 
(10 kDa MWCO; GE Healthcare) to 10 mg/ml. Purified sample was aliquoted and flash frozen in 
liquid nitrogen before final storage at -80°C. Additionally, gel bands of relevant size, were 
extracted using sterile razor blade and sent for mass spectrometry analysis (MS).  
4.2.2. Purification of human factor H (FH)  
FH was purified from pooled human serum using a three-step process. Serum was centrifuged 
(4,200 rpm for 30 min at 4oC) and filtered (0.45 µm filter), and pH adjusted to 6.0 prior to 
purification. For the first step a cation exchange column (CEX), (HisTrap SPFF; GE Healthcare) 
was used. This column was equilibrated with binding buffer (20 mM tri-sodium citrate, pH 6.0), 
and loaded with filtered serum. The column was then washed with binding buffer, until the 
absorbance reached 0 mAU. For elution, the ionic strength was increased across a linear gradient 
of 0-100% of 200 mM NaCl (20 mM Tris-HCl, 200 mM NaCl, pH 6.0). Fractions were collected and 
analysed using SDS-PAGE. Chosen fractions were pooled and dialysed overnight against 5 L of 
20 mM Tris-HCl pH 8.6 (4oC, stir) and then loaded onto an anion exchange column (AEX), HisTrap 
QFF (GE Healthcare) equilibrated by 20 mM Tris-HCl pH 8.6. Factor H was eluted with ionic 
strength increased across linear gradient 0-100% of 250 mM NaCl (20 mM Tris-HCl, 250 mM 
NaCl, pH 8.6). Fractions were collected and analysed using SDS-PAGE. For the final purification, 
the size exclusion column HiLoad 26/600 Superdex 200 pg (GE Healthcare) was used with 10 mM 
Tris, 150 mM NaCl, pH 7.5 buffer, and with a flow rate of 0.5 ml per minute. Eluted fractions 
were again analysed using SDS-PAGE. Fractions containing FH were pooled and either 
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concentrated using a Vivaspin 20 concentrator (10 kDa MWCO; GE Healthcare), and flash frozen 
in liquid nitrogen, or freeze-dried (using liquid nitrogen and Edwards Modulyo EF4 freeze-drier). 
Prior to freeze-drying sample was dialyzed for two days at 4oC against 5 L of 50 mM ammonium 
carbonate buffer (dialysis buffer was replaced after 24h). Both flash frozen and freeze-dried 
samples were stored at -80°C until required. Additionally, gel band of relevant size, was 
extracted from the final SDS gel using sterile razor blade and sent for mass spectrometry analysis 
(MS).  
4.2.3. SDS-PAGE and Western blotting 
Protein samples were resuspended in NuPAGE® LDS 4x Sample Buffer (Invitrogen, Thermo Fisher 
Scientific, Dartford, UK) for non-reducing conditions and the same buffer with the addition of 
5% β-mercaptoethanol for reducing conditions. Following denaturation by heating at 90oC for 5 
min, samples were loaded into precast  NuPAGE® 4-12% Bis-Tris 1.0 mm protein gels (Invitrogen, 
Thermo Fisher Scientific), and run for approximately 1 h at 160 V in running buffer (NuPAGE® 
MES SDS Running Buffer, Thermo Fisher Scientific). After electrophoresis, gels were stained 
using Coomassie Brilliant Blue.  
4.2.4. TEV protease preparation 
A recombinant catalytic domain of the Nuclear Inclusion a (Nia) protein from tobacco etch virus 
(TEV) was produced to allow proteolytic cleavage of the His-tag from a recombinant form of the 
HRG N1/N2-domain (see below). The TEV protease uses a catalytic triad of residues, Cys-Asp-His 
to catalyse peptide hydrolysis. The enzyme was expressed recombinantly using pRK793 vector 
in E. coli strain BL21 (DE3)-RIL  This domain is engineered to have an N-terminal His-tag and a C-
terminal polyarginine tag and is purified as MBP fusion protein that cleaves itself in vivo. 
Pre-culture of BL21 (DE3)-RIL expressing catalytic domain of TEV protease was set up from a 
glycerol stock in 20 ml of Luria broth (LB) supplemented with 100 µg/ml of ampicillin and grown 
for 12 h at 37oC with shaking (200 rpm). The following day, the main culture was set up in 1 L of 
the same medium in 1:100 dilution of initial culture and left at 37oC, 200 rpm until OD600 reached 
0.7 AU. Protein expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 
and the temperature lowered to 25oC. Cultures were incubated for 16 h with shaking (180 rpm). 
The bacterial pellet was harvested by centrifugation for 40 min, 6,000rpm at 4oC, then weighed 
and resuspended for 30 min at 4oC in binding buffer (50 mM Tris, 150 mM NaCl, 20 mM 
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imidazole, pH 8.0) at a 1:5 (w/v) ratio. Cells were lysed by sonication with Ultrasonic Cell 
Disruptor with 40 % amplitude for 2 min of 10 s pulses with 10s intervals. Cell debris was 
removed following centrifugation for 20 min, 20,000 rpm at 4oC. The supernatant was then 
filtered (0.44 μm membrane; Millipore, Consett, UK.) and applied to a His Trap HP column (GE 
Healthcare,) pre-washed with lysis buffer. Protein was eluted with a linear gradient up to 400 
mM imidazole (10 column volumes (CV) to reach 10% of elution buffer, 20 CV to reach 100% and 
then 100% over 5 CV). Eluted fractions were immediately diluted in a 1:1 (v/v) ratio with dialysis 
buffer (20 mM Tris HCl, 500 mM NaCl, pH 7.5) and then dialysed over night at 4oC with stirring. 
Protein was concentrated to 2 mg/ml using a Vivaspin 20 column (10 kDa MWCO; GE 
Healthcare), diluted 1:1 with glycerol, frozen with liquid nitrogen and stored at -80 oC.  
4.2.5. Production of recombinant HRG N1/N2 domain fragment  
4.2.5.1. Molecular cloning 
Construction of expression vectors 
To amplify the cDNA sequence encoding the N1/N2-domains of human HRG for insertion into 
pETM11 E. coli expression plasmid (Fig. 4.2), 10 ng of template DNA was used. The template was 
a plasmid I.M.A.G.E clone containing the full length human HRG coding sequence purchased 
from Source Bioscience (Nottingham, UK). To the template DNA, 25 µl of BIO-X-ACT™ Short Mix 
(Bioline, London, UK) was added. This is a ready 2× mixture of DNA polymerase, MgCl2 and dNTP. 
Forward (5'-TAAGCAGAATTCATGAAGCACCACCACCAC-3') and reverse primers (5'-
TGCTTAGCGGCCGCTCATTT GAGCTCT-3') (Eurofins Scientific, Luxembourg) were added at a final 
concentration of 0.6 µM. Molecular grade water was added to a final volume of 50 µl. The PCR 
amplification reaction was performed using a Phoenix 2 thermal cycler (Helena Bioscience, Tyne 
and Wear, UK). PCR cycling was as follows: 1 cycle as initial denaturation at 95oC for 2 min, 
followed by 40 cycles of denaturation at 95oC for 30 s, annealing at 64oC for 30 s, and extension 
at 72oC for 30 s. Final extension was in 1 cycle at 72oC for 5 min.  
 
 
124 
 
 
Figure 4.2. PETM-11 expression vector, used for the N1/N2 – domain expression. The multiple 
cloning site (MSC) was the location of gene insertion. The expression is driven by the T7-lac 
promoter. A kanamycin resistance gene allows for the selection of colonies. 
 
Restriction enzyme digest 
A double restriction enzyme digest was performed to cleave the pETM11 plasmid at the sites 
where N1/N2-domain will be inserted (inside the multiple cloning site and immediately 
downstream and in-frame from a hexameric His-tag and TEV protease site). A similar digest was 
also performed on the amplified dsDNA fragment to prepare this for insertion into pETM11 and 
to subsequently confirm the presence of proper insert (following insertion/transformation). For 
this 1 μg of DNA was digested with the high fidelity restriction enzymes SacI-HF® and NcoI-HF® 
(NEB, Hitchin, UK) in 1x CutSmart® Buffer (NEB). Reactions were incubated for 90 min at 37oC. 
Additionally, to prevent re-ligation of compatible ends, the DNA was treated with 1 μl of calf 
intestine alkaline phosphatase (NEB) in the appropriate buffer and incubated for additional 30 
min at 37oC. The treated DNA was then purified by agarose gel electrophoresis. 
Agarose gel electrophoresis 
Gels were prepared by melting 1% (w/v) agarose (Sigma-Aldrich, Haverhill UK) in Tris-acetate-
EDTA buffer (TAE) (40 mM Tris pH 7.6, 20 mM acetic acid, 1 mM EDTA) with ethidium bromide 
(0.5 μg/ml) to enable separation and detection of DNA bands. Wells were formed by inserting a 
comb before gel was set. PCR samples were mixed with 6x loading dye (Thermo Fisher Scientific). 
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Hyperladder I (200- 10,000 bp; Bioline) was loaded into one well to allow identification of DNA 
sizes. DNA bands were separated at 150 V for approximately 40 min. DNA was visualised in a Gel 
Doc XR+ Imager and analysed using the Image Lab 2.0 software (both Bio-Rad, Hemel 
Hempstead, UK). 
Extraction and purification of DNA bands 
Gel was placed on a blue light transilluminator (Life Technologies) which visualises DNA bands 
using UV-transmission. Bands were excised using a sterile razor blade, weighed and DNA was 
purified using the QIAquick Gel-Extraction kit (Qiagen, Venlo, Netherlands) according to the 
manufacturer’s guidelines. Following purification, DNA was eluted in 30 µl of nuclease free 
water. 
Ligation 
Amplified DNA fragments (corresponding to the HRG N1/N2-domain coding sequence) were 
ligated following digestion into similarly digested pETM11 plasmid (in a 3:1 insert:plasmid ratio, 
10 µl final volume) using 1 µl of T4 DNA ligase (NEB) in 1 × T4 DNA Ligase Buffer (NEB) for 10 min 
at room temperature. A control reaction without insert DNA was also set up. The ligation 
product was chilled on ice prior to bacterial transformation. 
Transformation of E. coli competent cells 
For propagation of ligation product and expression of recombinant protein, three strains of 
chemically competent E. coli were transformed: BL21, Shuffle T7 (NEB) and ArcticExpress (DE3) 
RP competent cells (Agilent Technologies, Edinburgh, UK). In each case, a 50 μl aliquot of 
competent cells, was thawed on ice for 10 min and 5 μl of ligation product or 1 μl of purified 
DNA was added to the cell mixture. The tube was flicked 5 times to facilitate mixing and placed 
on ice for 30 min. After heat shock at 42oC for 40 s (20 s for ArcticExpress) cells were placed back 
on ice for 5 min. Next 950 µl of room temperature SOC rich media was pipetted and the mixture 
was incubated at 37oC (BL21 and ArcticExpress) or 30oC (Shuffle T7) for 60 min, shaken (300 
rpm). An aliquot of transformed cells was plated onto a selection plate (LB supplemented with 
50 μg/ml of kanamycin) and incubated overnight at 37oC. Shuffle T7 had to be plated on LB agar 
supplemented with 30 μg/ml of kanamycin and incubated overnight at 30oC. Formed colonies 
were picked and grown in 10 ml of LB media supplemented with 30 μg/ml kanamycin and grown 
overnight at 37oC or 30oC (Shuffle T7) in a shaking incubator. Obtained cultures were used either 
for preparation of glycerol stocks or subsequent protein expression.  
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Plasmid purification 
For diagnostic purposes, five of successfully transformed colonies were grown in 5 ml of LB broth 
supplemented with 50 µg/ml of kanamycin overnight at 37oC, shaking at 200 rpm. DNA was then 
purified from 1 ml of culture using a QIAprep Spin Miniprep Kit (Qiagen) according to 
manufacturer’s protocol and eluted from columns with 40 μl of nuclease-free water. DNA 
concentration and purity were measured using a NanoVue spectrophotometer (GE Healthcare). 
A ratio of the absorbance at 260 nm and 280 nm of 1.8- 1.9 was regarded as sufficiently pure for 
downstream applications. Purified DNA was stored at -20oC in water until required. 
Generation of glycerol stocks 
For long-term storage of bacterial cultures, glycerol stocks were prepared by mixing 0.5 ml of 
overnight bacterial culture and 0.5 ml of 50% glycerol. Cryogenic vials were stored at -80oC until 
required. 
4.2.5.2. Small scale protein expression 
To optimize the production of N1/N2-domain of recombinant protein by competent strains of 
E. coli, the effect of varying two separate growth parameters was investigated: temperature and 
concentration of inducer, isopropyl β-D-1-thiogalactopyranoside (IPTG; Sigma-Aldrich). Cells 
were initially grown for 12 h in LB medium supplemented with 30 μg/ml kanamycin. Subsequent 
cultures were then set up as 1 in 100 dilution of initial culture in 50 ml aliquots of the same 
medium and grown at optimal temperatures until OD600 reached 0.7 AU (mid log growth phase). 
Protein expression was then induced with 0.01 mM, 0.2 mM or 1 mM of IPTG, respectively and 
the growth temperature adjusted to either 16oC, 25oC or 30oC. Cultures were incubated for 16 
h in a shaking incubator. Aliquots of the bacterial cultures were spun down at 13,000 rpm for 1 
min and supernatants transferred to new tubes. Pellets were re-suspended in 50 μl of reducing 
NuPAGE protein sample buffer and boiled for 15 min. Supernatant was mixed with reducing 
NuPAGE protein sample buffer and boiled for 5 min. Samples were then spun for 5 min at 14,000 
rpm and analysed by SDS-PAGE. Optimal conditions for protein production were determined.  
4.2.5.3. Large scale protein expression under non-denaturing conditions 
Initial culture of Shuffle T7 E. coli strain, expressing N1/N2-domain recombinant protein was set 
up from glycerol stock in 50 ml LB supplemented with 30 ug/ml of kanamycin. Culture was grown 
for 12 h at 30oC, with shaking at 200 rpm. The main cultures were set up in 1 L volumes of the 
same medium at 1:100 dilution of the initial culture and grown at 30oC, with shaking at 200 rpm 
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until the OD600 reached 0.7 AU. Protein expression was induced with 0.02 mM of IPTG and the 
temperature lowered to 25oC. Cultures were grown for 16 h, shaking at 200 rpm. Bacterial pellet 
was harvested by centrifugation for 40 min, 6,000 rpm at 4oC, and then frozen until required at 
-80oC. From each 1 L of bacterial culture around 4.5 g of pellet was harvested. Thawed Shuffle 
T7 pellet containing the expressed recombinant N1/N2 domain was resuspended in lysis buffer 
(50 mM Tris, 150 mM NaCl, 20 mM imidazole, pH 8) with the addition of complete EDTA-free 
protease inhibitor tablets (Roche, Basel, Switzerland) in addition to 1 mg/ml lysozyme and 20 
μg/ml DNase ( for 1 h at 4oC. Cells were lysed by sonication with Ultrasonic Cell Disruptor (40% 
amplitude, 10s pulses at 10s intervals for 3 min, on ice). Lysate was cleared by centrifugation at 
20,000 rpm at 4oC for 30 min and filtered through a 0.44 μm filter (Millipore). Cleared lysate was 
applied to a HisTrap column (GE Healthcare), pre-equilibrated with equilibration buffer (50 mM 
Tris, 150 mM NaCl, 20 mM imidazole, pH 8). Column was washed until the absorbance reached 
0 mAU. Protein was eluted with step-wise gradient up to 400 mM imidazole. Fractions were 
analysed using SDS-PAGE. Chosen fractions were mixed with TEV protease in a 1:10 ratio and 
dialysed overnight against equilibration buffer. Following dialysis, samples were run through a 
pre-equilibrated HisTrap column. HRG N1/N2-domain protein fragments with the His-tag 
cleaved by TEV protease should not bind to the HisTrap column, therefore column flow through 
was collected. Additionally, the column was washed with buffer containing a high concentration 
of imidazole (400 mM imidazole, 50 mM Tris, 150 mM NaCl, and pH 8). Eluted fractions were 
also collected. Column flow through and eluted fractions were analysed using SDS-PAGE. HisTrap 
flow through was subjected to further purification. Sample was concentrated to 5 ml before final 
purification, using a Vivaspin 20 column (10 kDa MWCO; GE Healthcare). For the final 
purification, the size exclusion column HiLoad 16/600 Superdex 75 pg (GE Healthcare) was used 
with 10 mM Tris, 150 mM NaCl, pH 8 buffer, and with a flow rate of 0.5 ml per minute. The 
recombinant HRG N1/N2-domain was eluted as a single peak and concentrated to 10 mg/ml. 
Purified sample was aliquoted and flash frozen in liquid nitrogen before final storage at -80oC 
until required. 
4.2.5.4. Large scale protein expression under denaturing conditions 
Bacterial culture of Shuffle T7 E. coli strain, expressing the HRG N1/N2-domain recombinant 
protein was grown as previously described and harvested pellet was frozen for one day. Thawed 
Shuffle T7 pellet was resuspended in lysis buffer, with the addition of 8 M urea for 1 hour at 4oC 
with stirring. Cells were then lysed by sonication (40% amplitude, 10s pulses at 10s intervals for 
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3 min, on ice). Lysate was cleared by centrifugation, filtered and applied onto the HisTrap 
column, washed with equilibration buffer. Protein was eluted with step gradient of up to 400 
mM imidazole (400 mM imidazole, 50 mM Tris, 150 mM NaCl, and pH 8). Eluted fractions were 
analysed by SDS-PAGE after which selected fractions were pooled together and dialysed twice 
for 12 h, at 4oC against 5 L of 50 mM Tris, 150 mM NaCl, pH 8 containing 5 mM dithiothreitol 
(DTT) in order to remove urea and aid refolding of the recombinant protein. Following dialysis, 
the sample was mixed with TEV protease at a 1:10 ratio to cleave the His-tag. The protein was 
then dialysed against 50 mM Tris-HCl, 150 mM NaCl, 20 mM imidazole, pH 8.0. Protein digestion 
and dialysis was carried out for 16 h at 4oC. Digestion was firstly assessed by SDS-PAGE, then 
fully digested protein was passed again through the HisTrap column and the flow-through 
(containing His-tag cleaved HRG N1/N2-domain protein) was concentrated using a Vivaspin 20 
column (10 kDa MWCO) down to a volume of 5 ml. For further purification, the sample was 
loaded onto a gel filtration column, HiLoad 16/600 Superdex 75 pg. The running buffer (50 mM 
Tris, 150 mM NaCl, pH 8) was applied at a flow rate of 1 ml/min. Fractions were concentrated to 
either 10 mg/ml or 20 mg/ml. Subsequently, another batch of protein was purified using the 
same method except for the TEV cleavage. All purified samples were aliquoted and flash frozen 
in liquid nitrogen before final storage at -80oC until required.  
4.2.5.5. Purification of recombinant HRG N1/N2-domain-green fluorescent protein (GFP) 
fusion protein 
Molecular cloning 
To amplify the cDNA sequence encoding the N1/N2-domains of human HRG for insertion into 
pEHISGFPTEV E. coli expression plasmid (for creation of a HRG N1/N2-GFP fusion protein), 10 ng 
of template DNA was used (Fig. 4.3; 4.4) As a template, the previously gel purified N1/N2-
domain insert (from 5.2.5.1) was used. The PCR amplification reaction contained: 1.5 µl of 
Velocity DNA polymerase (Bioline, London, UK), 10 µl of 5x Hi-Fi Buffer (contains 10 mM Mg2+), 
0.5 µl dNTPs (Sigma Aldrich) and forward (5’-AAAGCGGCCGCGTTAGTCCGACCGATTCGTCTGC-3’) 
and reverse (5’-TTTCTCGAGTCACACCTCGCAATTAATGACAAGGTTCTTC-3’) primers (Eurofins 
Scientific) at a final concentration of 0.6 µM. Additionally, molecular grade water was added to 
a final volume of 50 µl. PCR cycling was as follows: 1 cycle as initial denaturation at 98oC for 2 
min, followed by 40 cycles of denaturation at 98oC for 30 s, annealing at 61oC for 30 s, and 
extension at 72oC for 45 s. Final extension was in 1 cycle at 72oC for 7 min.  
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Figure 4.3. pET-30a(+) vector, was used to construct pEHISGFPTEV vector. The GFP encoding 
sequence was PCR amplified and cloned into pET-30a(+) using NdeI and NcoI restriction sites. 
pEHISGFPTEV expression vector, used for the N1/N2 – domain expression. The multiple cloning 
site (MSC) was the location of gene insertion. The expression is driven by the T7-lac promoter. 
Kanamycin resistance gene allows for the selection of colonies (Novagen, Merck, Darmstadt, 
Germany).  
 
 
Figure 4.4. Multiple cloning site of pEHISGFPTEV vector. Vector contains the f1 replication origin, 
kanamycin resistance gene, pB332 DNA replication origin, and lac repressor gene. Moreover, 
the cloning region shows the T7 promoter, lac operator, hexameric His-tag, TEV protease 
recognition site, restriction endonuclease sites for cloning, and the T7 terminator regions (Liu 
and Naismith, 2009).  
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Product was run on agarose gel, purified and cloned into pEHISGFPTEV vector using NotI and 
Xhol restriction sites as described above. This vector made by Liu and Naismith (2009) combines 
the advantages of the GFP-based solubility, His-tag affinity isolation and TEV protease-mediated 
cleavage of partner proteins. It is based upon the pET30a vector (Novagen, Cambridge, U.S.A.) 
and therefore has a T7 promoter. A sample of pEHISGFPTEV was kindly given to us by Prof. James 
H. Naismith (University of St Andrews). Shuffle T7 E. coli competent cells were subsequently 
transformed with the pEHISGFPTEV containing the corresponding HRG N1N2-domain encoding 
insert. Glycerol stocks were prepared as described above. 
Protein purification 
An initial culture of Shuffle T7 E. coli expressing N1/N2-domain recombinant GFP fusion protein 
was set up from glycerol stock in 50 ml LB media supplemented with 30 ug/ml of kanamycin. 
Culture was grown at 30oC for 16 h with shaking (200 rpm). Subsequent 800 ml cultures were 
set up in the same medium at 1:100 dilution of initial culture and grown at 30oC with shaking 
(200 rpm) until OD600 reached 0.7 AU. Following the addition of 0.7 mM of IPTG, the temperature 
was lowered to 25oC for an overnight incubation. The next morning, the bacterial pellet was 
harvested by centrifugation and resuspended in equilibration buffer (50 mM sodium phosphate, 
400 mM NaCl, 1 mM β-mercaptoethanol, 10 mM imidazole, pH 7.5) supplemented with 200 
µg/ml of lysozyme and EDTA-free protein inhibitor tablet (Roche). Cells were lysed at 4oC for 30 
min followed by sonication with Ultrasonic Cell Disruptor, using a large probe, at 50% amplitude 
in 3 cycles of 30 s with 1 min intervals to prevent sample overheating. The cell lysate was 
centrifuged at 18,000 rpm for 30 min at 4oC, supernatant filtered through a 0.2 µm filter and 
loaded onto a pre-equilibrated HisTrap column (GE Healthcare). The column was washed with 
10 CV of wash buffer (50 mM sodium phosphate, 400 mM NaCl, 30 mM imidazole, pH 7.5). The 
target protein was eluted using elution buffer (50 mM sodium phosphate, 400 mM NaCl, 300 
mM imidazole, pH 7.5). The eluted fractions were analysed by SDS-PAGE.  
4.2.6. Enzyme-linked immunosorbent binding assay (ELISA) 
The influence of zinc on binding of full-length human HRG and the HRG N1/N2-domains to 
complement proteins, C1q, C3 and FH was examined using an ELISA-based method. Also binding 
between heparin and the HRG N1/N2 domains was examined. For binding studies, native FH and 
HRG were purified as described previously (Brandstatter et al., 2012; Kassaar et al., 2015) and 
the N1/N2 domain of HRG expressed and purified as described above. C1q and C3 were 
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purchased from Fitzgerald Industries International (Acton, MA, U.S.A.). Binding experiments 
were performed in the absence and presence of zinc (10 µM ZnCl2).  
4.2.6.1. Protein biotinylation 
Antibodies directed against epitopes within the HRG N1/N2-domain were not commercially 
available. A strategy was therefore adopted whereby detection of bound protein was carried 
out using a streptavidin-linked enzyme following biotinylation of the HRG N1/N2 domain 
protein. For this 4 mg of purified HRG N1/N2-domain protein was biotinylated using the Biotin 
Protein Labelling Kit (Jena Bioscience, Jena, Germany) in accordance with the manufacturer’s 
instructions. Prior to assay, the biotinylated, protein was dialysed against an “ELISA” working 
buffer (50 mM HEPES, 150 mM NaCl, 0.2% Tween 20, pH 7.4) for 2 h at room temperature.  
4.2.6.2. The effect of zinc on binding of native HRG to complement proteins 
To examine the effect of zinc on HRG binding to C1q, C3 and FH, 96-well microtitre plates (Nunc 
Maxisorp; Sigma-Aldrich) were coated overnight with each protein (50 µl of 10 µg/ml 
concentration which corresponds to 25 µM C1q, 65 µM FH and 54 µM for C3) diluted in a coating 
buffer (75 mM sodium carbonate, pH 9.6) at 4oC. Plates were then washed 3 times for 5 min (50 
mM HEPES, 150 mM NaCl, 0.05% Tween 20, pH 7.4), as was similarly done after all the incubation 
steps. Following blocking (100 µl of 0.4% gelatine in wash buffer, supplemented with 0.2% 
Tween 20 at 25oC for 2 h) plates were incubated for 1 h at 25oC with HRG (purified from human 
plasma) diluted in binding buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 2 mM CaCl2). HRG was 
added at various concentrations ranging from 0-3 µM and was prepared in wash buffer 
supplemented with 10 μM zinc chloride or without zinc as a control. Plates were then incubated 
with anti-HRG primary antibody (Abnova, Taipei City, Taiwan), at 1:1000 dilution in blocking 
solution at 25oC and then with goat-α-rabbit alkaline phosphatase conjugate (Sigma-Aldrich) at 
1:10,000 dilution for 1h at 25oC. Bound HRG was detected using p-nitrophenylphosphate (Sigma-
Aldrich). The reaction was stopped after 1 h using 3 M NaOH. The absorbance at 405 nm was 
measured using a Dynex MRX microplate reader (Dynex Technologies, Worthing, UK). 
4.2.6.3. The effect of zinc on binding of N1/N2 domains of HRG to complement proteins 
To examine the effect of zinc on HRG N1/N2-domain binding to C1q, C3 and FH, 96-well 
microtitre plates were coated with complement proteins and blocked as described above 
(5.2.6.2). The plates were then incubated with biotinylated HRG N1/N2-domain for 2h at 30oC. 
Protein was added at various concentrations ranging from 0-10 μM in wash buffer (50 mM 
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HEPES, 150 mM NaCl, 0.05% Tween 20, pH 7.4) supplemented with 10 μM zinc chloride or 
without zinc as a control. Plate was then washed 3 times with wash buffer. A streptavidin-
alkaline phosphatase conjugate (Thermo Fisher Scientific) was prepared at 1:10,000 dilution in 
wash buffer (with and without zinc, respectively) and incubated for 1 h at 25oC. Unbound 
streptavidin was washed away and plate was incubated with p-nitrophenylphosphate substrate 
(dissolved in wash buffer) for 1h at 25oC in the dark. The reaction was stopped with the addition 
of 3 M NaOH and absorbance at 405 nm was measured as described above. 
4.2.6.4. The effect of zinc on binding of heparin to N1/N2-domain of HRG 
To examine the effect of zinc on HRG N1/N2-domain binding to heparin, Costar carbohydrate 
binding plates (Corning, New York, U.S.A.), which have a hydrazide surface that covalently binds 
to carbohydrate groups, were chemically cross-linked to heparin. Firstly, heparin was activated 
with periodate to ensure specific orientation of the biomolecule on the surface. For this 
unfractionated heparin (4 mg) was dissolved in 4 ml of ultrapure water, mixed with 6.4 ml of 15 
mM sodium periodate (solution in 0.1 M sodium acetate, pH 5.5) and incubated for 30 min at 
room temperature. The reaction was stopped by adding 400 μl of 1 % ethylene glycol. The 
mixture was then dialysed twice against 1 L of 0.1 M sodium acetate, pH 5.5, for 1 h at room 
temperature. Activated heparin was aliquoted and stored at -20oC for up to 3 weeks. The final 
concentration of heparin was estimated to be 0.37 mg/ml.  
The carbohydrate binding plates were then coated with 20 µg/ml of activated heparin diluted in 
0.1 M sodium acetate, pH 5.5, for 1 h at room temperature. Next the plate was washed with 
ELISA washing buffer (50 mM HEPES, 150 mM NaCl, 0.05% Tween 20, pH 7.4) and plates were 
blocked with 0.5% fish skin gelatine (Sigma-Aldrich) in wash buffer supplemented with 0.2% 
Tween 20, pH 8.2 for 2 h at room temperature. Following blocking, biotinylated HRG N1/N2-
domain of HRG was applied and incubated at 37oC for 2 h. Protein was added at various 
concentrations ranging from 0-10 μM in wash buffer with 10 μM zinc chloride or without zinc as 
a control. Plates were washed 3 times with ELISA wash buffer. The streptavidin-alkaline 
phosphatase detection method was the same as described above (5.2.6.3). Reaction was 
stopped with the addition of 3 M NaOH and absorbance at 405 nm was measured. 
4.2.6.5. Data presentation 
Data obtained from native HRG and N1N2-domanin of HRG binding studies, were fitted in 
GraphPad Prism v6 software, using a sigmoidal 4-parameter logistic (Sigmoidal 4PL) fit. 
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4.2.7. Hydroxyapatite-coated magnetic bead binding assay 
BcMag hydroxyapatite-modified magnetic beads (supplied by Bioclone, London, UK) are silica-
coated superparamagnetic beads around 2 μm in diameter which have hydroxyapatite 
functional groups added on their surface. These were used to establish a HAP-binding assay to 
probe the HAP-binding properties of HRG. For this, beads were preconditioned according to 
manufacturer’s instructions. Assays were performed in triplicate using 0.3 mg of beads per 
sample. Beads were washed twice with 50 mM Tris, 140 mM NaCl, pH 7.4 (or pH 6.5 and pH 8.0, 
respectively) using a magnetic separator test tube rack and incubated in 400 μl of 0-1 μM human 
HRG (in the same buffer) for 1 h at room temperature with rotary mixing. The binding buffer 
was additionally supplemented with 1 mM zinc chloride for some experiments. Protein-bound 
beads were washed twice with 50 mM Tris, 140 mM NaCl, pH 7.4 (or pH 6.5 and pH 8.0, or the 
addition of zinc respectively), followed by blocking with 1% BSA dissolved in the same buffer for 
1 h at room temperature with rotary mixing. Beads were resuspended in 300 μl of blocking 
solution with the addition of rabbit anti-human HRG antibody at 1:1000 dilution (Abnova) and 
incubated for 1 h at room temperature with rotary mixing. This was followed by two washes 
(with wash buffer as above) and incubation with horseradish peroxidase (HRP)-conjugated anti-
rabbit antibody at 1: 10,000 for 1 h at room temperature with rotary mixing. Detection was 
carried out using o-phenylenediamine dihydrochloride (OPD; Sigma-Aldrich) as a substrate. The 
absorbance at 492 nm was measured using a Dynex MRX microplate reader (Dynex 
Technologies). 
4.2.8. X-ray crystallography of native HRG and recombinant N1/N2 
domains of HRG 
In order to gain structural insight into the molecular interaction between HRG and its various 
binding partners, we aimed to structurally characterise HRG, using X-ray crystallography. N1 and 
N2 domains were of particular interest as they are thought to participate in complement 
binding. Previously the group successfully solved the structure of the N2 domain from rabbit 
HRG (Kassaar, 2014). Nevertheless, the structure of the N1 and N2 domains together (which are 
thought to fold together to form an interaction site for various molecules including complement 
proteins and heparins), or indeed the full-length protein remains unknown. Many parameters 
influence crystals creation therefore only proteins, proven by SDS-PAGE to be of high purity 
(>95%) and homogeneity, were used for crystallisation trials.  
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Firstly, crystallisation of the full-length HRG, purified from rabbit plasma was attempted. Protein 
was concentrated to 18 and 36 mg/ml and used to set up trials with commercially available 
crystal screens, PEG 4, PEG 2 and WIZARD (Qiagen, Manchester, UK). Secondly, crystal trials with 
a recombinant fragment of HRG containing the N1 and N2 domains at a concentration of 25 
mg/ml were set up using the same commercially available crystal screens, and additionally one 
custom made screen prepared in the Naismith laboratory (Biomedical Sciences Research 
Complex, University of St Andrews). The HRG N1/N2-domain crystallisation trials were 
attempted with and without the addition of a very pure preparation of low molecular weight 
heparin (200 µM, 1.8 kDa). The principle behind inclusion of heparin was to attempt obtain a 
heparin-bound structure of the HRG N1/N2 domain fragment. Trials were set up using an Art 
Robbins Gryphon crystallisation robot by sitting-drop vapour diffusion method. In this method, 
the protein is in the vapour-liquid equilibrium with precipitant and therefore concentrates over 
time, it is hoped, to the point when crystals form and grow.  
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4.3. Results  
4.3.1. Protein purification 
4.3.1.1. Purification of the native proteins 
Purification of human and rabbit HRG  
HRG was successfully purified from human/rabbit plasma using a two-step purification method 
(Fig 4.5, 4.6). Human HRG has a molecular mass of around 70 kDa, rabbit protein is around 58 
kDa (Kassaar, 2014). HRG as suggested by its name has an unusually high number of histidine 
residues, which makes it ideal for purification using a HisTrap column. However, following this 
procedure, SDS-PAGE analysis revealed that some contaminating proteins remained after this 
step (Figs. 4.5 A and 4.6 A). Therefore, to ensure maximum sample homogeneity, HRG was 
further purified by size exclusion chromatography. This final step removed all contaminating 
proteins, leaving pure HRG (Figs. 4.5 B and 4.6 B). Mass spectrometry studies involving tryptic 
peptide digestion confirmed the proteins to be human HRG (Fig 4.7 A) with 32% coverage and 
rabbit HRG (Fig. 4.7 B) with 22% coverage.   
 
 
Figure 4.5. SDS-Page images for rabbit HRG purification. On the image, each lane represents 
samples from 1 ml eluted fractions. (A) After initial purification with HisTrapTM Ni column 
fractions 1-6 were pooled together. (B) These were then purified further by gel filtration, HiLoad 
Superdex 200 pg. Here fractions 2-5 were then pooled, freeze-dried and stored at -80oC. LC 
MS/MS following SDS-PAGE analysis and in-gel tryptic digestion confirmed the purified protein 
to be rabbit HRG. 
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Figure 4.6. SDS-Page images for human HRG purification. On the image, each lane represents 
samples from 1 ml eluted fractions. After initial purification with HisTrapTM Ni column fractions 
3-11 (A) were pooled together. (B) These were then purified further by gel filtration, HiLoad 
Superdex 200 pg. Here fractions 2-3 were then pooled, freeze-dried and stored at -80oC. LC 
MS/MS following SDS-PAGE analysis and in-gel tryptic digestion confirmed the purified protein 
to be human HRG. 
 
Figure 4.7. MS/MS sequence analysis for identification of human HRG (A) and rabbit HRG (B). 
Significant peptide fragments are highlighted in red. 32% of analysed protein shows more than 
95% similarities with human HRG and 22% of analysed protein showed more than 95% 
similarities with rabbit HRG. That allowed as assuming that obtained proteins were human and 
rabbiting HRG respectively.  
A 
LIPTDCRTTKPLAEKALDLINKWRRDGYLFQLLRVADAHLDGAESATVYYLVLDVKETDCSVLSRKHWEDCDPDLTKRPSLDVIG
QCRVIATRYSDEYQTLRLNDFNCTTSSVSSALANTKDSPVLFDFIEDTEPFRKSADKALEVYKSESEAYASFRVDRVERVTRVK
GGERTNYYVDFSVRNCSRSHFHRHPNAFGFCRADLSFDVEASNLENPEDVIISCEVFNFEEHGNISGFRPHLGKTPLGTDGS
RDHHHPHKPHKFGCPPPQEGEDFSEGPPSQGGTPPLSPPSGPRCRHRPFGTNETHRFPHHRNFSEHHPHGPPPHGHHPH
GPPPHGHHPHGPPPHGHPPHGPPPHGHPPHGPPPHGHPPHGPPPHGHPPHGPPPHGHPPHGPPPHGHPPHGPPPH
GHPPHGHGFHDHGPCDPPSHKEGPQDLHQHGHGPPPKHPGKRGPGKGHFPFHWRRIGSVYQLPPLQKGEVLPLPEAN
FPSFSLRNHTHPLKPEIQPFPQVASERCPEEFNGEFAQLSKFFPSTFPK 
 
B 
ATLQCSWALTPTDCKTTKPLAEKALDLINKWRRDGYLFQLLRVADAHLDGAESATVYYLVLDVKETDCSVLSRKH
WEDCDPDLTKRPSLDVIGQCKVIATRYSDEYQTLRLNDFNCTTSSVSSALANTKDSPVLFDFIEDTEPFRKSADKA
LEVYKSESEAYASFRVDRVERVTRVKGGERTNYYVDFSVRNCSRSHFHRHPAFGFCRADLSFDVEASNLENPEDV
IISCEVFNFEEHGNISGFRPHLGKTPLGTDGSRDHHHPHKPHKFGCPPPQEGEDFSEGPPLQGGTPPLSPPFRPR
CRHRPFGTNETHRFPHHRISVNIIHRPPPHGHHPHGPPPHGHHPHGPPPHGHPPHGPPPRHPPHGPPPHGHP
PHGPPPHGHPPHGPPPHGHPPHGPPPHGHPPHGHGFHDHGPCDPPSHKEGPQDLHQHAMGPPPKHPGKR
GPGKGHFPFHWRRIGSVYQLPPLQKGEVLPLPEANFPQLLLRNHTHPLKPEIQPFPQVASERCPEEFNGEFAQLS
KFFPSTFPK 
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Purification of human complement Factor H (FH) 
Complement factor H (FH) is the main regulator of alternative complement pathway. FH has a 
molecular weight of 150 kDa. Prior to binding studies, it was purified from human serum using 
a three-step chromatography procedure. For initial purification, cation and anion exchange 
columns were used, however SDS-PAGE revealed that the obtained sample was still a mixture 
of FH and contaminating proteins (Fig. 4.8 A and B). As a final purification step, size exclusion 
chromatography was used, which removed most of the contaminating proteins, leaving FH with 
only a trace of two contaminating proteins of a size similar to FH (Fig. 4.8 C). To reduce the risk 
of protein degradation all steps were carried either on ice or at 4oC when possible. Mass 
spectrometry studies involving tryptic peptide digestion confirmed the proteins to be human FH 
(Fig. 4.9). Fractions 1-7 (Fig. 4.8 C) were pooled and concentrated using Vivaspin protein 
concentrators. The purified protein was quantified, flash frozen in liquid nitrogen and stored in 
small aliquots at -80oC to be used for all subsequent studies. Additionally, when stored for longer 
than 6 months, the sample of protein was analysed by SDS-PAGE gel prior to use. This was 
necessary to make sure that storing conditions are appropriate and that the protein did not 
degrade over time.  
 
Figure 4.8. SDS-Page images for FH purification after running through 1st (A) (cation exchange 
column, CEX) and 2nd (B) (anion exchange column, AEX). Each lane represents 5 ml of elutant. 
After overnight ammonium carbonate dialysis samples were run through the second column. 
Factor H was identified in fractions 1-5 from CEX column and in fractions 1-6 from AEX. For 
further purification fractions 1-4 from AEX were pooled and purified using gel filtration column 
HiLoad Superdex 200 pg (C). Fractions 1-7 were pooled, concentrated and stored at -80oC. FH is 
marked with an arrow.  
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Figure 4.9. LC MS/MS sequence analysis for identification of human FH. Significant peptide 
fragments are highlighted in red. 13% of analysed protein shows more than 95% similarities with 
FH, which is sufficient to confirm that the obtained protein is FH. 
 
The method used for FH purification was essentially that carried out previously by Brandstatter 
et al., (2012) with some minor modifications. Cation and anion exchange columns were 
substituted with equivalents from other brands. In addition, in the last purification step gel 
filtration was used rather than hydroxyapatite affinity chromatography.  
4.3.1.2. Production and purification of recombinant proteins 
HRG is believed to bind most of its ligands via its N-terminus, including heparin (Koide et al., 
1989), heparan sulphate, plasminogen and to cell-surface GAG of T-cell lines (Jones, 2004). It is 
therefore postulated that this region of the protein may interact with complement proteins, 
heparin and other ligands that modulate the immune system and/or can contribute to the 
development of some diseases, including AMD. To examine those interactions, the recombinant 
HRG fragment consisting of the N1/N2 domains was produced using an E. coli expression system.  
MRLLAKIICLMLWAICVAEDCNELPPRRNTEILTGSWSDQTYPEGTQAIYKCRPGYRSLGNIIMVCRKGEWVALNPL
RKCQKRPCGHPGDTPFGTFTLTGGNVFEYGVKAVYTCNEGYQLLGEINYRECDTDGWTNDIPICEVVKCLPVTAPE
NGKIVSSAMEPDREYHFGQAVRFVCNSGYKIEGDEEMHCSDDGFWSKEKPKCVEISCKSPDVINGSPISQKIIYKEN
ERFQYKCNMGYEYSERGDAVCTESGWRPLPSCEEKSCDNPYIPNGDYSPLRIKHRTGDEITYQCRNGFYPATRGNT
AKCTSTGWIPAPRCTLKPCDYPDIKHGGLYHENMRRPYFPVAVGKYYSYYCDEHFETPSGSYWDHIHCTQDGWSP
AVPCLRKCYFPYLENGYNQNYGRKFVQGKSIDVACHPGYALPKAQTTVTCMENGWSPTPRCIRVKTCSKSSIDIEN
GFISESQYTYALKEKAKYQCKLGYVTADGETSGSITCGKDGWSAQPTCIKSCDIPVFMNARTKNDFTWFKLNDTLD
YECHDGYESNTGSTTGSIVCGYNGWSDLPICYERECELPKIDVHLVPDRKKDQYKVGEVLKFSCKPGFTIVGPNSVQ
CYHFGLSPDLPICKEQVQSCGPPPELLNGNVKEKTKEEYGHSEVVEYYCNPRFLMKGPNKIQCVDGEWTTLPVCIVE
ESTCGDIPELEHGWAQLSSPPYYYGDSVEFNCSESFTMIGHRSITCIHGVWTQLPQCVAIDKLKKCKSSNLIILEEHLK
NKKEFDHNSNIRYRCRGKEGWIHTVCINGRWDPEVNCSMAQIQLCPPPPQIPNSHNMTTTLNYRDGEKVSVLCQ
ENYLIQEGEEITCKDGRWQSIPLCVEKIPCSQPPQIEHGTINSSRSSQESYAHGTKLSYTCEGGFRISEENETTCYMGK
WSSPPQCEGLPCKSPPEISHGVVAHMSDSYQYGEEVTYKCFEGFGIDGPAIAKCLGEKWSHPPSCIKTDCLSLPSFE
NAIPMGEKKDVYKAGEQVTYTCATYKMDGASNVTCINSRWTGRPTCRDTSCVNPPTVQNAYIVSRQMSKYPSGE
RVRYQCRSPYEMFGDEEVMCLNGNWTEPPQCKDSTGKCGPPPPIDNGDITSFPLSVYAPASSVEYQCQNLYQLEG
NKRITCRNGQWSEPPKCLHPCVISREIMENYNIALRWTAKQKLYSRTGESVEFVCKRGYRLSSRSHTLRTTCWDGKL
EYPTCAKR 
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Protein purification under non denaturing conditions 
High-level expression of non-native proteins in E. coli very often results in the production of 
misfolded protein, which can generate insoluble protein aggregates. Those aggregates are 
known as inclusion bodies and are almost exclusively formed by proteins foreign to E. coli. It is 
possible and relatively easy to purify proteins from inclusion bodies, but the refolding is 
complicated and time consuming. To overcome potential protein insolubility, Shuffle T7 
competent cells were chosen for the production of recombinant HRG N1/N2-domain. This strain 
is engineered to express DsbC isomerase, which facilitates the expression of proteins containing 
disulfide bonds, in the cytoplasm, and to fix mis-oxidised proteins into their correct form.  
After successful cloning of the appropriate coding sequence into the pETM11 vector, a His-
tagged HRG N1/N2-domain fragment was expressed in Shuffle T7 cells. Cells were grown on LB 
agar plates with the addition of kanamycin for selection. After an initial overnight liquid culture, 
main cultures were set up in 50 ml aliquots to evaluate the conditions that would give highest 
protein yield. Effect of two parameters was investigated: temperature and concentration of 
inducer (IPTG). Cultures were grown at optimal temperature until reaching the mid-log growth 
phase, and then protein production was induced with the addition of 0.01 mM, 0.4 mM or 1 mM 
of IPTG and the temperature lowered to 16oC, 25oC or 30oC for 16h. The following day a sample 
of each culture was taken, spun down, lysed and analysed with SDS-PAGE. The culture condition 
that resulted in the highest protein yield was the one induced with 0.01 mM IPTG and grown at 
25oC (Fig. 4.10). This was judged by subjective comparison of the thickness of the bands at 30 
KDa at different culture conditions  
 
Figure 4.10. Optimizing growth conditions for recombinant HRG N1/N2-domain expression by 
Shuffle T7 cells. Nine different growth conditions were tested. Each lane represents one of the 
conditions. Protein production was induced with 0.01, 0.2 and 1 mM of IPTG and then 
temperature lowered to 16, 25 or 30oC (top row). 
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Once the growth conditions were optimised, a preparative scale culture for protein expression 
was set up. Cultures were grown according to the optimal conditions (0.01 mM IPTG and grown 
at 25oC). Subsequently, the bacterial pellet was lysed in a buffer containing lysozyme, and 
sonicated. The filtered lysate was loaded onto a HisTrap HP column. The N1/N2-domain was 
eluted with 30-50% of Elution buffer. Chosen fractions (Fig. 4.11 A, fraction 3-6) were pooled 
and mixed with TEV protease to cleave the His-tag from the N1/N2-domain. To determine 
whether the protein bound to the column (and thus whether cleavage was successful), the 
column flow through was analysed by SDS-PAGE (Fig 4.11 B), which showed no protein of 
expected size suggesting the His-tag had been successfully removed. 
 
Figure 4.11. SDS-PAGE images for the first step of N1N2-domains purification. On the image, 
each lane represents samples from 1 ml eluted fractions. Eluted fractions 3, 5 and 6 (A) reveal a 
band of around 30 kDa (an arrow). Those fractions were then pooled for further purification. 
The HRG N1/N2-domain fragment is indicated by the arrow. Column flow-through (B) showed 
no protein of the expected size (30 kDa), therefore all protein present in the sample was bound 
to the HisTrapTM Ni column. 
 
After dialysis, the cleaved protein was run through a HisTrap HP column. The TEV protease 
removes the His-tag. Therefore, the cleaved protein should not bind to the column and should 
be present in the flow through, which was collected. Additionally, fractions bound to the column 
(and later eluted), were also analysed to check if cleavage was sufficient. SDS-PAGE revealed 
that only a relatively small amount of protein was present in the flow through (Fig. 4.12 B, 
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fractions 1-4). SDS-PAGE revealed that TEV cleavage was insufficient, and most of the protein 
was bound to the column (Fig. 4.12 B, fraction 6).  
 
 
Figure 4.12. SDS-PAGE images for second step of HRG N1/N2-domain purification. On the image, 
each lane represents samples from 1 ml eluted fractions. After TEV cleavage, prior to the second 
HisTrap column, the sample was run on the gel, to make sure N1/N2-domain did not degrade 
during an overnight dialysis (A). Protein without His-tag, should not bind to HisTrap column, yet 
only trace amount was present in the flow through (B, fractions 1-4). Proteins bound to the 
column were later eluted with 50 – 100% of elution buffer (B, fraction 6).  
 
Solubility screening 
It was suspected that most of the expressed recombinant HRG N1/N2-domain fragment was 
formed within insoluble inclusion bodies during bacterial growth. To confirm this, a solubility 
screen was performed. Transformed Shuffle T7 cells were grown, an aliquot of the bacterial 
culture was lysed, and the supernatant (Fig. 4.13, fraction 2) and pellet (Fig. 4.13, fraction 1) 
were analysed separately by SDS-PAGE. Additionally, an aliquot of bacterial culture was lysed 
and sonicated prior to SDS-PAGE analysis, with pellet (Fig. 4.13, fraction 3) and supernatant (Fig. 
4.13, fraction 4) run separately. The results strongly suggested that most of the protein was 
present in insoluble fractions (in pellet, Fig. 4.13, fractions 1 and 3). This soulubility screen 
provided a proof that solubility was indeed a problem and most of the protein is probably 
trapped in insoluble inclusion bodies formed during bacterial growth. 
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Figure 4.13. SDS-PAGE images of solubility screen for N1/N2-domain in Shuffle T7. On the image 
each lane represents either the pellet (1 and 3) or the supernatant fraction (2 and 4) of bacterial 
culture. Samples 1 and 2 were lysed prior to analysis, and samples 3 and 4 lysed and additionally 
sonicated. All samples were reduced with β-mercaptoethanol prior to analysis.  
 
Culturing E. coli at low temperatures to increase protein solubility 
It was reported by San-Miguel et al. (2013), that the production of soluble proteins in E. coli can 
be improved when bacteria are cultured at low temperature. To facilitate this they induced 
protein production at early log phase (OD600 = 0.1 AU), then lowered the temperature to 4oC. As 
a result, they obtained a much higher yield of soluble protein, compared to a standard culture 
method. A similar method was therefore employed for recombinant HRG N1/N2-domain 
production. For this, 50 ml cultures of previously transformed Shuffle T7 cells were set up in 
aliquots and grown until OD600=0.1 AU. IPTG was then added to induce expression and the 
temperature was lowered to either 4oC (Fig. 4.14 A) or 15oC (Fig. 4.14 B) and cells were incubated 
for 72 h and 48 h, respectively. Analysis by SDS-PAGE revealed that the HRG N1/N2-domain was 
still present in the insoluble fractions (Fig. 4.14 A, fractions 1, 3 and 6; Fig. 4.14 B, fractions 1, 3 
and 6). Furthermore, more protein was expressed when the culture was grown at 15oC for 48 h, 
than when grown at 4oC for 72 h.  
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Figure 4.14. SDS-PAGE analysis of solubility screens for expressed HRG N1/N2-domains in Shuffle 
T7 cells grown at 4oC (A) and 15oC (B). For both each lane represents either pellet (1, 3 and 6) or 
supernatant fractions (2, 4 and 5) of the bacterial culture. Samples 1 and 2 were not lysed prior 
to analysis, samples 3 and 4 were lysed, and samples 5 and 6 were lysed and additionally 
sonicated. All samples were reduced with β-mercaptoethanol prior to analysis. Red arrows show 
HRG N1/N2-domain at approximately 30 kDa.      
 
This approach may have failed due insufficient E. coli chaperonin functioning. Chaperonins are 
enzymes that assist proper protein folding by stabilising unfolded and partially-folded proteins. 
E. coli chaperonins lose up to 70% (chaperonin complex GroEL/ES) of their activity at low 
temperatures (Ferrer et al., 2003). However, there are commercially available E. coli strains 
engineered to co-express cold-adapted chaperonins to improve protein processing ability at low 
temperatures. ArcticExpress competent cells express chaperonins Cpn10 and Cpn60 from the 
psychrophilic bacterium, Oleispira antarctica, which exhibit very high activity at low 
temperatures (4-12oC). For HRG N1/N2-domain expression, the DE3 lysogen strain was chosen, 
as it is designed for T7 promoter-driven expression (as per PETM11 expression plasmid). An 
aliquot of ArcticExpress cells was transformed with pETM11 containing the HRG N1/N2-domain 
insert. Cultures were set up and grown at 37oC until OD600 = 0.6 AU, then protein production was 
induced by the addition of IPTG and temperature lowered to 4oC and 10oC for up to 72 h. The 
resultant bacteria were collected, lysed and sonicated. Pellets (Fig. 4.15 A) and supernatants 
(Fig. 4.15 B) were reduced with β-mercaptoethanol and analysed separately by SDS-PAGE. A 
band corresponding to protein of expected size was present in pellet fractions only (Fig. 4.15 A, 
black arrow). No protein of 30 kDa was seen in supernatant fractions (Fig. 4.15 B). That led to 
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the conclusion that the recombinant N1/N2-domain was still insoluble when expressed in these 
cells. 
 
Figure 4.15. SDS-PAGE analysis of solubility screens for expressed HRG N1/N2-domains in 
ArcticExpress cells grown at low temperatures. The images represent either pellet (A) or 
supernatant fractions (B) of the bacterial culture. Samples 1-3 represent the culture grown at 
4oC, samples 4-6 at 10oC. Samples 1-3 and 4-6 were taken at 24 h intervals.       
 
GFP fusion protein 
Green fluorescent protein (GFP) from the jellyfish, Aequorea victoria is widely used in biological 
assays. It is non-toxic for E. coli cells and highly soluble, which makes it a perfect fusion partner 
to increase solubility of recombinant proteins. To this end, expression of a HRG N1/N2 domain-
GFP fusion was attempted to determine whether this might aid in the production of a soluble 
fragment for further study. In order to achieve this the coding sequence of the HRG N1/N2 
domain was cloned into the pEHISGFPTEV expression vector. This plasmid allows production of 
an N-terminal, TEV protease cleavable His-tagged GFP fusion protein. It uses a T7 promoter and 
a T7 terminator and therefore is suitable for expressing a target protein in E. coli strains 
expressing T7 RNA polymerase such as Shuffle T7.  
The coding sequence for the HRG N1/N2-domain was cloned into pEHISGFPTEV using NotI and 
XhoI restriction sites. Shuffle T7 competent cells were transformed, colonies were picked and 
grown for DNA isolation. Plasmid minipreps were performed and the resulting DNA was 
145 
 
quantified and subjected to further analysis (commercial sequencing and diagnostic restriction 
digest) to confirm that cloning was successful. For protein purification, a transformed culture 
was grown in LB until the mid-log growth phase, then protein production was induced with IPTG 
and grown overnight at 25oC. Following centrifugation and lysis, the filtered bacterial lysate was 
then applied to a pre-equilibrated HisTrap HP column. Eluted fractions were analysed by SDS-
PAGE revealing a protein of expected size (Fig. 4.16 A, red arrow). The desired protein should be 
around 61.7 kDa as it is a fusion of HRG N1/N2-domain, which has a calculated mass of 30 KDa 
plus 31.7 kDa corresponding to HisGFP. Fractions 3-8 were pooled and dialysed overnight with 
TEV protease to cleave GFP fusion protein. SDS-PAGE of a digested sample showed a band of 
around 30 kDa, thought to be the HRG N1/N2-domain. However mass spectrometry analysis 
identified this protein to be TEV protease (Fig. 4.16 B), suggesting that both proteolytic cleavage 
did not work and proteins remained fused or, perhaps more likely, that the expressed fusion 
protein was not soluble.  
 
Figure 4.16. SDS-PAGE analysis of HRG N1/N2-GFP fusion protein purification after preliminary 
purification with HisTrap (A) column and after TEV cleavage (B). Each line represents 1 ml of 
elutant. The HRG N1/N2-GFP fusion protein had a calculated molecular weight of 61.7 kDa (red 
arrow), therefore after initial purification (A) fractions 3-8 were pooled and dialysed over-night 
with TEV protease. The next day, the sample was run on SDS-PAGE which revealed a protein of 
appropriate size to be present (B, red arrow). However, LC MS/MS analysis identified the protein 
as TEV protease rather than HRG N1/N2.  
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Denaturing conditions 
Two strains of competent E. coli cells, Shuffle T7 and ArcticExpress, were used with various 
culture conditions, but neither resulted in the expression of soluble, recombinant HRG N1/N2. 
Formation of inclusion bodies prevented the production of soluble protein. Therefore, to 
recover protein from those aggregates, purification of the protein over denaturing conditions, 
followed by refolding to its native state was attempted. 
An initial culture of transformed Shuffle T7 competent cells was grown from glycerol stock. The 
following day, two 1 L cultures were set up. When OD600=0.7 AU, protein production was induced 
with IPTG and temperature was lowered to 25oC for an overnight culture. The bacterial pellet 
was lysed with addition of 8 M urea to denature proteins. The lysate was loaded onto a HisTrap 
HP column. Eluted fractions 4-16 (Fig. 4.17 A) were pooled together and dialysed twice against 
a buffer containing DTT, which reduces unwanted disulphide bond formation to help the protein 
refold into its native structure. The protein sample was mixed with TEV protease in order to 
cleave the His tag, and was then dialysed overnight. The following day, the sample was run 
through a HisTrap HP column. After TEV cleavage, the protein should not bind to the HisTrap HP 
column and therefore be present only in the column flow through. SDS-PAGE analysis revealed 
a protein of the expected size in both the column flow through (Fig. 4.17 A, fractions 1-7) and 
fractions eluted from the HisTrap column (Fig. 4.18 A, fractions 8-15). That would suggest that 
except His tags, the protein has some other histidine residues in its structure.  
 
Figure 4.17. SDS-PAGE analysis of expressed HRG N1/N2-domains following first HisTrap 
purification, purified under denaturing conditions. Each lane represents samples from 1 ml 
eluted fractions, except lane number 1, which shows the lysed and filtered sample prior to 
loading. Protein was eluted using an imidazole gradient. Fractions 4-16 revealed a band of 
approximately 30 kDa, which corresponds to HRG N1/N2-domains. Those fractions were then 
pooled for further purification.  
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Figure 4.18. SDS-PAGE analysis of expressed HRG N1/N2-domain following second HisTrap step, 
purified under denaturing conditions. After an overnight proteolytic cleavage, sample was 
loaded onto HisTrap column. Each lane represents samples from 1 ml fractions. Both, column 
flow through (fractions 1-7) and eluted fractions (8-15), revealed the band of around 30 kDa, 
which corresponds to the HRG N1/N2-domain.  
 
The column flow through and fractions eluted from the column were treated separately. Firstly, 
column flow through was run through a size exclusion column (Fig. 4.19) and concentrated to 
10 mg/ml. Mass spec analysis proved the protein to be the N1/N2 domain of HRG with 54 % 
coverage (Fig. 4.20). Unfortunately, the protein was still not completely pure as there was a 
trace of an additional contaminant, identified by mass spectrometry as the E. coli molecular 
chaperone, Dnak. However, the obtained protein (estimated to be around 90% pure) was 
deemed of sufficient purity to set up crystallisation trials and to be used in subsequent binding 
studies. Next, the fractions eluted from a HisTrap HP column were purified by size exclusion 
chromatography. It was not possible to separate two proteins, whose molecular weights were 
very similar using this method (Fig. 4.21). The higher band is most likely the HRG N1/N2-domain 
(30 kDa) and the lower band is TEV protease (28 kDa) (Fig. 4.20). The purity of this sample was 
not satisfactory and therefore was not used for further experiments. 
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Figure 4.19. SDS-PAGE analysis of expressed HRG N1/N2-domain from column flow through 
purified by size exclusion chromatography. Each lane represents samples from 1 ml fractions (1-
4), which revealed the band of around 30 kDa corresponding to the HRG N1/N2-domain. A trace 
amount of the 75 kDa E. coli protein, Dnak was also present in these fractions. 
 
 
 
Figure 4.20. LC MS/MS sequence analysis for identification of recombinant N1/N2-domain 
purified over denaturing conditions revealed 54% coverage. Identified peptide fragments are 
highlighted in red.   
 
 
MKHHHHHHPMSDYDIPTTENLYFQGAMAVSPTDSSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHL
DRVEATTVYYLVLDVQESDCSVLSRKYWADCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFAC
TTSSVSSALANTKDSPVLIDFFEDTERYRKQANKAPEKYKEENDDFASFRVDRIERVARVRGGEGTGY
FVDFSVRASPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEV 
149 
 
 
Figure 4.21. SDS-PAGE analysis of expressed HRG N1/N2-domain from the second HisTrap 
column purified by size exclusion chromatography. Each lane represents samples from 1 ml 
fractions (1-9), which each revealed the band of around 30 kDa corresponding to the HRG 
N1/N2-domain (larger of the bands is HRG N1/N2-domain and the smaller one TEV protease, 28 
kDa). It was not possible to separate two proteins using size exclusion due to the similarity in 
their molecular weights. 
 
Many approaches were attempted to express the recombinant HRG N1/N2-domain. Besides 
many parameters being assessed, including temperature, IPTG concentrations and length of 
culture, expression and purification under native conditions failed. Overexpressed non-native 
proteins in E. coli system are sometimes insoluble and form protein aggregates. To enhance 
protein solubility the protein was purified with the addition of denaturant, 8 M Urea. This 
approach helped, and finally, soluble HRG N1/N2-domain protein fragment was produced. This 
was extremely important as it is thought that most of the interactions between HRG and 
immune system molecules, including complement proteins, occur via N-terminus. Synthesis of 
this protein allowed to subsequent binding studies and crystal trials to be performed.  
4.3.2. The role of zinc in the regulation of HRG–complement protein 
interactions 
Complement proteins constitute a major part of innate immunity. They make up approximately 
5% of the total protein content of human blood plasma (Nayak et al., 2010). C1q is the first 
component of the classical pathway. C3 is a central complement protein and supports the 
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activation of all three pathways of complement activation. It is probably the most versatile and 
multifunctional complement protein, possessing structural features that allow it to interact with 
at least 25 different proteins (Sahu and Lambris, 2001). Factor H is not a complement protein in 
the strictest sense, but through its interactions with the variety of proteins, acts as a main 
regulator of the alternative complement pathway. 
As zinc is known to affect both complement protein and HRG functioning and that it has been 
demonstrated that HRG can interact with a number of complement proteins, we explored 
whether those interactions are influenced by zinc. Binding studies with purified HRG and 
complement proteins FH, C1q and C3, were performed using an ELISA based method. The 
binding studies were conducted in the absence/presence of 10 µM zinc, which is within the 
physiological range for plasma (10-20 µM; Sarkar, 1989). However, it is important to point out 
that under normal conditions most of the total zinc is bound to albumin and other plasma 
proteins including HRG. Despite this, it appears that there are circumstances where levels of 
“labile” zinc in plasma can achieve such concentrations in vivo. These include local sites at the 
surface of platelets and immune cells following zinc release (Leung et al., 1983) or under 
pathological conditions where zinc binding to serum albumin is disrupted (Kassaar et al., 2015).   
To examine HRG complement protein binding, microtiter plates were coated overnight with 10 
µg/ml of complement proteins C1q, C3 and FH. The following day plates were blocked with 0.4% 
gelatine, to avoid non-specific binding. Various concentrations of HRG were added to the plate 
and levels of bound protein were detected using an HRG-specific primary antibody and an 
alkaline phosphatase-linked secondary antibody. For each binding study, control and 
experimental groups were run on the same plate in parallel to make the results fully comparable. 
The results revealed that native HRG has very high affinities for the three examined complement 
proteins as indicated by Kd values which are all in nanomolar range. Moreover, zinc has 
inhibitory effect on those interactions, with the affinity of HRG towards FH decreasing more than 
twice, from Kd of 0.66 nM to Kd of 1.46 nM after the addition of zinc (Fig. 4.22 A). The inhibitory 
effect of zinc was also observed on the affinity of HRG towards C3, with Kd increased from 0.44 
nM to 1 nM when 10 µM zinc was added during the binding (Fig. 4.22 C). The affinity of HRG 
towards C1q also decreased after the addition of zinc, however the effect was less pronounced 
than that observed for C3 and FH, Kd increased from 0.64 nM to 0.97 nM (Fig. 4.22 B). 
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Figure 4.22. Binding of full-length human histidine rich glycoprotein to complement proteins: FH 
(A), C1q (B) and C3 (C). Dissociation constant (Kd) values were calculated using Graphpad Prism 
v6 (software) with Sigmoidal 4PL fit. The experiment was performed in the presence and 
absence of 10 µM zinc. Assays were performed in triplicate. Error bars represent calculated S.D. 
 
It has been postulated that HRG interacts with many of its ligands through its N-terminus; 
therefore, the next step was to examine the interaction of a recombinant HRG N1/N2-domain 
fragment with C1q, C3 and FH. Due to the unavailability of an N-terminally directed anti-HRG 
antibody, the recombinant fragment was biotinylated to allow detection using alkaline 
phosphatase-linked streptavidin. Covalent cross-linking of biotin to the protein is rapid and 
specific, and does not interfere with the proteins function. The results revealed that zinc has no 
effect on the binding affinity of biotinylated N1/N2-domain towards FH with the Kd values ca. 
0.23 µM (Fig 4.23 A), and toward C1q with the Kd values 0.22 µM (Fig. 4.23 B). In the contrary, 
zinc had a strong stimulatory effect on the binding affinity of N1/N2-domain towards C3, and 
the Kd decreased from 2.798 µM to 0.406 µM (Fig. 4.23 C).  
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Moreover, the results may suggest that the HRG N1/N2-domain fragment (Fig. 4.23) has much 
lower affinity for the three examined complement proteins compared to full-length protein as 
the Kd values are all in micro molar range (Fig. 4.22). However, due to differences in the 
experimental procedures, the results from the two experiments cannot be directly compared. 
For full-length protein, a two-step, antibody detection method was used, whereas for the HRG 
N1/N2 domain the protein was biotinylated, which in itself may have influenced complement 
protein binding.  
 
 
Figure 4.23. Binding of the N1N2-domain of HRG to complement proteins: FH (A), C1q (B) and 
C3 (C). Kd values were calculated using Graphpad Prism v6 (software) with Sigmoidal 4PL fit. The 
experiment was performed in the presence and absence of 10 µM zinc. Assays were performed 
in triplicate. Error bars represent calculated S.D. 
 
Heparin is a known ligand for HRG (Koide et al., 1989) and is thought that this may occur, at least 
in part, via the proteins N-domain (Kassaar et al., 2015). It has been speculated that HRG can 
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bind heparins through both zinc-dependent and zinc-independent mechanisms, with the zinc-
dependent mechanism being of higher affinity and involving the HRR region of the protein 
(Kassaar et al., 2015). The interaction of HRG with heparins is important for binding of the 
protein to the surface of cells (via heparan sulfate) including immune cells (Jones, 2004) and also 
plays a significant role in the neutralisation of heparins to promote coagulation (Borza and 
Morgan, 1998). To aid determination of whether the N1/N2 domain of HRG participates in 
heparin binding and whether zinc may influence this process, the binding of biotinylated 
recombinant HRG N1/N2-domain fragment to heparin-coated plates was performed in the 
presence of different concentrations of the fragment with and without 10 µM zinc. The results 
show that the addition of zinc did not affect the binding affinity of N1/N2-domain toward 
heparin, with Kd values remaining approximately the same (from 0.17 nM to 0.13 nM after the 
addition of zinc; Fig. 4.24). Additionally the affinity of binding is very strong as Kd values are in 
the nanomolar range. This interaction is therefore ~1000 times stronger than the binding 
observed between the HRG N1/N2-domain and complement proteins (Fig. 4.23). 
 
 
  
Kd no zinc =0.17 nM 
Kd 10 µM zinc = 0.13 nM 
Figure 4.24. Binding of N1N2-domain of HRG to unfractionated heparin. Kd values were 
calculated using Graphpad Prism v6 (software). The experiment was performed in triplicate in 
the presence and absence of 10 µM zinc. Error bars represent calculated S.D. 
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4.3.3. The role of zinc and pH in the regulation of HAP-protein interactions 
4.3.3.1. The influence of zinc on HAP-protein interactions using an ELISA based method 
Numerous insoluble HAP spherules are present within sub-retinal pigment epithelial (RPE) 
deposits. These deposits are associated with cell death in age-related macular degeneration 
(AMD). Metals, such as zinc, iron and copper are also present in sub-RPE deposits and may alter 
the binding characteristics of HAP. The influence of zinc on HAP binding by human HRG and FH 
was examined.   
BcMagTM Hydroxyapatite-Modified Magnetic Beads are silica-coated superparamagnetic, 2 μm 
diameter beads with HAP functional groups added on the surface. A series of experiments were 
performed using these beads in an ELISA-based method. Each condition was prepared and run 
in triplicate. The first step was to establish whether elevated zinc has an influence on human 
HRG-HAP interactions. Two supraphysiological zinc concentrations were picked in relevance to 
AMD; 100 µM and 1 mM. Although the experiment was performed in 1.5 ml tubes, after the 
enzymatic reaction was stopped, samples were transferred onto 96-well microtitre plates and 
the absorbance was measured using a plate reader. 
Results were plotted using GraphPad Prism v6 and dissociation constant values (Kd) calculated 
automatically using a “one site binding” model. No difference in the affinity of binding was 
observed between HAP beads pre-conditioned with 1 mM zinc and a non-zinc treated control, 
with the Kd = 4.17 nM ± 0.98 nM and Kd= 4.72 nM ± 0.95 nM respectively (Fig. 4.25). However, 
when HAP beads were pre-conditioned with 1 mM zinc and additionally the same concentration 
of zinc was present during HRG binding, the affinity of human HRG towards HAP increased 
almost 2-fold (Kd= 1.92 nM ± 0.43 nM; Fig. 4.25). Therefore, it suggested that pre-incubation of 
the beads with 1 mM zinc does not permanently change the surface of beads in the way that 
would influence the binding. Nevertheless, zinc at this concentration enhances the interaction 
between hydroxyapatite and human HRG.  
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Figure 4.25. The influence of zinc on HRG-hydroxyapatite binding. Results are presented as 
binding curve (A) and bar chart (B) representing the same set of data. When HAP beads were 
pre-treated with zinc, no influence on binding was seen. However, when zinc was additionally 
present during HRG binding, the binding affinity increased significantly. Kd values were 
calculated using Graphpad Prism v6. Error bars on both graphs represent ± S.D. 
4.3.3.2. Binding of HRG and FH to pre-coated HAP magnetic beads 
It has been shown recently that protein aggregates on HAP spherules within drusen include FH 
(Thompson et al., 2015) as well as HRG (Fig. 4.1). The mechanism of formation of these 
aggregates is still unknown. To explore this, a HAP binding assay incorporating a pre-incubation 
of HAP beads with either HRG or FH was established. The aim being to examine if either of these 
two proteins has the potential to initiate deposit formation by binding directly to HAP spherules 
and facilitate further protein binding. Firstly, FH binding to HAP spherules with and without pre-
coating with HRG was assessed and corresponding data was fitted using a sigmoidal fit (Fig. 
4.26). When HAP beads were pre-coated with HRG prior to FH, no significant difference in the 
binding affinity of FH toward HAP was observed, Kd value being 17.86±23.51 nM, and 
54.53±66.50 nM respectively. That shows that the FH was still able to bind to HAP beads, even 
pre-coated with HRG. To test the second model, where FH binds to the HAP spherules firstly and 
then HRG binds to FH, beads were pre-coated with FH and HRG was bound on top to form 
binding curve (Fig. 4.27). The data was again fitted using a sigmoidal fit. When beads were pre-
coated with FH, HRG was still able to bind to HAP, however decrease in binding affinity of HRG 
toward HAP was observed, with 2-fold increase in Kd values, from 0.67 ±0.13 nM, to 1.53 ±0.3 
nM, compared to HRG binding to bare beads.  
A B 
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Figure 4.26. Binding of FH to hydroxyapatite pre-coated with HRG. HAP beads were either 
precoated with human HRG prior to FH binding, or left without HRG as a control. Results are 
presented as binding curve (A) and bar chart (B) representing the same data set. No difference 
in affinity of binding was observed. Kd values were calculated using Graphpad Prism v6. Error 
bars on both graphs represent ± S.D. 
 
 
Figure 4.27. Binding of HRG to hydroxyapatite pre-coated with FH. Hydroxyapatite beads were 
either precoated with FH prior to HRG binding, or left without HRG as a control. Results are 
presented as binding curve (A) and bar chart (B) representing the same data set. Increased 
affinity of binding was observed when beads were pre-coated with HRG. Kd values were 
calculated using Graphpad Prism v6. Error bars on both graphs represent ± S.D. 
A B 
 
 
 
A B 
 
 
 
157 
 
4.3.3.3. The influence of pH on HAP-HRG interaction 
The natural pH of the eye is 7.11±1.5 (Thai-Lim et al., 2014) but can become more alkaline during 
aging (Coles and Jaros, 1984). Potential small changes in pH that could happen at the Bruch’s 
membrane in the eye could be a factor in drusen formation. Therefore, the next step was to 
examine the influence of pH on HRG-HAP as a factor in drusen formation. Three experimental 
groups were prepared in buffers of equal composition (140 mM NaCl, 50 mM Tris) but of varying 
pH of 6.5, 7.5 and 8.0. Values picked are close to physiological pH of human blood and are likely 
to represent that of the mammalian retina, which is 7.1-7.8 (Dmitriev and Mangel, 2001). Slightly 
elevated or acidic pH may occur during aging or in some pathological conditions, including 
inflammation. After the enzymatic reaction was stopped, samples were transferred onto 96-well 
plates and the absorbance was measured using a plate reader. The data was fitted using 
sigmoidal fit and Kd values were calculated. 
No changes in binding affinities of human HRG towards HAP were observed upon pH alterations, 
with Kd value calculated to be 2.36 ±0.92 nM, for the binding at pH 6.5 and 2.49  0.61 nM at pH 
8.0, compared to the control, where Kd value was 2.51 ±1.05 nM (Fig. 4.28). As elevated zinc 
(Fig. 4.25) and pH (Fig. 4.28) separately showed no influence on examined interaction, it was 
interesting to see whether those two parameters combined will show any impact.  
Firstly, pH 6.5 combined with 1 mM zinc was examined (Fig. 4.29 A). Secondly, pH 8.0 together 
with zinc (Fig. 4.29 B). For both experiments, control was prepared at pH 7.5 and without the 
addition of zinc. Unfortunately, the data obtained could not be fitted to a simple “one site 
binding” model, therefore Kd values could not be calculated. Nonetheless, based on the 
absorbance, the data suggest that low pH in combination with addition of 1 mM zinc had no 
effect on the binding of HRG to the HAP beads. Alkaline pH together with 1 mM zinc potentiates 
the binding, which is represented as an increase in absorbance (Fig. 4.29 B). 
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Figure 4.28. The influence of pH on HRG-hydroxyapatite binding. Results are presented as 
binding curve (A) and bar chart (B) representing the same data set. Neither low, nor elevated pH 
had an influence on the interaction between HAP and HRG as compared to the control (pH 7.5). 
Kd values were calculated using Graphpad Prism v6. Error bars on both graphs represent ± S.D. 
 
 
Figure 4.29. The combined influence of altered pH and zinc on HRG-HAP binding. Results are 
presented as bar charts. (A) Low pH (pH 6.5) together with 1 mM zinc does not influence the 
interaction between HRG and HAP magnetic beads. (B) High pH (pH 8.0) combined with 1 mM 
zinc, increase the binding of HRG to HAP magnetic beads. Control represents the binding of HRG 
to HAP magnetic beads at pH 7.5 and without the addition of zinc. Error bars on both graphs 
represent ± S.D. 
A B 
 
 
 
A B 
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4.3.4. Crystallography  
In order to gain structural information relating to HRG-complement interactions we aimed to 
structurally characterise HRG using X-ray crystallography. Of particular interest was the N1 and 
N2 domains, which together are thought to participate in complement protein and heparin 
binding. Previously, our research group successfully solved the structure of the N2 domain of 
rabbit HRG (Kassaar, 2014). However, the structure of the N1 and N2 domains together, or 
indeed the whole protein, remains unknown. Crystallisation was attempted using two 
approaches. Firstly, we attempted to crystallise the whole protein purified from plasma. 
Secondly, we aim to crystallise the recombinant HRG N1/N2 fragment.  
Many parameters influence crystal creation, including protein purity, homogeneity and 
concentration. For the crystallisation trials, a vapour diffusion method was used in which protein 
is put in the vapour-liquid equilibrium with precipitant and therefore concentrated over time to 
the point when crystals are being formed.  
Crystallisation was attempted with rabbit HRG (18 and 36 mg/ml) purified from plasma. Trials 
were set up using an Art Robbins Gryphon crystallisation robot. The first crystals appeared after 
3 months. In house analysis of these crystals revealed that they were unable to diffract X-ray 
effectively. Later crystals were re-analysed at the synchrotron at DIAMOND, but were also 
unable to diffract sufficiently to allow structural characterisation. 
Recombinant N1/N2 domain, purified under denaturing conditions was used to set up 
crystallisation trials. Obtained protein was of satisfactory purity (approx. 95%) as revealed by 
SDS-PAGE (Fig. 4.30) and then concentrated to 25 mg/ml. Crystal trials were set using three 
commercially available crystal trials (PEG 4, PEG 2 and WIZARD) and one of the in house trials, 
with the addition of 200 µM, low molecular weight heparin (1.8 kDa) and also without heparin. 
Crystallography plates were checked in weekly intervals over 3 months; however, no crystals 
were observed.  
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Figure 4.30. SDS-Page images for N1/N2-domain purification after running through HisTrap (A) 
and size exclusion column (HiLoad Superdex 75 pg) (B). Each line represents 1 ml of elutant. Last 
line on each gel shows the purity of the sample before loading onto column. Fractions 1-11 (B) 
were pooled, concentrated and crystal trials were set up. The presence of the N1/N2-domain is 
indicated by an arrow (A and B).  
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4.4. Discussion 
4.4.1. The role of zinc in the regulation of HRG–complement protein 
interactions 
HRG is known to modulate the activity of several complement proteins: C8, C9, D and S-protein. 
These interactions occur in a time- and concentration-dependent manner (Chang et al., 1992). 
HRG has also been shown to bind to C1q, FH, C4b-binding protein, C4 and C3 (Manderson et al., 
2009). The results presented here, confirm that HRG binds strongly to several complement 
proteins, C1q, C3 and Factor H. Furthermore, it is shown for the first time that these interactions 
are zinc-dependent.  
To examine whether the interaction between HRG and complement proteins occurs via HRG N-
terminus, and if zinc plays any role in this interaction, a series of binding experiments were 
performed utilising a recombinant fragment of HRG constituting the N1/N2 domains. The results 
showed that zinc decreases the affinity of full length HRG for complement proteins C1q, FH and 
C3. The greatest effect was observed for FH and C3 where the Kd was increased 2-fold. When 
the same study was repeated with N1/N2-domain of HRG, zinc showed no effect on binding 
between N1/N2-domain and FH, and between N1/N2-domain and C1q. However, the affinity of 
HRG N1/N2-domain towards C3 was increased almost 7-fold by the presence of zinc. The results 
suggest for the first time, that binding of complement proteins to HRG is not solely dependent 
on the N-terminus, as it was previously thought. Other protein domains are likely contribute to 
the binding.  
The idea that zinc can influence HRG activity came after finding that activated platelets can 
release zinc in localised areas and simultaneously HRG (Leung et al., 1983). HRG activation by 
zinc is possible when plasma fatty acid levels are elevated. In those conditions albumin binds 
fatty acids and does not bind zinc, which in fact leaves more zinc available to bind HRG (Stewart 
et al., 2003; Stewart et al., 2009; Lu et al., 2012). Zinc is crucial for proper innate and adaptive 
immune response (Maares and Haase, 2016). It is known that zinc modulates HRG immune 
complex clearance activity. In the presence of physiological zinc concentrations, HRG 
potentiates the binding of IgG containing immune complexes to FcγRI receptor on THP1 cells 
(Gorgani et al., 1999a). Insufficient clearance of immune complexes and apoptotic cells is 
dangerous and can lead to systemic lupus erythematosus-like symptoms (Skattum et al., 2011). 
HRG has also a big role in apoptotic and necrotic cells clearance. By binding to human monocyte-
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derived macrophages and apoptotic Jurkat T-cells via FcγRI receptor, HRG accelerates apoptosis 
(Gorgani et al., 2002). Interestingly, C1q also takes part in apoptotic and necrotic cell clearance 
(Elward et al., 2005).  
It was suggested that the binding affinities of HRG to IgG and C1q are affected by physiological 
concentrations of zinc, such that HRG’s interaction with C1q is weakened (Gorgani et al., 1997a). 
Those results correspond to current findings as it was also observed that the affinity of HRG for 
C1q is lower, after addition of 10 µM zinc. It was also shown that micromolar zinc concentrations 
potentiate FH functioning through its ability to bind cofactor C3b resulting in strong inhibition 
of complement functions and causing protein precipitation (Blom et al., 2003). Additionally, FH 
forms oligomers consisting of 4-10 molecules in the presence of zinc, which could form 
aggregates and therefore block binding sites and decrease the affinity between FH and HRG 
(Perkins et al., 1991). The results presented here show decreased binding between FH and HRG, 
and between C3 and HRG in the presence of micromolar zinc.  
Previous evidence together with current results and in vitro experiments showed that the 
formation of potentially harmful insoluble immune complexes (IICs) is partially inhibited at 
physiological HRG concentrations (~ 2 µM) (Gorgani et al., 1997a). This leads us to propose a 
new model of interaction between HRG and complement proteins. At physiological zinc 
concentrations, C3 binds HRG with high affinity. Moreover, zinc inhibits binding between HRG 
and FH. That may allow FH to bind with its ligand, C3b, which is crucial to control complement 
function through its inhibition. When the level of zinc is low, HRG binds FH. The complement 
pathway is not inhibited when it lacks the main regulatory protein (FH), and can result in the 
eventual destruction of “self” tissue. 
It appears zinc can influence immune responses by affecting both alternative and classical 
complement pathways. However, the current investigation was limited to only three 
complement proteins (C1q, C3 and FH). Considerably more work should be done to determine 
the influence of zinc on the complement system as a whole in vivo. 
Heparin and its derivative heparan sulfate, are other known ligands for HRG (Jones et al., 2004, 
Vanwildemeersch et al., 2006). The polysaccharide heparan sulphate is ubiquitously expressed 
on cell surfaces. It has multiple roles in inflammatory responses including initial adhesion of 
leukocytes to the inflamed endothelium, the subsequent chemokine-mediated transmigration 
through the vessel wall and the establishment of both acute and chronic inflammatory reactions 
(Parish, 2006). 
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It was shown previously that, two regions of HRG interact with heparin, N1/N2 region and the 
HRRs. Additionally it was shown that binding to the HRR is Zn2+-dependent (Jones et al., 2004, 
Vanwildemeersch et al., 2006). Later Kassaar et al. (2015) demonstrated that the binding of 
heparin occurs in a Zn2+-independent manner, for small heparin chains. However, when larger 
heparin chains are used, binding affinity of HRG towards heparin is enhanced by Zn2+. It was 
suggested by Kassaar et al (2015) that heparin binding via the N1/N2 domain is Zn2+-independent 
and that binding via the HRR is Zn2+-dependent. The results presented in this chapter revealed 
no difference in the binding affinity of the N1/N2 domain towards unfractionated heparin in the 
presence of 10 µM Zn2+, which is in agreement with this theory.  
4.4.2. The role of zinc and pH in the regulation of HAP-protein interactions 
AMD is the leading cause of irreversible vision loss in the elderly population of developed 
countries. Late, advanced stage of AMD is diagnosed as either “wet” neovascular AMD, "dry" 
atrophic AMD or as both forms (Khan et al., 2016). In this disease, maculopathy is caused by the 
formation of sub-RPE deposits on Bruch’s membrane called drusen. Small numbers of hard 
drusen is normal for the ageing eye, however the soft drusen indicate AMD-related changes 
(Ardeljan and Chan, 2013). They are composed of proteins from both degraded retinal cells and 
plasma, including vitronectin, clusterin (ApoJ), apolipoprotein E (ApoE), (serum), amyloid P (SAP) 
and amyloid-b (Thompson et al., 2015), and complement proteins (C2, C3, C9) (Johnson et al., 
2001; Johnson et al., 2002). They are also recently linked to blood circulation specific proteins 
like albumin, haptoglobin (Anderson et al., 2002) and histidine-rich glycoprotein (HRG; Dr Imre 
Lengyel, UCL Institute of Ophthalmology, unpublished data). It has been recently discovered that 
soft sub-RPE deposits include cholesterol containing lipid droplets coated by insoluble 
hydroxyapatite (HAP) (Thompson et al., 2015). It has been also shown that proteins can form 
aggregates on drusen’s surfaces (Kobayashi et al., 2014) and those aggregates include FH 
(Thompson et al., 2015) and HRG (Dr Imre Lengyel, UCL Institute of Ophthalmology, unpublished 
data).  
HAP is a calcium-containing mineral usually found in bones. Nonetheless, it can be found in other 
tissues as calcification is a normal process during ageing, or as a response to inflammation or 
injury (Anderson et al., 2002). The mechanism by which it occurs is different for different tissues. 
Most of those calcified deposits are just results of other primary age-related changes. These can 
cause age-related, irreversible tissue damage including calcification of the pineal gland during 
Alzheimer’s disease, calcified atherosclerosis lesions and HAP spherules in AMD.  
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It is known that some proteins including HRG can bind to HAP. This led to the idea of using HAP-
coated beads as a model of HAP spherules in the AMD affected eye. This allowed 
characterisation of the HAP-associated binding properties of HRG and give clues as to how this 
protein contribute to deposit formation.  
It has been suggested that one of the factors that increases sub-RPE deposits formation is a local 
increase in zinc levels. In AMD, the Bruch’s membrane contains almost three times more zinc 
than in a healthy eye. There is even higher zinc content in the deposits (Lengyel et al., 2007) and 
therefore it is feasible that interaction between HRG, complement proteins and HAP are 
essential for drusen formation and it occurs when zinc levels are elevated (Perkins et al. 2010). 
Naturally, zinc should then increase the binding of HRG to HAP spherules. To test this hypothesis, 
HAP-coated magnetic beads were pre-conditioned with high concentration of zinc prior to HRG 
binding. No difference in binding was observed compared to the control (not preconditioned 
with zinc). However, when beads were pre-conditioned with zinc and additionally zinc was 
present during HRG binding, the affinity of HRG towards HAP increased almost twice. That 
suggests, that zinc does not bind strongly to the surface of the beads and can be washed away. 
The increased affinity of binding in the presence of zinc is likely a result of zinc interacting with 
HRG to alter its ability to interact with HAP.  
The inflammation process also promotes drusen formation (Anderson et al., 2002). Complement 
activation as part of the inflammatory response, should normally result in phagocytosis and 
removal of degraded plasma proteins and organelles from RPE. Polymorphisms in a number of 
complement proteins including FH, C2, C3 and C9, result in not fully functional complement 
pathways (Perkins et al., 2010; Yates et al., 2007; Khan et al., 2016). This may cause inadequate 
removal of cellular and non-cellular debris. One of the factors known to regulate the response 
from alternative complement pathway is pH (Fishelson et al., 1987), and since it is feasible that 
drusens are formed in the place of local inflammation (Anderson et al., 2002), the influence of 
pH on HAP-HRG interaction was examined as a possible factor contributing to AMD 
development. Neither slightly alkaline (pH 8.0) nor acidic (pH 6.5) environment had any 
influence on the interaction when compared to binding at a physiological pH 7.5. The obtained 
results did not prove whether HRG is initiating deposit formation by accumulating on HAP 
spherules. It seemed that next, it should be examined whether combined elevated zinc levels 
and pH changes would alter the binding between HRG and HAP. Those conditions would be a 
more representative model for AMD onset. At pH 6.0, high zinc levels had no influence on 
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binding, however at alkaline pH 8.0, zinc increased the binding affinity of HRG to HAP. The 
natural pH of the eye is 7.11±1.5 (Thai-Lim et al., 2014), however, it becomes more alkaline 
during aging, especially in females (Coles and Jaros, 1984). It is then possible, that in the aging 
eye, where pH is increased and in the presence of zinc, the formation of HAP coated deposits is 
favoured.  
As mentioned before, polymorphisms in the gene coding for FH are risk factors for AMD 
development. Additionally, FH has been identified in sub-retinal deposits as one of the proteins 
coating HAP spherules (Fig. 5.1). Already knowing that HRG binds to HAP, it is very likely that 
HAP spherules would bind plasma proteins, including HRG, then FH and other proteins can bind 
on top, building up deposits. Alternatively HAP spherules could be initially coated with FH, with 
HRG binding on to. This is of course a very simplified picture, compared to many proteins present 
in the eye in vivo. It is however possible that protein locally produced, and therefore abundant 
in the eye can initiate deposit formation (Mandal and Ayyagari, 2006). The results showed that 
FH can bind to HAP even when beads were pre-coated with HRG. In contrast, when beads were 
pre-coated with FH, the binding of HRG to HAP was restricted, meaning there was less space for 
HRG binding.  
Current results, together with previous research, supports the idea that together, FH-HRG 
binding, the interaction between HRG, complement proteins, and HAP are essential for drusen 
formation, which occurs when zinc levels and pH are elevated. Additionally, results presented in 
this chapter show for the first time that interaction between HAP and proteins present in the 
eye during AMD, is zinc and pH dependent. 
It is possible that not only HRG and FH, but also other proteins involved in inflammatory reaction 
can bind to the surface of drusen and contribute to sub-RPE deposit formation. Those would 
include amyloid beta and vitronectin (Thompson et al., 2015). This study investigated only the 
influence of Zn2+ and pH on HAP binding properties of HRG and FH. To get more detailed insight 
into factors controlling the formation of sub-RPE deposits prior to the development of AMD and 
possibly other diseases with significant tissue calcification, HAP binding properties of other 
complement factors, including C3 and C1q should be investigated. It is also known that zinc is 
not the only metal present in sub-RPE. Iron accumulation has been demonstrated in the eyes 
affected with AMD and therefore its influence on HAP binding should also be examined (Hahn, 
2013).  
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4.4.3. Attempts to structurally characterise HRG 
HRG can interact with numerous ligands, including: haem, plasminogen (Lijnen et al., 1980), 
heparanases (Poon et al., 2010b), fibrinogen (Leung et al., 1983), heparin (Kassaar et al, 2015) 
and also components of the immune system including the complement proteins within both the 
classical and alternative pathways, antibodies, Fc receptors on immunoglobulins and membrane 
attack complex components. HRG also modulates formation and function of immune complexes. 
The interactions of HRG with its ligands occur mainly through the N- and C-terminal domains. Of 
particular interest was the N1 and N2 domains, which together are thought to participate in 
complement protein and heparin binding. 
Previously, our research group successfully solved the structure of the N2 domain of rabbit HRG 
(Kassaar, 2014). However, the structure of the N1 and N2 domains together, or indeed the whole 
protein, remains unknown. Crystallisation was attempted using two approaches. Firstly, we 
attempted to crystallise the whole protein purified from plasma. Secondly, we aimed to 
crystallise the recombinant HRG N1/N2 fragment; and also N1/N2 fragment with the addition of 
200 µM, low molecular weight heparin (1.8 kDa).  
Despite trying variety of concentrations of protein in combination with commercial and in-house 
crystallisation screens, only two sets of crystals were formed, both from rabbit HRG protein. 
Unfortunately they were unable to diffract effectively. Many parameters influence crystal 
creation, including protein purity, homogeneity and concentration. To maximise the chances of 
gaining crystals, only the protein of the highest obtained purity was used to set up the trials. For 
the crystallisation trials, a vapour diffusion method was used in which protein is put in the 
vapour-liquid equilibrium with precipitant and therefore concentrated over time to the point 
when crystals are being formed The use of Art Robbins Gryphon crystallisation robot, allows high 
throughput crystallization screening. For each crystal screen used, 96-different conditions were 
set up. 
 
 
 
 
 
167 
 
Chapter 5. Conclusion 
Collectively, the aim of this thesis was to examine the complex roles of zinc in many aspects of 
immune response. The role of zinc in adaptive immunity was shown by the influence of zinc on 
DC function as antigen presenting cells, and by observed changes in zinc homeostasis during DCs 
maturation. In innate immunity zinc influences both alternative and classical complement 
pathways and can contribute to the formation and clearance of immune complexes.  Also 
characterisation of the HAP-associated binding properties of HRG give clues as to how this 
protein contribute to calcified deposit formation in the inflammatory diseases associated with 
tissue calcification.   
The importance of zinc for cellular immunity is well described; however, the exact mechanisms 
by which zinc acts are still not clear. Here we show that LPS-mediated stimulation of TLR4 
influences zinc homeostasis in DCs, the key antigen presenting cells (Fig. 5.1).  
 
 
Figure 5.1. Zinc homeostasis in moDC upon LPS stimulation. NIR Western blot analysis of zinc 
transporters ZnT1 (A), ZnT7 (B), Zip6 (C) and Zip7 (D) and real-time PCR of the relative amounts 
of mRNA transcripts encoding for those transporters. DCs were treated with LPS for up to 72h. 
NIR WB results were normalised to the amount of β-actin and qPCR results were normalised to 
the amount of two housekeeping genes, β-actin and RPLP0. Results (A-D) are presented as a fold 
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change of the untreated control (0h). Results are the mean ± S.D. based upon three (NIR WB) or 
six (qPCR) independent experiments. Upon 24h of LPS treatment the expression of all examined 
zinc transporters (ZnT1, ZnT7, Zip6 and Zip7) decreased, followed by the increase in relative 
amounts of mRNA transcripts encoding for those transporters (E). After 72h of LPS treatment 
the relative amounts of zinc transporters increased, followed by the decrease in the relative 
amounts of mRNA transcripts.  
 
The results presented here have firstly confirmed that our monocyte-derived DCs exhibit a 
characteristic morphological appearance, which helps to validate our cell model. Microscopy 
imaging in both bright field and using fluorescence antibodies revealed an abundance of 
cytoplasmic projections upon LPS-induced maturation, which are characteristic for DCs. 
Furthermore, the presented results demonstrated the importance of zinc transporters in 
maintaining intracellular zinc level during DC maturation. It was shown by qPCR that the levels 
of mRNA transcript encoding for ZnT1, ZnT7, Zip6 and Zip7 were altered upon LPS-induced 
maturation of DCs. These alterations were also reflected in the expression of zinc transporter 
proteins, by western blotting (WB) and immunofluorescence (IF) which revealed a decrease in 
the expression of all examined zinc transporters after 24 h of LPS-induced maturation. It was 
also shown that the Zip7 transporter, which is located on ER, was gradually activated during DCs 
maturation. The phosphorylation of this transporter was measured using flow cytometry, WB 
and visualised with IF. The microscopy results have also revealed that only minor fluctuations in 
intracellular zinc levels occur during DCs maturation. The zinc levels were assessed using flow 
cytometry with zinc-specific membrane permeable fluorophore, ZnAF-2F DA.  
The data have therefore demonstrated that TLR4 signalling upon LPS binding, alters the 
expression of zinc transporters, most likely to maintain a stable concentration of intracellular 
free zinc. This indicates the importance of zinc at every level of DCs maturation, beginning with 
antigen recognition, through antigen processing and cell migration to the lymphatic organs to 
finally, antigen presentation to T-cells. This helps build a fuller picture of zinc homeostasis and 
its importance for the initiation of immune response. 
Here we also presented a global picture of proteomic changes that occur in maturing DCs. Due 
to the novel method used (SWATH proteomics), changes are described for the first time in a fully 
quantitative manner. The results showed 3-7 fold increases in the expression of 
histocompatibility complex proteins (MHC I), involved in the antigen presentation, along with 
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other upregulated proteins involved in either response to cytokines or cell remodelling. Most of 
the identified proteins however, were downregulated upon LPS induced maturation. Those were 
mostly proteins involved in carbon metabolism, but also ribosomal and ER proteins responsible 
for protein translation and post-translational modifications. Among the downregulated proteins 
were also members of antigen presentation pathways, including MHC II.  
The presented proteomic data suggest that during the maturation process, DCs likely respond 
to self-secreted interferon, which is shown by the 30 to 40-fold increase in the IFN induced 
proteins upon maturation. It is therefore possible that DCs generate a self-enhancement (or 
positive-feedback) loop, which mostly results in the expression of MHC I. Secondly, the results 
suggest that many cellular processes are slowed during cell maturation. It is however also 
possible that the global decrease in protein expression observed is simply a consequence of the 
downregulation of translational machinery. Finally, the results presented reveal that MHC I plays 
a key role in LPS-mediated antigen presentation. This is a little surprising as it is widely 
acknowledged to be a role for MHC II. It should be highlighted that further study including 
further time points is required to be sure that other important changes are overlooked. 
Therefore LPS may indeed be presented via MHC II in the early stage of maturation and later 
(around 24 h), MHC I takes over the antigen presenting role and presents proteins that were 
stored for several hours in cytoplasmic aggregates. This potential insight into antigen 
presentation alters the current understanding of the mechanisms mediating this immune 
response.  
In addition, presented study for the first time uses HAP to induce DC maturation and provides 
quantitative analysis of subsequent proteomic changes. In a similar manner to LPS-induced 
maturation, most of the identified proteins were downregulated upon HAP-induced maturation. 
The majority of these are key metabolic enzymes and proteins forming part of the translation 
machinery. This observation brings important insight into the pathology of inflammatory 
diseases associated with tissue calcification, such as age-related macular degeneration, 
atherosclerosis and Alzheimer’s disease and into the mechanisms of bone graft rejection. To 
further understand the proteomic changes that occur during DCs maturation, future work 
should examine the changes in early stages of maturation.  In addition, it would be beneficial to 
identify proteome profiles related to the functionally different dendritic cell phenotypes, which 
could then serve as diagnostic tool in interpretation of clinical proteomic data. 
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The importance of zinc was also shown in innate immunity through its role in regulating the 
interaction of complement proteins with HRG. The results revealed that in the presence of 
physiological concentrations of zinc the affinity of full length HRG to complement proteins C1q, 
FH and C3 is decreased, with the greatest effect observed for FH and C3 where the binding 
affinity decreased 2-fold. When a similar study was carried out using a recombinant protein 
constituting only the N1/N2-domain of HRG, the presence of zinc had no effect on binding 
between N1/N2-domain and FH or C1q. However, the affinity of HRG N1/N2-domain towards 
C3 was increased almost 7-fold by the presence of zinc. These results suggest for the first time 
that binding of complement proteins to HRG is not solely dependent on the N-terminus, as it 
was previously thought. Other protein domains are likely contribute to the binding. It appears 
zinc can influence immune responses by affecting both alternative and classical complement 
pathways. However, the current investigation was limited to only three complement proteins 
(C1q, C3 and FH). Considerably more work should be done to determine the influence of zinc on 
the complement system as a whole in vivo. 
The effect of zinc in modulating interactions between the N1/N2 domain and heparin was also 
assessed. However, no difference in the binding affinity of the HRG N1/N2 domain towards 
unfractionated heparin was identified in the presence and absence of physiological zinc 
concentrations.  It had been previously suggested that the heparin binding via the N1/N2 domain 
is Zn2+-independent and that binding via the HRR region of HRG is Zn2+-dependent, which is in 
agreement with presented results. This interaction between HRG and different heparins is 
believed to be important in innate immunity. For example, it is known that the heparin 
derivative, heparan sulfate plays a multiple roles regulating inflammatory responses.  
Following establishment of a novel magnetic bead assay, it was revealed that zinc together with 
pH can influence HRG-hydroxyapatite interactions. Such interactions may be involved in the 
onset of the eye disease, AMD. Protein binding to HAP-coated spherules (that form in an age-
dependent manner) have recently been implicated as playing a crucial role in the development 
of AMD. Here we demonstrated that HRG and the complement protein, FH (which is associated 
with familial forms of the disease) can bind to HAP beads. The binding of FH to HAP was still 
possible even when beads were pre-coated with HRG. In contrast, when beads were pre-coated 
with FH, the binding of HRG to HAP was restricted. The results also demonstrated that the binding 
of HRG to HAP beads was enhanced when the high, supraphysiological zinc concentration was 
present, but not influenced by the alteration of pH. Nonetheless, alkaline pH together with 1 
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mM zinc potentiated the binding of HRG to the HAP beads, but low pH in combination with 
addition of 1 mM zinc had no effect. The study was limited only to FH and HRG interaction with 
HAP beads and the role of zinc in this interaction. However it is known that other plasma proteins 
and proteins involved in inflammatory reaction as well as HRG and FH can bind to HAP spherules 
in vivo. To get more detailed insight into factors controlling the formation of sub-RPE deposits 
prior to the development of AMD and possibly other diseases with significant tissue calcification, 
the HAP binding properties of other complement factors including C3 and C1q should be 
investigated. It is also known that zinc is not the only metal present in human retina. Therefore 
other divalent cations previously detected in retina, such as iron and copper should be also 
investigated in relation to drusen formation.   
The last very ambitious aim of this study was to structurally characterise HRG. Current structural 
information relating this protein had mostly come from sequence analysis and spectroscopic 
studies. The only published X-ray crystal structure is available for the N2 domain of rabbit HRG, 
which shares great homology with human N2 domain. Crystallisation was attempted using two 
approaches. Firstly, we attempted to crystallise the whole protein purified from rabbit and 
human plasma. Unfortunately, despite multiple crystal growth conditions being tested, including  
attempts with a variety of concentrations of protein in combination with commercial and in-
house crystallisation screens, only two sets of crystals were formed, both with plasma-purified 
rabbit HRG protein. Unfortunately however, these crystals were unable to diffract effectively to 
yield a 3-D structure.  
One of the many parameters influencing crystal formation is protein purity and homogeneity. 
Our group have previously crystallised native N2 domain, therefore it was suspected that the 
problem laid within PRR and HRR domains, which have a high probability of being disordered 
and thus not amenable for production of crystals that would diffract to high resolution. The 
second approach was to crystallise a recombinant form of HRG constituting on the N1/N2 
domains and thus omitting PRR and HRR domains. Crystals were set up with and without the 
addition of low molecular weight heparin (1.8 kDa). This would bring an answer on how exactly 
HRG and heparins interact. So far it is only known that HRG can bind heparins via N-terminus 
and HRR domains. These attempts unfortunately failed to yield any crystals. The recombinant 
protein used for crystallisation trials was purified using denaturing and subsequent refolding 
method following expression in E. coli. This might have led to heterogeneity of the resultant 
protein and therefore hindered crystal formation. Future attempts should focus on establishing 
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a better recombinant system for the expression of soluble recombinant full length and truncated 
HRG. There are also other alternative strategies for structural characterisation of the molecules. 
One of them, cryo-electron microscopy (cryo-EM), is a form of transmission electron microscopy 
where the sample is studied at cryogenic temperatures. This method in contrast to 
crystallography, allows the observation of protein structure without forced crystal formation 
and therefore in its native state. Another method that could be used is a multi-dimensional 
nuclear magnetic resonance spectroscopy (3D-NMR). This method is used to assign specific 
resonance signals to specific atoms in an isotopically enriched protein. Nevertheless, structural 
characterisation of HRG using 3D-NMR may be difficult as there are many histidine residues 
present and these would be very difficult to individually assign to signals in the resultant spectra 
hindering solution of the structure. 
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Appendices 
Appendix 1 
Β-actin RPLP0 
  
SLC30A1 SLC30A7 
  
SLC39A6  
 
B 
Target R2 Primer 
efficiency 
Error 
ZnT1 0.993 97.91 0.101 
ZnT7 0.995 75.3 0.119 
Zip6 0.994 96.65 0.109 
Zip7 0.995 96.77 0.092 
Β-actin 0.998 88.9 0.051 
RPLP0 0.996 91.96 0.075 
 
 
SLC39A7 
 
Figure 1. Standard amplification curves were plotted for each primer pair using serial dilution 
of DNA (A). Reaction efficiencies and correlation coefficient (R2) (B) were calculated 
automatically by ViiA™ 7 Real-Time PCR System Software based on standard curves plotted. 
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